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Outline of the thesis 
 
In this thesis the role and regulation of the negative p53 regulator Hdmx (Mdmx/Mdm4) 
are the main topics. Whereas the role of its close homolog Hdm2 is elaborately studied, the 
function of Hdmx in tumourigenesis less understood. Post-translational modification of 
Hdmx is abundant and may play an important role in the regulation of it function. However, 
relatively little is known about the nature of these modifications. The aim of this thesis was 
to provide more insight in the putative oncogenic role of Hdmx and to elucidate some of the 
mechanisms by which Hdmx function is regulated.  
 
The work in this thesis is presented as follows: 
Chapter 1 introduces the p53 pathway and it describes the main aspects of the regulation of 
p53 by Hdm2 and Hdmx. 
In Chapter 2 the present knowledge about the regulation of Hdmx in relation to the p53 
response is presented.  
Chapter 3 describes the effects of c-Abl mediated phosphorylation on tyrosine residues 55 
and 99 of Hdmx, which both modulate the interaction with p53.  
In chapter 4 the oncogenic functions of Hdmx have been investigated, using an in vitro 
transformation model of human primary fibroblasts and embryonic retinoblasts.  
The function of Hdmx overexpression and alternative splicing in osteosarcoma is described 
in Chapter 5. A model for a role of Hdmx in early tumours and loss of Hdmx in later stage 
tumours is proposed, with a key role for the change in ratio between the expression of the 
alternative Hdmx splice variant, Hdmx-S and full length Hdmx.  
Chapter 6 shows that p53 and its regulators Hdm2 and Hdmx are SUMOylated and 
ubiquitinated and how the SUMO-specific ubiquitin E3 ligase RNF4 might be involved in 
these processes.  
In chapter 7 the function of the FAU gene, encoding the ubiquitin-like protein FUBI and the 
ribosomal S30 protein, has been studied in osteosarcoma cells. 
Chapter 8 is a general discussion and provides a summary of the thesis.   
 
  
Chapter 1 
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Chapter 1   General Introduction 
 
Tumour suppressor p53 is regulated by Hdm2 and Hdmx 
Cell growth and proliferation are under tight control of the tumour suppressor p53, to 
prevent uncontrolled cell division or replication of damaged DNA, thereby maintaining the 
genomic integrity and inhibiting the formation of tumours 1. When cells are stressed or 
when DNA damage occurs, p53 gets activated, leading to a p53 response which eventually 
may lead to growth arrest or even apoptosis when damage is unrepairable 2. The importance 
of this “Guardian of the Genome” function 3 is illustrated by the high frequency (~50%) of 
p53 mutations in tumours 4,5, whereas in wild-type p53 tumours the p53 tumour suppressor 
pathway is assumed to be functionally inactivated 6. Furthermore, mice that lack p53 
develop almost normally, but are very susceptible to spontaneously formed tumours 7. 
Obviously, a tight control of the activity of p53 is essential for normal cell growth and cell 
cycle progression, as well for an appropriate response to damage and stress 8,9. Two of the 
main p53 regulators are Hdm2 (Mdm2, Mouse double minute 2) and Hdmx (Mdmx/Mdm4, 
mouse double minute x/4) 10, the importance of which has been demonstrated by the 
embryonic lethality of Mdm2- and Mdmx-deficient mice, which could both be rescued by 
p53 loss 11-15. Hdm2 and Hdmx are homologues, showing high similarity in their general 
structure, and their amino acid sequence is highly similar in the N-terminal p53 binding 
domain and RING finger domain 16 (Fig. 1).  
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Figure 1. Protein structure of Hdm2 and Hdmx 
Protein structure of Hdm2 and Hdmx, indicated are the functional domains of both proteins. Percentage of 
similarity between both proteins is shown in between. NLS: nuclear localisation signal; NES: Nuclear Export 
Signal; Zn: Zinc finger; RING: Really Interesting New Gene; NoLS: Nucleolar Localisation Signal. Adapted from 
Marine et al. (2007) 108.  
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Both proteins bind p53 at the N-terminus, thereby inhibiting p53’s transcriptional activity 
17,18. Hdm2 is an E3 ubiquitin ligase for p53, targeting p53 for ubiquitination and 
proteasomal degradation 19,20, which is dependent on the RING and acidic domains 21,22. In 
contrast to Hdm2, Hdmx is unable to fulfil this function by itself, despite its similarity with 
Hdm2, although dimerization of both proteins stabilizes Hdm2 and enhances the E3 ligase 
activity towards p53 23-25. Furthermore, Hdm2 is not only an E3 ubiquitin ligase for p53, but 
also ubiquitinates Hdmx and itself, especially after several types of cellular stresses, like 
DNA damage 26-28. 
Other ubiquitin E3 ligases for p53 have been described 29,30; however, it is generally 
believed that Hdm2 is the main E3 ligase in the regulation of p53 stability. 
 
Regulation of Hdmx levels 
Whereas under normal growth conditions the Hdmx protein is stable, after DNA damage its 
levels rapidly decrease, due to Hdm2-mediated degradation 31. For a long time, Hdmx 
expression was considered to be regulated only at the protein level. However, the group of 
Jiandong Chen showed that the Hdmx promoter is responsive to mitogenic stimulation via 
the Ets-transcription factor family members 32. Recently it was discovered that, similar to 
Hdm2, the Hdmx gene contains a p53 responsive promoter, which is activated upon p53 
activation, thereby creating a negative feed-back loop to attenuate the p53 response 20,33-35. 
The mRNA synthesized from the p53-responsive P2-promoters of both Hdm2 and Hdmx 
are much more efficiently translated than the mRNAs transcribed from the constitutive P1-
promotors 34,36-38.  
Several alternative splice variants of Hdm2 have been described 39 and up to now six 
alternative spliced forms of Hdmx have been detected 40,41. At least one of these Hdmx 
splice variants, Hdmx-S, might be implicated in tumourigenesis, as its mRNA expression 
was found to be upregulated in a number of tumours and the expression of Hdmx-S 
correlates with worse patient survival 42-45.  
 
Hdmx can act as an oncogene 
Whereas a lack of Hdm2 or Hdmx in normal cells containing wild-type p53 in most cases is 
lethal for cells, overexpression or amplification of these genes can lead to tumourigenesis. 
By overexpression of one of these proteins, p53 activity can be sufficiently repressed or 
inactivated to overcome oncogenic stress-induced growth arrest or senescence. Up to 10% 
of all tumours show overexpression of Hdm2, usually in the presence of wild-type p53, 
revealing Hdm2 as an oncogene 46. Similarly, Hdmx can act as an oncogene; increased 
Hdmx mRNA expression was found in 20% of tumours in a study of common tumour types 
47 and a subset of gliomas showed amplification of the Hdmx gene 43. In a large number of 
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wild-type p53 tumour cell lines upregulated or aberrant Hdmx protein expression was 
found 48. Furthermore, retinoblastomas, which nearly all retain wild-type p53, show 
amplification of the hdmx gene in a particularly high proportion of tumours, thereby 
overcoming the p53-mediated apoptosis after Rb (Retinoblastoma protein 1) loss during 
tumour progression 49. Moreover, around 90% of Ewing Sarcomas show wild-type p53 and 
a high number of these tumours show Hdmx overexpression 50. 
 
Danovi et al. (2004) were the first to demonstrate an oncogenic activity of murine Mdmx, 
by showing that overexpression of Mdmx combined with HRasV12 in mouse embryonic 
fibroblasts resulted in immortalization and neoplastic transformation 47. Recently, two 
transgenic mouse models have been described that widely overexpress the Mdmx gene 51,52. 
Interestingly, only in one model the development of spontaneous tumours was found. The 
oncogenic activity of Hdmx in human cells had not yet directly been investigated. We show 
in this thesis, Chapter 4, that increased Hdmx levels can replace the loss of p53 in the 
transformation of human fibroblasts and embryonic retinoblasts. 
A putative role for Hdmx as a driving factor for tumourigenesis may also be found in the 
bone malignancy osteosarcoma. Since only around 20% of high-grade osteosarcoma has 
p53 mutations 53-55 and Hdm2 was found to be amplified in only 10-35% of osteosarcoma 
53-56, Hdmx overexpression might be an additional way to overcome p53 inhibition. In this 
thesis, Chapter 5, we show that Hdmx overexpression may be a mechanism to inhibit p53 in 
early stage osteosarcoma, whereas in later stages, p53 is usually inactivated in other ways. 
We found that Hdmx expression in these late stage tumours with inactivated p53 is reduced, 
whereas the alternative Hdmx splice variant Hdmx-S is strongly upregulated. This change in 
the ratio between these splice-variants turned out to be a stronger prognostic marker than 
p53 mutational status only.  
 
Treatment of tumours that retain wild-type p53 with compounds that reactivate p53 is a 
promising therapy. By relieving the inhibitory pressure of Hdm2 or Hdmx on p53, an 
effective anti-cancer therapy might be developed. Small molecule inhibitors such as Nutlin-
3, which interferes with the binding of Hdm2 and p53 57, have already been used in many 
studies and are being tested in clinical trials. More recently, also specific inhibitors of 
Hdmx have been developed 58,59. An interesting development is the use of Nutlin-3 and 
similar inhibitors in so-called cyclotherapy, in which the activation of p53 serves as a 
chemoprotectant in normal cells, whereas tumour cells will become even more sensitive to 
the chemotherapeutic treatment 60. This approach will also function in the treatment of 
mutant p53 tumours, since these cells, in contrast to normal cells, will not arrest in G1 and 
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G2 after p53 activation and, therefore, specifically the tumour cells will be targeted by the 
following chemotherapy.   
 
Post-translational modifications in the p53 pathway: Cross-talk on the lysines. 
The regulation of p53 levels and activity is mainly at the protein level; changes in protein 
stability and decreased functional inhibition allow p53 and p53 target gene levels to rise 
very quickly upon stress signals. Post-translational modifications play a critical role in the 
p53 regulation. The most obvious modification is the conjugation of ubiquitin to p53 by 
Hdm2, resulting in altered subcellular localization when p53 is mono-ubiquitinated, or 
proteasomal degradation as a result of poly-ubiquitination 61-63. Several other ubiquitin-like 
modifications have been reported to be involved in p53 regulation, such as SUMOylation 
and NEDDylation, of which the conjugation of the small ubiquitin related modifiers, 
SUMO’s, is the best studied. The conjugation of SUMO to p53 by Hdm2 or PIAS family 
members has been reported to inhibit p53 transcriptional activity, although others found an 
activation of p53 activity upon SUMOylation 64-66. Hdm2 and Hdmx are also SUMOylated 
on two or more lysines, which have been implicated in the function of Hdm2 67-70. 
Interestingly, the conjugation of SUMO and ubiquitin cross-talk in several ways 71. 
SUMOylation of proteins has been reported to interfere with ubiquitination. On the one 
hand by shielding the target lysine for ubiquitination, or by SUMOylation of components of 
the ubiquitination system 72. Moreover, the recent discovery of SUMO Targeted Ubiquitin 
Ligases (STUbLs), such as the human Ring Finger Protein 4, RNF4, adds a new twist to the 
interplay between ubiquitination and SUMOylation 73,74. This type of E3 ubiquitin ligases 
specifically ubiquitinates (poly-)SUMOylated targets, through recognition by a SUMO 
Interacting Motif (SIM), of which the ubiquitination of poly-SUMOylated PML 
(promyelocytic leukemia protein) by RNF4 was the first example 75-77.  
Other post-translational modifications on lysines such as acetylation and methylation have 
also been implicated in the regulation of the activity and interactions of p53, Hdm2 and 
Hdmx. Acetylation of p53 C-terminal lysines is upregulated after DNA damage and has 
been suggested to have an activating effect, by shielding these residues for ubiquitination or 
other inhibiting modifications. NEDDylation, methylation and SUMOylation can occur at 
unique lysines in p53, but may also compete with ubiquitination and acetylation for the 
same residues, resulting in a fine-tuning mechanism of p53 activity and stability 78-82.  
 
Post-translational Modifications in the p53 pathway: Phosphorylation  
For the activation of p53 upon DNA damage, certain phosphorylation events on p53, Hdm2 
and Hdmx are crucial. Upon DNA damage, kinases such as ATM, ATR, DNA-PK and 
others are activated and start a phosphorylation signaling cascade. Numerous 
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phosphorylations on p53 are known, including a cluster of N-terminal residues of which 
S15, T18 and S20 are the most well studied. Phosphorylation on S15 appears to increase the 
interaction between p53 and the transcriptional co-factors p300/CBP, while 
phosphorylation of T18 and S20 results in decreased affinity for Hdm2 83,84. 
Phosphorylation of S46 is associated with the induction of apoptosis 84,85. Of the C-terminal 
phosphorylations, phosphorylation of S392 has been reported to stabilize p53 
tetramerization and enhance specific DNA binding, while S351 phosphorylation was 
suggested to activate p53 transcription activity 80. Next to the activating phospho-
modifications on p53 itself, the negative regulators of p53, Hdm2 and Hdmx, are 
inactivated due to phosphorylation upon DNA damage. The phosphorylation of sites near 
the RING domain of Hdm2 prevents the oligomerization of Hdm2, thereby attenuating p53 
ubiquitination and degradation 86. Phosphorylation of Hdmx C-terminal serines S342, S367 
and S403 promotes its degradation by Hdm2 87-89. Similarly, the phosphorylation of Hdm2-
S395 by ATM induces auto-ubiquitination of Hdm2 90. Furthermore, c-Abl-mediated 
phosphorylation of Hdm2 on the adjacent Y394 inhibits the nuclear export and degradation 
of p53 91-93. Additionally, phosphorylation of S17 on Hdm2 by DNA-PK has been reported 
to disrupt the Hdm2-p53 binding 94 and we have shown that tyrosine-99 phosphorylation of 
Hdmx by c-Abl exerts a similar function (this thesis, Chapter 3, 95) 
Phosphorylations on p53, Hdm2 and Hdmx affect the affinity of the Ubiquitin Specific 
Protease USP7 (HAUSP) for these proteins. Under normal growth conditions, USP7, a de-
ubiquitylase (DUB), removes ubiquitin from Hdm2 and Hdmx, which is essential for 
maintaining levels that are sufficient to inhibit p53 activity.  However, upon DNA damage 
the interaction of USP7 with Hdm2 and Hdmx is attenuated, leading to their destabilization 
and inability to inhibit p53, while p53 still is a USP7 target 96,97.  
Whereas the above described phosphorylations on Hdm2 and Hdmx are induced by DNA 
damage and prevent the inhibition and degradation of p53, phosphorylations by other (pro-
survival) kinases such as Akt, CK1-alpha or GSK3 are involved in the stabilization and 
functional regulation of Hdm2 and Hdmx and have been reported to inhibit p53 function 
78,98,99. 
 
The FAU gene encodes the S30 ribosomal gene and the ubiquitin-like FUBI and 
functions in apoptosis. 
Another Ubi-Like protein, probably the least studied, is FUBI. FUBI is translated from the 
FAU (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-Associated Ubiquitously 
expressed gene) mRNA, as a fusion product with the ribosomal S30. Like ubiquitin-
precursor proteins, cleavage occurs after a Gly-Gly motif, generating the mature FUBI 
protein. The FAU gene was originally identified as a pro-apoptotic gene 100 and its 
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downregulation is associated with tumourigenicity and drug resistance 101-104. Moreover, a 
number of reports demonstrate the binding between the pro-apoptotic p53 target Bcl-G and 
FUBI, which seems to be essential for the induction of apoptosis by FAU 102,103,105,106. On 
the other hand, in the osteosarcoma cell line HOS, FAU and FUBI overexpression was 
found to have transforming capabilities, whereas FAU and S30 overexpression conferred 
arsenite resistance 107. In this thesis, Chapter 7, we investigated the function of the FAU 
gene in osteosarcoma and found, in contrast to what was published before, that FAU 
expression is essential for normal proliferation. Furthermore, we demonstrated that FAU 
expression affects the sensitivity to several drugs.  
General Introduction 
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Abstract 
The MDM family proteins MDM2 and MDMX are two critical regulators of the p53 tumor 
suppressor protein. Expression of both proteins is necessary for allowing the embryonal 
development by keeping the activity of p53 in check. Upon stresses that need to activate 
p53 to perform its function as guardian of the genome, p53 has to be liberated from these 
two inhibitors. In this review we will discuss the various mechanisms by which MDMX 
protein levels are downregulated upon various types of stress, including post-translational 
modifications of the MDMX protein and the regulation of mdmx mRNA expression, 
including alternative splicing. In addition, the putative function(s) of the described MDMX 
splice variants, particularly in tumor development, will be discussed. Lastly, in contrast to 
common believe, we have recently shown the existence of a p53-MDMX feedback loop, 
which is important for dampening the p53-response at later phases after genotoxic stress. 
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Introduction 
 
The tumor suppressor protein p53 is maintaining genome integrity following stress signals 
by either inducing a cell cycle arrest, allowing a complete check-up of the genome before 
resuming DNA replication, inducing senescence, or by stimulating apoptosis when the cell 
is beyond rescue [1]. In addition, p53 has been shown to directly affect DNA repair by 
modulating expression of number of DNA repair genes [2]. During tumor development, 
inhibition of angiogenesis is part of the tumor suppressor function of p53 [3]. In recent 
years, it has been shown that p53 also affects the metabolic switch which occurs in many 
tumors, in which energy is obtained by glycolysis rather than via oxidative phosphorylation 
[4]. p53 is activated by a plethora of stimuli, including DNA damage, hypoxia and 
oncogene activation, the final outcome of the activation being very dependent on the 
strength and type of the stimulus and the type of targeted cell.  
Whatever stimulus used to activate p53, it has become clear that for full, but controlled p53 
activation, a tight control of activity and levels of the main p53 inhibitors, MDM2 and 
MDMX is necessary [8] [9]. Various mouse models provide the best evidence regarding the 
importance of MDM2 and MDMX in controlling p53 activity under normal conditions. 
Loss of either MDM2 or MDMX expression leads to embryonal lethality, which is rescued 
by simultaneous loss of p53. Tissue-specific deletion of either the mdm2 gene or the mdmx 
gene showed differences between cell types for their dependency on MDM2 and MDMX to 
keep p53 in check. These mouse models have recently been discussed in two excellent 
reviews [9] [10]. 
 
The MDMX and MDM2 proteins have a similar structural organization (Figure 1). 
MDM2 and MDMX bind via their N-terminal hydrophobic region to a short alpha-helical 
stretch within the p53 N-terminus [11]; this N-terminal region is best conserved between 
the two proteins. Other conserved structures include the C-terminal RING finger domain, a 
Zn-finger and a central acidic region. The RING finger domains of MDMX and MDM2 are 
involved in their homo- and hetero-multimerization [12]. MDM2 has convincingly been 
shown to form both homo-oligomers and hetero-oligomers with MDMX. In contrast, no 
significant homo-oligomerization of MDMX could be found. This deficiency could have 
strong implications for the function of MDMX (see below).  
MDM2 is an E3 ubiquitin ligase that targets p53 for ubiquitination and degradation. 
Essential for p53 ubiquitination are both the MDM2 C-terminal region including the RING 
finger and the acidic domain. Corresponding regions of MDMX cannot fulfill this function 
[13-14]. MDM2-mediated mono-ubiquitination of p53 leads to nuclear export, thereby 
inhibiting the p53’s function as a transcription activator.  
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Figure 1. Schematic representation of MDMX protein structure in comparison with MDM2. 
Most indicated protein modification sites and protein-protein interactions shown are discussed in the text. 
Modifications of MDMX by sumoylation (K254, K379) have not yet shown to affect function or regulation of 
MDMX [5] . Phosphorylation of S298 stimulates the association of MDMX to p53 [6], and phosphorylation of 
S96 has been reported to affect the regulation of subcellular localization of MDM2 [7]. 
 
 
Moreover, it has become evident that Mdm2-dependent mono-ubiquitination of p53 
promotes the localization of p53 to the mitochondria, where stress induced HAUSP-p53 
complexes result in non-ubiquitinated, apoptotically active p53 [15]. Low levels of Mdm2 
favor mono-ubiquitination of p53, leading to this mitochondrial transcription-independent 
induction of apoptosis upon stress. In contrast, high levels of Mdm2 and/or in combination 
with p300/CBP, promote poly-ubiquitination, which results in proteasome-dependent 
degradation of p53 [16]; [17]. As mentioned, MDMX has no detectable ubiquitin-ligase 
itself, but has been proposed to inhibit p53 in a dual way. First, MDMX binds tightly to the 
N-terminal transcription activation domain of p53, in that way inhibiting its function as 
transcription activator [18]. Binding of MDMX to this part of p53 prevents the interaction 
of p300, which results in reduced acetylation of p53 which is involved in activation of p53 
[19-20]. Interestingly, p300 acetylates several lysines at the C-terminal region of p53 that 
are also targeted by Mdm2-mediated ubiquitination [17]. This might implicate that MDMX 
indirectly stimulates the MDM2-mediated ubiquitination by reducing the acetylation of 
those lysines. It should be noted that the importance of modifications of the C-terminal 
lysines for correct regulation of p53 stability and activity in vivo appears to be limited. 
Krummel et al. [21] showed that a knock-in mutant mouse in which the C-terminal lysines 
were replaced by arginines developed normally. Several assays showed no difference in 
regulation of wild-type p53 and p53-7KR. Only a minor increased activation of p53 in the 
thymus upon ionizing radiation was found, and, interestingly, p53-7KR MEFs could not 
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escape from senescence, in contrast to normal MEFs, indicating an increased activity of 
p53-7KR. The difficulty with interpretation of the results is that one cannot distinguish 
between the functions of the various possible modifications on the lysines (ubiquitination, 
sumoylation, neddylation, methylation, acetylation). It could well be that a certain 
modification on one lysine counteracts the effect of a different modification on a nearby 
lysine. In Mdmx-deficient MEFs we have seen increased acetylation of the one analyzed 
lysine in p53, K379. A full proteomic/mass spec approach would be interesting to analyze 
the ratio of various lysine modifications at the p53 C-terminus, and the effect of different 
MDMX expression levels on that ratio. 
What has become quite clear is that the ratio between the levels of MDM2/MDMX strongly 
determines the outcome on p53 stability. A relative high level of MDMX might compete 
p53 away from MDM2, leading to p53 stabilization [22]. In addition, as mentioned above, 
MDM2 and MDMX interact via their respective C-terminal RING finger domains, and it 
has been proposed that under non-stress conditions the MDM2/MDMX heterodimer 
functions as a more active ubiquitin ligase via providing an extended interaction motif with 
the E2 protein [23-25]. One might argue that only a dimer/oligomer of MDM2/MDMX 
RING fingers can bind the E2; since MDMX cannot homo-dimerize, MDMX on its own is 
defective as a ubiquitin ligase. This might certainly be true, but is not the whole explanation 
since it has been shown that just replacing the MDMX RING with an MDM2 RING cannot 
rescue the ubiquitin-ligase activity of MDMX [13-14].  
In this review we will focus on the regulation of MDMX expression upon various forms of 
stress. In most cases, a downregulation of MDMX protein is observed, which is needed for 
full p53 activation. On the other hand, under certain lethal conditions, a positive role for 
MDMX in p53-induced apoptosis has been found. These various and apparently 
contradictory results will be discussed. This includes the recently discovered p53-MDMX 
feedback loop, which affects the outcome of genotoxic insults in cells.  
 
MDMX regulation upon genotoxic stress 
 
Inactivation of MDMX at the protein level 
Interestingly, initial reports indicated that MDMX levels were not affected by DNA damage 
or differentiation or during cell growth [18, 26]. These wrong conclusions were caused by 
the absence of high-affinity antibodies and by our limited insight into the ways MDMX 
mRNA levels were regulated. The first to notice that DNA damage influences MDMX were 
Jiandong Chen and co-workers. They observed that DNA damage induces the nuclear 
translocation of exogenously expressed MDMX, but an effect on MDMX protein levels 
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was not discovered [27]. Although it had been reported that MDMX could be degraded by a 
proteasomedependent mechanism, which is enhanced by p53- and Adriamycin-induced 
caspase- dependent cleavage of MDMX [28], only a year later it was recognized that 
MDMX is a target of the ubiquitin-ligase activity of MDM2, and that endogenous MDMX 
protein is degraded upon DNA damage, in an MDM2-dependent fashion [29-31]. 
Importantly, overexpression of MDMX prevented p53 stabilization and activation [31]. 
Notably, in these studies no effect on the total amount of MDMX mRNA by ionizing 
radiation (10 Gy) was observed. Others and we subsequently showed that the MDM2-
mediated degradation of MDMX is strongly stimulated upon ATM-dependent 
phosphorylations on three serine residues, S342, S367 and S403 [32-34]. These 
phosphorylations have multiple effects, including the temporal nuclear accumulation of 
MDMX in a 14-3-3 dependent manner [34-36]. 
Increased association of MDM2 with MDMX upon phosphorylation of the latter has been 
suggested [32] as an explanation for the increased ubiquitination and degradation of 
MDMX. Alternatively, we have shown that upon ATM-dependent MDMX phosphorylation 
the interaction with the deubiquitinase HAUSP is strongly decreased, and that HAUSP 
interaction/expression is needed to maintain endogenous MDMX levels [35, 37]. Whether 
the observed increased interaction with 14-3-3 proteins and the decreased interaction with 
HAUSP are causally related has not been proven. Interestingly, recently the interaction 
motifs for HAUSP on human MDMX have been mapped. It was found that both an N-
terminal motif (8AQCS11) and more C-terminal motif (398AHSS401) in MDMX can interact 
with HAUSP [38]. The latter is very close to the S403, which is directly phosphorylated by 
ATM. Although not tested for this particular motif, it was found that phosphorylation of a 
serine residue two positions C-terminal of the core motif could strongly inhibit the 
interaction with HAUSP as assayed by peptide arrays. So, possibly both the direct 
phosphorylation event on S403, and the interaction of 14-3-3 around phosphorylated S342 
and S367, are involved in decreasing the HAUSP/MDMX interaction. 
 
Although one of the HAUSP interaction motifs in MDM2 is also close to the 
phosphorylation targets Y394 and S395, these phosphorylation events do not appear to 
affect the interaction with HAUSP [38]. Even though MDM2 lacks classic consensus sites 
for interaction, 14-3-3 proteins have also been shown to bind MDM2. Two sites have been 
mapped; one within the middle domain of MDM2, dependent on phosphorylation by Pim1-
kinase on S166 and S186 [39]. However, this event appears to stabilize MDM2. On the 
other hand, 14-3-3σ was shown to interact with the RING finger domain of MDM2, in a 
phosphorylation-dependent manner, and this interaction enhanced MDM2 ubiquitination 
and degradation [40]. 
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Unfortunately, the involved phosphorylation events (target sites, signaling cascade) have 
not been investigated, but the 14-3-3σ interaction domain was found rather far downstream 
of S395, which is needed for the temporarily destabilization of MDM2 upon ionizing 
radiation [41], so a causal relation is not obvious. In addition, whether the observed effects 
on MDM2 stability are dependent on this specific isoform of 14-3-3 has not been 
extensively investigated. 
 
The above reported regulation of MDMX protein levels via ATM/Chk2 phosphorylations 
and 14-3-3/HAUSP interactions were all upon treatment of cells with IR or IR-mimetic 
NCS (neocarzinostatin). Surprisingly, UV-C induced DNA damage also increases 
phosphorylation of MDMX/Ser367 in a Chk1-dependent manner, but in this case the 
increased interaction with 14-3-3 results in cytoplasmic sequestering of MDMX [42]. This 
manner of MDMX inactivation also turned out to be important for a full p53-stabilization 
upon DNA damage. Unfortunately, the authors did not investigate total levels of 
endogenous MDMX after longer time-points after UV-C irradiation; it is not excluded that 
the observed change in localization, seen three hours after UV-C, is a first step in the 
inactivation of the MDMX protein, followed by a total disappearance of full length MDMX 
protein either via proteasomal degradation or via alternative splicing of the MDMX pre-
mRNA (see below). The physiological relevance of the UV-C mediated responses is 
questionable, since humans are not exposed significantly to UV-C. The use of UV-A or 
UV-B irradiation would have been better in that respect. 
A recent elegant study with the use of a mouse knock-in model has shown the importance 
of the S342, S367 and S403 MDMX phosphorylations, not only for a DNA damage 
response, but also in the regulation of tumor suppression by p53 [43]. As could be 
extrapolated from the cell culture studies, thymocytes or MEFs derived from the 3SA 
mutant mice show decreased degradation of MDMX upon ionizing radiation or 
neocarzinostatin treatment, and a concomitant reduced p53 stabilization and activation. 
More striking is the observation that crossing the 3SA mutant mice with Eμ-Myc knock-in 
transgenic mice strongly decreased the latency period for tumor formation. In the 
developing tumors, no selection for p53 mutation was found in the 3SA mice, indicating 
that the expression of the mutant, degradation resistant MDMX is sufficient to inhibit p53's 
tumor suppressor function. Although the involvement of other mechanisms cannot be 
excluded, it was found that the overexpression of the Myc transgene did result in activation 
of the double-strand DNA break DNA damage response, which could explain the 
observation that prevention of DNA damage-associated phosphorylations of MDMX 
impact on the tumor development [43]. It should be noted that it is not excluded that other, 
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yet undefined, kinases are involved in the phosphorylation of MDMX which can be 
activated by Myc overexpression. 
In addition to the serine phosphorylations mentioned above, also tyrosine phosphorylation 
of MDMX upon imposing double-strand DNA breaks has been reported [44]. Tyrosine 55 
and tyrosine 99 were identified as targets of the c-Abl tyrosine kinase. Phosphorylations on 
these sites increased upon DNA damage. Interestingly, Y99 phosphorylation was found to 
inhibit the p53/MDMX interaction, which was supported by structural modeling. Function 
of Y55 phosphorylation is not yet known, but appeared to be dependent on Y99 
phosphorylation and the authors suggest a possible role for Y55 phosphorylation in the 
recovery phase of p53 activation. These results indicate that double-strand DNA breaks not 
only targets MDMX to activate p53 via the ATM/Chk2 pathway to reduce MDMX levels, 
but also via a very quick pathway, c-Abl mediated phosphorylation that inhibits the 
MDMX/p53 interaction. 
 
Inactivation of MDMX at the post-transcriptional mRNA level 
Extensive alternative mRNA splicing of mdm2 has been observed, especially in tumor cells 
[45]. In addition, existence of some splicing variants of mdmx has also been reported, 
mainly in tumors/tumor-derived cell lines (Reviewed recently by [46]). The so far identified 
mdmx mRNA variants obtained by alternative splicing are depicted in figure 2. Lozano and 
colleagues investigated whether genotoxic stresses would also affect the splicing pattern of 
mdm2 and mdmx [47]. It was observed that mdm2 showed alternative splicing upon 
treatment with rather high doses of UV-C or cisplatin, but IR did not affect the splicing 
pattern. Similarly, mdmx alternative splicing was observed upon 30 or 50 J/m2 UV-C, but 
not with 10 J/m2. Unfortunately, the effect of cisplatin treatment on mdmx mRNA splicing 
as not tested in this study. What is missing from these studies is a clear quantification of the 
levels of the alternative spliced mRNAs compared to the normal spliced mRNA. Even 
better would have been to investigate whether the putatively produced alternative protein 
products are indeed synthesized endogenously. For MDMX that might be difficult, because 
only few high quality antibodies are available, but for MDM2 it could have been 
performed. Possible functions of the protein products of splicing variants have been 
investigated almost only by strong overexpression, which might not reflect the 
physiologically relevant situation. Therefore, no conclusions can be drawn regarding a 
physiological function of the alternative splicing after these high levels of DNA damage. 
The authors note that they also detect low levels of another mdmx splicing variant, mdmx-S 
[47]. This splicing variant, a result of exon 6 skipping, was first described by Rallapalli and 
colleagues [48]. The alternative splicing was mainly found in some cancer cell lines, and 
could be increased in non-transformed cells upon serum-stimulation. The mdmx-S mRNA 
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encodes essentially only the p53 binding domain, and a number of unique C-terminal amino 
acids (Figure 2). In overexpression studies the MDMX-S product was found to be a 
stronger inhibitor of p53 activity, most likely because this short protein localized into the 
nucleus much more efficiently than full length MDMX [49]. 
 
 
Figure 2. Schematic representation of the MDMX protein, the mdmx mRNA and the reported mdmx 
splicing variants. 
 
 
Importantly, in recent experiments we found that after exposure of normal human 
fibroblasts or MCF-7 cells to relatively low levels of UV-C (10 J/m2), splicing of mdmx 
mRNA is changed, but that preferentially the mdmx-S variant is expressed (Figure 3). This 
is a relative quick event in the human skin fibroblasts, and occurs somewhat slower in the 
MCF-7 cells. Under these conditions, the X-Alt1 and X-Alt2 splice variants as described by 
Chandler et al. (2006) could not be detected. In addition, we found that cisplatin (30 μM) 
strongly induced the switch in ratio between full-length mdmx- and mdmx-S mRNAs in the 
breast carcinoma MPE600 cell line (Figure 3). Similar results were obtained in other tumor 
cell lines, such as U2OS, upon treatment with comparable concentrations cisplatin or with 
20 μM doxorubicin (data not shown). 
At the moment it is not known via which mechanism alternative splicing of mdmx is 
induced upon genotoxic stress. From literature a few mechanisms can be proposed. First, it 
has been shown that upon stress the subcellular localization of proteins involved in splice 
site selection is affected, like the hSlu7 protein (3’ site selection) and the hnRNP A1 
proteins (5’ site selection). Treatment of cells with osmotic shock or UV-C leads to 
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cytoplasmic localization of hnRNP A1, which affects the choice of 5' splice site [50]. Since 
with mdmx the change is the choice of the 3' splice site, involvement of hSlu7 is more likely 
[51]. However, in that publication it is mentioned that cisplatin treatment does not affect 
hSlu7 subcellular localization, so regulation of hSlu7 is most likely not the single 
mechanism by which the splicing of mdmx mRNA is altered. More recently it was reported 
that alternative splicing upon UV-C treatment is co-regulated with the inactivation of RNA 
polymerase II by inducing the hypophosphorylation of the CTD region [52]. Although such 
a mechanism can not be excluded at the moment in the alternative splicing of mdmx 
mRNA, changes in subcellular localization of certain factors involved in splicing are likely 
to play a role in the alternative splicing of mdmx mRNA. We have found that the treatment 
of several types of cells with Leptomycin B, which blocks nuclear export of proteins 
containing a Rev-like nuclear export signal, strongly increases alternative splicing of mdmx, 
leading to increased levels of mdmx-S mRNA and reduced mdmx full length mRNA (Figure 
3), accompanied with a reduced MDMX protein level (not shown). 
Even so, it is unclear what the biological importance of this alternative splicing is. It can be 
a means to reduce the amount of full length MDMX protein (which indeed is found after 
sublethal doses of UV-C [31, 53]), needed for full activation of p53. In this case, alternative 
splicing would lead to a loss-of-function. On the other side, it could be a mechanism to 
produce an MDMX protein form that is resistant to MDM2-mediated degradation, which 
could have a function in attenuating the p53 response at later time-points after the damage. 
In that case, it would be a gain-of-function. Putative biological functions of protein 
products of the mdmx splicing variants will be discussed later. 
 
 
Figure 3: The ratio between mdmx-S and mdmx-fl mRNA is increased by various types of DNA 
damage and by inhibition of nuclear export. RT-PCR analysis of RNAs extracted from various cell lines, 
treated for the indicated time periods with a variety of agents. The mdmx-specific PCR primers are located in exon 
3 and exon 8. The doses genotoxic/drug treatments used: UV-C: 15 J/m2; cisplatin: 30 μM; LMB (Leptomycin B): 
10 nM; Eto (Etoposide): 20 μM; Nutlin-3: 10 μM. 
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Markey and Berberich [54] have recently uncovered another mechanism leading to 
reduction of MDMX protein levels upon genotoxic agents. They found that exposing cells 
to doxorubicin (0.5 μg/ml; which is ~ 0.85 μM) leads to a strong reduction in the total 
mdmx mRNA levels; this effect was found to be fully p53-independent. Similarly, cisplatin 
reduces mdmx mRNA levels in doses varying from 25 to 100 μM, on various cell lines, 
independent of their p53 status. In addition, the authors show that the  decrease of MDMX 
protein levels after doxorubicin treatment could not efficiently be rescued by proteasome-
inhibition or knock-down of p53 and MDM2, when measured 24hrs after start of treatment. 
It would have been nice if the authors would have shown a time-course of doxorubicin-
treatment and analyzed both MDMX protein and mRNA. It could well be that initially 
degradation of the MDMX protein occurs upon the activation of the DNA damage signaling 
cascade, and that the reduced mRNA level is a later effect. These authors also investigated 
the alternative splicing of mdmx mRNA upon doxorubicin treatment. The remarkable 
observation here is that for this experiment they use a 100 μM concentration of 
doxorubicin, which is more than 100-fold higher than used in their initial experiment, so it 
cannot be compared to the earlier experiment. It could be, but that is not commented upon, 
that at the lower concentration of doxorubicin no significant alternative splicing can be 
found. Anyway, the authors do find some increase in X-Alt2 levels, but actually a small 
decrease in X-Alt1. Again, total levels of mdmx mRNA strongly decrease, indicating that X-
Alt2 only represents a very small fraction of the total mdmx mRNA. Interestingly, the 
decrease in mdmx mRNA levels is caused by decreased stability of the mdmx mRNA. The 
authors suggest a putative involvement of microRNA miR-34a in this regulation of mdmx 
mRNA stability. This is interesting in the view of the earlier observation that transcription 
of the miR34 family members is upregulated upon p53 activation, which has been shown to 
be important for a full p53 response upon DNA damage [55-56]. However, the regulation 
of miR-34a by p53 does not explain the p53 independency of the mdmx mRNA 
destabilization upon DNA damage. Unfortunately, it was not addressed in this study 
whether the decrease in mdmx mRNA after doxorubicin or cisplatin treatment is important 
for the biological outcome of the treatment. So, the physiological importance of the 
observed mdmx mRNA reduction still has to be investigated. 
 
A pro-apoptotic function of MDMX upon lethal doses of stress 
In all the experiments presented above, the idea was that a decrease in MDMX expression 
is needed to get a full-blown p53-response upon DNA damage. And indeed, in most cases a 
decrease in MDMX levels is observed and some experiments have shown that prevention of 
that MDMX degradation is inhibiting the p53 response [31, 35]. However, these 
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experiments were all done with a sub-lethal dose of IR or treatment with IR-mimetic agents 
like NCS. 
The group of Fabiola Moretti has obtained results that appear to be in conflict with what 
has been discussed above. In an initial report it was presented that in an (inducible) 
overexpression system high levels of MDMX actually stimulate doxorubicin (adriamycin)-
induced apoptosis [57]. This correlated with an increased induction of Bax transcription, 
while p21WAF1 was induced similarly in control- and MDMX-overexpressing cells, 
suggesting that high MDMX expression facilitated p53-mediated induction of pro-apoptotic 
genes specifically. These experiments were all performed with the use of non-transformed 
mouse or human cells, with doxorubicin as the genotoxic agent. The main drawback of this 
study is that a pro-apoptotic function of endogenous levels of MDMX protein was not 
investigated. Furthermore, it could be that MDMX has a different function in 
untransformed versus tumor cells upon adriamycin-treatment. In this respect it is of interest 
to note that in the colorectal tumor cell line HCT116 an active p53 seems to inhibit 
adriamycin-induced apoptosis [58], so a pro- or anti-apoptotic function of MDMX could 
very well be strongly cell type specific. 
 
In a follow-up study the authors made the very intriguing observation that a fraction of 
MDMX is localized to the mitochondria, and that upon lethal stress MDMX could function 
as an anchor for S46-phosphorylated p53, leading to transcription-independent apoptosis 
[53]. Unfortunately, the genotoxic agents used were now UV-C and cisplatin, which makes 
comparison with the earlier publication difficult. Strikingly, it was found that low levels of 
UV-C irradiation did reduce MDMX protein levels in MCF-7 cells, but that high, lethal 
doses (40 J/m2) of UV-C did not or much less. At these high doses, reduced levels of 
MDM2 were found, fitting with earlier reports that lethal doses of genotoxic agents can 
inhibit mdm2 transcription [59-60], partly by activation of HIPK2 [61, 62]. The results also 
lead to two tentative conclusions. First, that the observed alternative splicing of mdmx 
mRNA after high UV-C doses in MCF-7 cells [47] would not lead to a reduction in full 
length MDMX protein. Second, that under these conditions the earlier reported 
downregulation of mdmx mRNA levels upon genotoxic stress [54], admittedly a different 
type, is not occurring. Most strikingly in this study is the observation that reducing MDMX 
levels by siRNA did decrease the induction of apoptosis upon UV-C irradiation. A similar 
result was obtained upon treatment of control- and MDMX-knockdown MCF-7 cells with 
α-amanitin, which blocks polymerase II transcription but is reported to induce a p53-
dependent apoptosis strictly by stimulating translocation of p53 to the mitochondria. 
Similarly, reducing MDMX levels in A2780 cells partly prevents cisplatin-induced 
apoptosis (20 μM cisplatin). This concentration of cisplatin did not induce significant 
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alternative splicing of mdm2 mRNA in MCF-7 or U2OS cells [47]. The effects on mdmx 
mRNA were not investigated in this study, but a similar dose of cisplatin (25 μM) caused a 
small upregulation of mdmx mRNA in MCF-7, but already a downregulation in some other 
cell lines [54]. We found recently in a few osteosarcoma cell lines that 20 μM cisplatin 
reduces the total levels of mdmx mRNA, and increases the mdmx-S: mdmx-FL ratio, 
independent of the p53 status (Lenos et al., manuscript in preparation). 
 
It is difficult to reconcile the data from Moretti and colleagues with the earlier presented 
data. However, there are a number of points to keep in mind. The data obtained with 
ionizing radiation or IR-mimetic usually did not induce a high level of apoptosis, but 
mainly a cell cycle arrest. When UV-C was used, it was at relative low doses (5 or 10 J/m2), 
which might give some apoptosis induction, but not very high. The alternative splices as 
described by Chandler et al. (2006) [47] were only seen at rather high doses of UV-C or 
cisplatin; these are in the same range as Moretti and colleagues used, but Chandler et al. did 
not investigate effects on protein levels. What can be noticed from that study is that while 
the dose of UV-C resulted in almost complete alternative splicing of mdm2 mRNA (full 
length is hardly detectable anymore), the main mdmx mRNA expressed upon treatment with 
50 J/m2 UV-C is still the full length mRNA. So, it is possible that under these ruthless 
conditions MDMX protein is still expressed. 
What we do find somewhat surprising, though, is that apparently the induction of apoptosis 
by 40 J/m2 is largely dependent upon the targeting of p53 into the mitochondria. In several 
cellular systems it has been reported that UV-C (and cisplatin) can induce apoptosis in p53-
null or p53-mutant cells [52, 63-65], indicating that wild-type p53 status is not a universal 
essential factor for UV-C or cisplatin-induced apoptosis. It will be interesting to see 
whether modulation of MDMX levels in p53-deficient cells also affects the UV-C or 
cisplatin-induced apoptosis. 
 
In an attempt to understand and reconcile the various and sometimes contradicting results, a 
very well structured study should be performed in which one or two wild-type p53 
expressing cell lines, if possible with their p53-deficient counterparts, were treated with 
various types of stress-inducing agents, mainly genotoxic agents like doxorubicin, cisplatin, 
IR and UV-C irradiation, but also with a Polymerase-II transcription inhibitor like α-
amanitin. Cells should be extensively analyzed at early and late time-points for expression 
of relevant genes (p53, MDM2, MDMX, p53-targets) at protein and mRNA level 
(including analyses of splicing variants) and for the biological outcome of the treatment. 
The latter can be done primarily by FACS analyses to determine DNA profile (PI staining), 
apoptosis (Annexin V staining), and DNA replication (BrdU incorporation). The 
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importance of MDMX regulation can be determined by using MDMX knockdown 
derivatives of the used cell lines. Such a study should be able to provide the answers to 
several questions regarding the regulation of MDMX by the various agents, and the 
importance of that for the biological response. 
 
Role of MDMX in the ribosomal stress response: essential part of the 
DNA damage response? 
The last years a strong link between nucleolar- and ribosomal stress and p53 activation has 
been established. Very importantly, Rubbi and Milner showed that disturbance of nucleolar 
integrity is important for the DNA damage response [66]. As such, they already showed 
that the DNA damage response and ribosomal stress are causally linked. Several groups 
subsequently showed that upon nucleolar disruption, ribosomal proteins are released, and 
several of those interact with MDM2 and prevent the MDM2-mediated degradation of p53 
(recently reviewed by [67-68]). Very striking, none of the ribosomal proteins shown to 
interact with MDM2 interact with MDMX, suggesting a selective targeting by ribosomal 
proteins [69]. However, that does not imply that MDMX is not important for the ribosomal 
stress response. Indeed, these researchers show that upon treatment of cells with 
Actinomycin D or 5-FU, at concentrations that are reported not to induce a significant DNA 
damage response but only to give ribosomal stress, MDMX levels are downregulated.  
Importantly, that downregulation is needed for full p53 activation. The MDMX degradation 
is MDM2-dependent, but is not associated with increased phosphorylation of 
MDMXSerine367, so is distinct from the ATM/Chk2-stimulated MDMX degradation. 
Interestingly, the treatment with these compounds leads to release of L11 protein from the 
nucleoli, which binds MDM2 and inhibits MDM2-mediated degradation of p53, but 
stimulates the MDMX ubiquitination by MDM2 [69]. MDMX overexpressing cells showed 
an increased resistance to apoptosis induction by 5-FU, and indeed MDMX also inhibited 
the growth-suppressing effects of 5-FU on xenografts of HCT116 cells. Also in this case 
words of caution are needed. In the model tested, the HCT116 cells, the 5-FU effects are 
largely dependent to wild-type p53 function, as shown earlier [58]. However, other studies 
indicate that the effects of 5-FU on colorectal tumor cells are only very limited dependent 
on p53 status, and then only at really low concentrations [70]. Furthermore, in a small panel 
of 4 breast cancer cell lines, all expressing wild-type p53 and sensitive to Nutlin-3, only 
two showed a partial p53- dependence on growth inhibition by 5-FU, while one cell line 
actually is sensitized for 5-FU by reduced p53 levels [71]. The differential effects can 
possibly in part be explained by a difference in pRB status, which seems to dictate the 
dependence of 5-FU responsiveness on wild-type p53 status [72]. Therefore, it would be of 
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importance to investigate whether in other settings (e.g. p53 proficient, but pRB-deficient) 
MDMX levels also have an impact on 5-FU sensitivity. 
 
A recent study from the Prives' lab showed another crosstalk between ribosomal proteins 
and MDM2/MDMX regulation of p53 [73]. They identified the small ribosomal subunit 
protein S7 as an MDM2-interacting protein, which can inhibit the MDM2-mediated 
degradation of p53. Interestingly, they found that S7 could only perform its function 
efficiently in the presence of MDMX. A putative involvement of S7 in MDM2-mediated 
degradation of MDMX was not investigated. A striking observation of these investigators 
was also that knockdown of either the ribosomal protein L11 or S7 attenuated the p53 
activation not only by agents inducing ribosomal stress, but also DNA damaging agents like 
doxorubicin and neocarzinostatin. These data confirm the earlier mentioned observations by 
Rubbi and Milner, who already showed that DNA damage only affects p53 stability when it 
is causing nucleolar disruption [66]. 
 
Alternative splicing of MDMX mRNA: what's its use? 
At the moment 6 different splicing variants of MDMX have been described, which are 
schematically depicted in figure 2. As mentioned before, the first reported splicing variant 
is the mdmx-S mRNA, expression of which seemed to correlate with transformed cells and 
with normal cells stimulated to grow after serum-stimulation [48]. This was attributed to 
the fact that MDMX-S protein, which essentially comprises only the p53-binding domain 
(amino acids 1-114), and 26 unique C-terminal amino acids, is a stronger inhibitor of p53 as 
assayed by overexpression studies [49]. What is important to note is that the authors denote 
a protein of about 32 kDa in COS cells as the endogenous MDMX-S protein, which is 
significantly larger than the predicted molecular weight of approximately 16 kDa. The 
authors propose that this shift is caused by post-translational modification of the MDMX-S 
protein, but the type of modification was not determined. Strikingly, in vitro translation of 
the mdmx-S mRNA yielded also the 32 kDa protein, and a protein of about 17 kDa, which 
could represent the 'real' MDMX-S protein. We have recently obtained evidence that the 32 
kDa protein is most likely not representing the true MDMX-S protein. Transfection of an 
MDMX-S expression vector, encompassing the total MDMX coding region but just lacking 
exon 6, with an N-terminal HA-tag, results in expression of a protein around 24 kDa 
detected with anti-HA antibody (Figure 4). Expression level of this protein is much lower 
than that of full length HA-MDMX protein upon transfection of same amount of plasmid 
DNA. In addition, smaller proteins around 18 kDa and 14 kDa are found, which are even 
lower expressed. However, we also made an expression vector in which we truncated the 
mdmx cDNA at an XbaI restriction site, just downstream of the predicted stop codon of 
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MDMX-S protein in exon 7. So, this construct theoretically has the same coding potential. 
When this construct is expressed, only the smaller proteins of about 18 and 14kDa can be 
detected with anti-HA, again at low levels compared to full length HA-MDMX. 
Importantly, an antibody raised against the C-terminal unique amino acids of MDMX-S 
(Frank Bartel, personal communication) recognizes only the 18 kDa protein, identifying 
that as the real MDMX-S protein. The anti-MDMX antibody MX-82, with its epitope 
around amino acid 100 of MDMX, recognizes both the 18 kDa and 14 kDa protein, but not 
the 24 kDa protein. Two conclusions can be drawn from these results. First, the 24 kDa 
protein, possibly reflecting the 28 kDa protein mentioned by Rallapalli et al. [48], is most 
likely an artifact of the overexpression of the mdmx-S cDNA, because it appears to lack the 
MX-82 epitope which should be included in the MDMX-S protein. Secondly, the smaller 
protein of about 14 kDa lacks a C-terminal part of MDMX-S; again most likely some 
artifact of the overexpression. Importantly, when we use same expression plasmids for in 
vitro translation, we only detect the 18kDa protein, either with an anti-MDMX antibody 
(1328; raised against bacterially produced MDMX-S protein) or with anti-MDMX-S 
specific antibody (Figure 4). In addition, His6-tagged bacterially produced MDMX-S 
protein also has an apparent molecular weight of about 18 kDa. 
 
As mentioned, we find that the MDMX-S protein is much lower expressed compared to full 
length MDMX, in contrast to previous reports, but confirming our previous finding [20]. 
This is not a result of transfection efficiency, as can be seen by the expression of the 
transfection control (Figure 4), and similar results were obtained after transduction of cells 
with lentiviral expression vectors for MDMX-S (not shown). Furthermore, real-time Q-
PCR analysis showed that mdmx-S mRNA was even higher expressed than full length 
mdmx in these transfections (Figure 4B). Notably, treatment of transfected or transduced 
cells with proteasome inhibitor MG132 strongly increased the MDMX-S protein level, 
suggesting that the protein is very unstable. The levels of full length MDMX protein are 
only mildly increased upon MG132 treatment, while no effect is seen on the 24 kDa 
protein. Although we have no evidence at the moment, the rapid degradation of MDMX-S 
is possibly caused by the unfolded protein response (UPR); it is possible that this truncated 
MDMX protein is not properly folded, and as such is targeted via UPR for degradation. 
 
In addition, we have put much effort in detecting the endogenous MDMX-S protein, which 
we expected not to be such a problem because the recently developed monoclonal antibody, 
MX-82, has its epitope within the MDMX-S region. However, even in cell lines that 
express more mdmx-S mRNA compared to FL-mdmx mRNA, only full length MDMX 
protein can be detected (data not shown). Therefore, we propose that the induction of 
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mdmx-S mRNA is a means of reducing full-length MDMX levels, and not so much the 
generation of a new MDMX protein with important physiological functions. This is also 
illustrated in figure 3, where it can be seen that full length mdmx mRNA decreases as 
mdmx-S mRNA levels increase upon various stress conditions, whereas MDMX-S protein 
levels are still undetectable (not shown). 
 
 
Figure 4: Expression of Mdmx-S protein is much lower compared to full-length Mdmx and 
increased upon MG132 treatment, whereas mRNA levels are even higher in transfection 
studies. MCF7 cells were transfected with the indicated constructs (6-well plates; 1 μg of each construct/well; all 
well were also transfected with 250 ng of CMV-eGFP expression vector as transfection control). Twenty four hrs 
after transfection, the cells were either mock treated or treated with 20 μM MG132 for 7 hours. Cell lysates were 
analyzed by Western Blotting with the indicated antibodies (6658 = MDMX-S specific antibody) and extracted 
RNA was analyzed by quantitative real-time RT-PCR. 
 
 
The MDMX-A and MDMX-G variants were cloned from C33A cells; a somewhat 
exceptional cell line in that it expresses high levels of mutant p53 but also high levels of 
MDMX [30]. The corresponding MDMX proteins could not unequivocally be identified, no 
biological function has been determined, and whether this particular splicing event is 
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affected by any event, like stress conditions, is unknown. Therefore, these splicing variants 
will not be discussed here any further. 
 
As mentioned above, UV-C irradiation was found to lead to alternative splicing of MDMX, 
resulting in X-Alt1 and X-Alt2. Again, no functional studies have been performed, synthesis 
of predicted alternative MDMX proteins has not been investigated, and the ratio between 
the full length MDMX and the alternative splicing variants is not known. Therefore, a 
biological relevance of these splicing variants is still hypothetical. Moretti and colleagues 
are the only group to report functional experiments on an endogenously expressed MDMX 
splice variant [74]. They identified an mdmx mRNA variant, which they called mdmx211, 
in a thyroid tumor cell line (ARO), which has structural similarity to the X-Alt2 variant (see 
Figure 2). The protein products produced by these variants both lack the major part of the 
p53-binding domain, but still contain the C-terminal domain including the RING finger. A 
difference is that the X-Alt2 variant contains all exon 11 encoded amino acids, including the 
Zn-finger, while the mdmx211 variant lacks the N-terminal part of the exon 11. 
Overexpression experiments indicate that MDMX211 protein can stabilize MDM2, and 
prevents the degradation of p53 by MDM2, reflecting what has been published about full 
length MDMX protein [75]. Overexpression of MDMX211 increased colony formation of 
both p53-wt and p53-negative cells, indicating a p53-independent oncogenic role of 
MDMX211.  
Physiologically more relevant is the specific knockdown of this MDMX variant in ARO 
cells. Reducing levels of mdmx211 mRNA about 50% reduces the viability of this cell line, 
suggesting that both full length MDMX and the alternative MDMX211 form are 
contributing to the proliferation of these cells. However, the effects of specific knockdown 
of full length MDMX was not investigated in parallel, nor were relative levels of MDMX 
and MDMX211 proteins compared. Knockdown of MDMX211 did reduce MDM2 levels, 
but p53 levels or activity was not investigated, probably because these cells harbor a mutant 
p53. Again, these results are indicating a p53-independent oncogenic function of 
MDMX211. It is unfortunate that the authors have not studied the effect of specific 
knockdown of MDMX211 and full length MDMX in the FRO cell line, which appears to 
express similar levels of MDMX211, but contains a wild-type p53 gene [76]. The 
comparison between MDMX211 and FL-MDMX in this cell line would especially have 
been interesting in the experiment investigating the sensitivity to adriamycin-treatment.  
As mentioned earlier, Moretti and colleagues published that overexpression of full length 
MDMX could increase the sensitivity to adriamycin [57], so one would predict that 
knockdown of MDMX would increase the number of viable cells after adriamycin-
treatment. This would then indeed be opposite from the effects of knockdown of 
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MDMX211 in ARO cells, which increases the sensitivity to adriamycin in these thyroid 
tumor cells [74]. All in all, these results indicate that MDMX-211 has oncogenic potential, 
but whether that is increased compared to full length MDMX is not known at the moment. 
 
A number of studies investigated the expression levels of mdmx mRNA and of mdmx 
splicing variants in a panel of tumors. An analysis of malignant gliomas showed an 
amplified mdmx gene in a subset of tumors, none of which had p53 mutation. Interestingly, 
ratio between mdmx-S/mdmx-FL mRNA was found to be significantly higher in grade IV 
glioblastomas compared to grade III anaplastic gliomas or grade II gliomas [77]. Bartel and 
colleagues studied 66 soft tissue sarcomas for mdmx gene amplification and mdmx-
FL/mdmx-S mRNA expression [78]. They also found an association between tumor grade 
and overexpression of the mdmx-S splice form. Furthermore, from their analyses they 
concluded that the mdmx-S is a prognostic factor that predicts a poor outcome and a 
significantly shortened survival time for STS patients. No correlation between p53 status 
and mdmx-S expression was evident. 
Keeping in mind that our analyses so far suggest that increase in the ratio of mdmx-S 
mRNA compared to mdmx-FL mRNA is more a means to decrease full length mdmx, it 
could imply a tumor suppressor function for the MDMX protein, as is also suggested from 
the study of Moretti and colleagues [79]. They found that in 57 papillary thyroid tumors, 
which all contain a wild-type p53 gene, a decrease of full length MDMX is associated with 
tumor stage (stage 1 versus others), indicating downregulation of MDMX protein levels 
during tumor progression.  
An increased ratio mdmx-S:mdmx-FL (ratio ≥1.5) mRNA is found in a significant 
percentage of these thyroid tumors, but is not associated with any clinical data. Expression 
of the mdmx211 mRNA is also found in a subset of tumors, again not correlating with any 
patient data. Together, these data on the expression of mdmx-FL and mdmx mRNA splice 
variants in combination with other analyses of mdmx gene amplification, mdmx mRNA 
expression and MDMX protein analyses in tumors [80-83] strongly indicate that the 
function of MDMX in tumorigenesis is strongly dependent on the tumor type. Although in 
several tumor types MDMX appears to have an oncogene function, in others it seems to be 
anti-oncogenic. So far the study by Moretti and colleagues has been the only indicating a 
tumor suppressor role of MDMX in wild-type p53 expressing human tumors; unfortunately, 
the authors do not show any data on the levels of p53 in these tumors. Possibly, the p53 
gene is still wild-type but the expression of the p53 mRNA is silenced yielding an essential 
p53-null tumor. This is important in the light of other publications in mouse models 
indicating an anti-proliferative function of MDMX [84-85]. In the first study a growth 
suppressive function of mouse MDMX in a p21WAF1-deficient background was observed 
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[84]. In addition, in a p53-null background loss of MDMX increased the growth of mouse 
embryo fibroblasts and endogenous levels of MDMX suppressed tumorigenicity in p53-null 
mice [85]. In p53-null cells MDMX prevents the chromosome loss in hyperploid cells by 
inhibiting spindle multipolarity, in that way stimulating genome stability. Thus, under 
certain conditions MDMX indeed can function as an antioncogene. It would be interesting 
to investigate whether the reduced MDMX expression in later stage thyroid tumors [79] is 
correlated with low expression of p21WAF1 and/or aneuploidy.  
Recently two mouse models have been published that overexpress an mdmx transgene. 
Unfortunately, the mice show different phenotypes, which cannot easily be explained at the 
moment. In the first model, the generally overexpressed MDMX protein induces 
spontaneous tumor formation, mostly sarcomas, indicating an oncogene function of 
MDMX [86]. MDMX overexpression also strongly accelerated the tumor development of 
p53 heterozygous mice. Unfortunately, the effect of MDMX overexpression was not 
investigated in a p53-null background. In the light of the study of Jones and colleagues 
[85], showing that loss of MDMX in p53-null mice accelerates tumor formation, one might 
predict that overexpression of MDMX should reduce the rate of spontaneous tumor 
formation in the p53-null mice.  
Surprisingly, the second mdmx transgenic mouse model, in which a Myc-tagged MDMX is 
overexpressed, does not accelerate tumor formation, neither the spontaneous nor the Eμ-
Myc induced tumorigenesis [87]. Interestingly, only a heterozygous myc-mdmx transgenic 
mouse is viable; the homozygous transgenic mice die during embryogenesis in a p53-
independent manner, due to massive vascular maturation defects. An in-depth side-by-side 
comparison between the two mdmx transgenic mouse models could possibly explain the 
observed differences in phenotypes. 
In conclusion, most available data suggest that the human mdmx gene functions as an 
oncogene when overexpressed in tumors still expressing wild-type p53, which is supported 
by most mouse models. However, the question whether expression of MDMX or alternative 
MDMX proteins produced by alternative splicing has an oncoprotein or a tumor suppressor 
protein function in tumors lacking p53 (or p21) or expressing a mutant p53 has still to be 
answered. 
 
Transcriptional regulation of MDMX expression 
Up till recently it was only Jiandong Chen and colleagues who investigated regulation of 
transcription initiation of the mdmx gene [88]. They found that, like the mdm2 P2 promoter, 
mitogenic signaling stimulates transcription of the mdmx promoter. Especially two Ets-
family binding sites are important in that respect, and the MEK/ERK signaling pathway 
was found to be involved in the induction of MDMX promoter activity upon growth factor 
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stimulation. Expression of oncogenic K-Ras also activated the MDMX promoter. 
Importantly, in a panel of colon tumors they find an increasing MDMX expression with 
tumor stage, and this increased expression of MDMX does correlate to some extent with 
increased activity of the MAPK pathway as measured by phospho-ERK staining. It is 
intriguing to note that around 50% of later stage colon tumors stain positive for MDMX in 
this study, and that approximately 50% of colon tumors contain p53 mutations. It would 
have been interesting had the authors determined the p53 status of the samples they used for 
MDMX staining to investigate a putative -negative- correlation. 
These results indicate that enhanced mitogenic signaling in tumor cells which have lost 
p14ARF expression might inhibit the tumor suppressor activity of p53 by enhancing both 
mdmx and mdm2 gene transcription [88-89].  
 
More recently, a new twist to the p53/MDM2/MDMX interactions has been added. Wei and 
colleagues had reported that the intron 1 of the human mdmx gene contains a p53RE, as 
identified in a global p53 ChIP experiment [90]. Li et al. were the first to publish that this 
p53RE indeed mediates transcriptional activation of the mdmx gene upon activation of p53 
by Nutlin-3 [91]. Furthermore, they provide evidence that reducing MDMX levels in the 
TGCT (testicular germ cell tumor) cell line NT2/D1 induces low levels of apoptosis, but 
strongly sensitizes these cells for growth inhibition by Nutlin-3. However, this effect was 
not observed in other TGCT cell lines tested. The authors do suggest that in the NT2/D1 
cells MDMX is involved in a negative feedback loop, similar to MDM2. These studies do 
not distinguish between the importance of the constitutive mdmx transcription and the p53-
induced transcription. In collaboration with the groups of Jeremy Blaydes and Frank Bartel 
we also recently reported that the previous identified p53RE in the first intron of mdmx is 
directing p53-induced transcription of the mdmx gene [92]. In addition to the earlier 
publication we showed that the p53RE initiates transcription from an alternative promoter 
(mdmx P2), which includes an alternative first exon (named exon 1β) in the mdmx mRNA. 
This exon contains an in-frame upstream ATG relative to the canonical first ATG, which 
results in the synthesis of 18 extra N-terminal amino acids. It was found that the mdmx P2 
promoter can be induced in almost all cells tested that express wild-type p53 (only a few 
primary human cell cultures showed a very low or undetectable expression). Furthermore, 
every type of p53 activation (Nutlin-3, DNA damage, ribosomal stress, Leptomycin B, 
activation of p14ARF expression) increased transcription from the mdmx P2 promoter. 
Most importantly, the inclusion in the mdmx P2 mRNA of a unique exon provided us with 
the opportunity to investigate specifically the contribution of the p53-induced mdmx mRNA 
expression in the p53 response. Indeed, shRNA targeting sequences in the unique exon 1β 
increased the p53 response upon treatment of cells with Nutlin-3 or DNA damage 
Chapter 2 
- 38 - 
(etoposide) and enhanced the p53-induced growth inhibition. These results together 
strongly establish mdmx as a p53 target gene, involved in a negative feedback loop to 
attenuate the p53 response. 
 
Conclusions and future perspectives 
When the identification of the mdmx gene was presented in 1996 [18], the p53 field was not 
immediately impressed. The added value of MDMX to MDM2 could not be recognized. 
MDM2 was expected to be sufficient to keep p53 in check, and to regulate the p53 
response. However, the p53-dependent embryonal lethality of mdmx knockout mice 
established MDMX as an essential regulator of p53 activity. In more recent years it has 
become clear that during development MDM2 is the more general regulator of p53 activity. 
However, the intricate regulation of MDMX has been shown to be essential for a controlled 
p53 response upon various forms of stress, as much as MDM2 regulation. Although great 
insight into regulation of MDMX expression and activity has been obtained, much has still 
to be learned. How is MDMX degraded upon ribosomal stress, since DNA-damaged 
induced phosphorylations are not involved? How is the alternative splicing of MDMX upon 
certain types of genotoxic stress regulated? Do the various identified mdmx mRNAs encode 
proteins with important biological functions in the coordination of stress response or in 
tumorigenesis? Under which circumstances is MDMX acting as an oncogene, and when is 
it stimulating the p53 tumor suppressor response? The answers on these questions will be 
important for understanding the role of MDMX in tumorigenesis, and for obtaining more 
insight into the possibility to regard MDMX as a target for therapeutic intervention in 
cancer. 
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Abstract 
Upon exposure to DNA damage the p53 tumor suppressor is accumulated and activated to 
stall cellular growth. For this to occur, p53 must be relieved from its major inhibitors, 
Mdm2 (Hdm2 in humans) and Mdmx (Mdm4; Hdmx in humans). A key mechanism 
controlling this relief is the post-translational modifications of p53 and its inhibitors. We 
have previously demonstrated that the stress-activated tyrosine kinase, c-Abl, contributes to 
the relief of p53 from Hdm2. Because Hdmx is the major inhibitor of p53 activity, the 
additional possibility that c-Abl protects p53 through targetingHdmxwas explored in this 
study. c-Abl was found to interact with and to phosphorylate Hdmx. This phosphorylation 
was enhanced in response to DNA damage. Importantly, we mapped the sites of 
phosphorylation to the p53 binding domain of Hdmx. One of these phosphorylations, on 
tyrosine 99, inhibited Hdmx interaction with p53. This inhibition is consistent with the 
predicted role of this residue in the interaction with p53 based on the crystal structure of the 
interaction site. Our results show that c-Abl not only targets Hdm2, but also Hdmx, which 
together contribute to p53 activation in response to DNA damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The abbreviations used are:  
wt, wild type;  
HA, hemagglutinin;  
KD, kinasedefective;  
aa, amino acids;  
IP, immunoprecipitation;  
ATM, ataxia telangiectasia mutated;  
GFP, green fluorescent protein;  
BD, binding domain. 
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Introduction 
Tight regulation of the p53 protein is critical for tumor suppression, for a proper cellular 
response to stress, and for mouse development (1). P53 stability and activity are regulated 
by two major inhibitors, Mdm2 and Mdmx (Mdm4; Hdmx in humans), respectively. The 
importance of the Mdm genes as p53 regulators was best exemplified by the demonstration 
that elimination of p53 fully rescues mdm2 and mdmx null embryos from lethality (2). 
Mdm2 acts as the direct E3 ligase of p53, promoting it for proteasomal degradation and 
nuclear export (3). Unlike Mdm2, Mdmx lacks detectable ubiquitin E3 ligase activity and, 
hence, does not target p53 for degradation but, rather, inhibits p53 transcriptional activity 
by binding to its transactivation domain (for review, see Ref. 4). Down-regulation or 
mutations in Mdmx increase the induction of p53 target genes without a change in p53 
expression levels (4, 5). The importance of Mdmx as a regulator of p53 is further 
demonstrated by its link to cancer development. Hdmx is overexpressed or amplified in 10–
20% of human cancers including breast, stomach, colon, and lung cancers (for review, see 
Ref. 6) and in 65% of retinoblastomas (7). Interestingly, in papillary thyroid carcinomas 
Hdmx expression is down-regulated, although certain Hdmx variants with p53 inhibitory 
properties were abnormally expressed in these tumors (8). Importantly, overexpression of 
Mdmx correlates well with a normal status of p53, supporting the notion that this inhibitory 
pathway is sufficient to suppress p53 and, thus, negates the need for p53 mutation. Thus, 
abrogating Mdmx function may be an important approach for reactivating p53 in cancer 
cells (for review, see Ref. 2).  
Mdm2 and Mdmx form homo- and heterodimers through their RING domains (9, 10); the 
ratio of these forms affect their protein stability and the extent of p53 inhibition (4, 11). An 
important link between the two proteins has been reported under stress conditions. After 
DNA damage, Mdmx accumulates in the nucleus (11, 12) where it inhibits p53 activity (4, 
13), and it is subsequently degraded in an Mdm2-dependent manner (14–16). Mdmx 
degradation together with the self-degradation of Mdm2 contributes considerably to p53 
activation and stabilization upon stress (for review, see Ref. 17). An important mechanism 
leading to p53 activation in response to DNA damage involves post-translational 
modifications, which are mediated by several upstream positive regulators (for review, see 
Ref. 18). One such activator is the c-Abl non-receptor tyrosine kinase (19). c-Abl has been 
implicated in the cellular response to stress by promoting cell cycle arrest or apoptosis (20, 
21). c-Abl is critical for the accumulation of p53 in response to DNA damage (22). c-Abl 
activates p53 by neutralizing the inhibitory effects of Hdm2 (22–25). Given the important 
inhibitory role of Mdmx in p53 regulation and the link between c-Abl and Hdm2, we asked 
whether c-Abl also protects p53 through targeting Hdmx. We report here a physical and 
biochemical link between c-Abl and Hdmx. c-Abl interacts with and phosphorylates Hdmx. 
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These phosphorylations are enhanced in response to stress. Tyrosine phosphorylations of 
Hdmx were mapped to the p53 binding domain of Hdmx, and one of these 
phosphorylations inhibits p53 binding. Overall, our results reveal that Hdmx is a new target 
of c-Abl, which together with Hdm2 contributes to p53 activation in response to stress. 
 
Experimental Procedures 
Cell Lines, Transfection Assays, and Cell Treatments―H1299 lung adenocarcinoma cells, lacking 
p53 expression, were grown in RPMI 1640 medium supplemented with 10% fetal calf serum. 293 and 293T 
human embryo kidney epithelial cells, MCF-7 breast carcinoma cells, and mdm2/p53 double null (2KO) 
fibroblasts were cultivated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum. Cells 
were transfected by the calcium phosphate method as described previously (26). Transfections using 
polyethyleneimine (PEI; Sigma) were done by mixing DNA with PEI reagent in serum-free medium for 5 min. 1 
µl of polyethyleneimine (1 mg/ml) was used for 1 µg of DNA. The polyethyleneimine-DNA complex was applied 
to the cells for 5–7 h before the medium was replaced. Transfections with FuGENE 6 (Roche Applied Science) 
were performed in 9-cm dishes according to the manufacturer’s instructions. The FuGENE 6-DNA complex was 
applied to the cells for 24 h before the medium was replaced.Aconstant amount of plasmid DNA in each sample 
was maintained by supplementing with empty plasmid. Usually, cells were transfected with 5–8 µg of the 
indicated plasmid for a 9-cm plate and with 2–5 µg for a 5-cm plate. For measuring the cellular response to stress, 
cells were treated with 3mM H2O2 (Merck, Germany) together with 1mM sodium orthovanadate (Sigma) for the 
indicated times. To induce DNA damage, cells were treated with either 2–2.5 g/ml doxorubicin hydrochloride 
(Sigma) or 500 ng/ml neocarzinostatin (Sigma) in the dark. To inhibit proteasomal degradation, the proteasome 
inhibitor MG132 (Sigma) was added for 4 h. 
Plasmids, in Vitro Site-directed Mutagenesis, and Generation of Lentivirus―Expression 
plasmids used in this study were human wild-type (wt) p53 (pRC-CMV-p53), mouse wt non-tagged and HA-
tagged c-abl (pCMV-c-abl, type IV), mouse kinase-defective (KD) c-abl (pCMV-c-ablK290H, type IV) (24), p53-
responsive cyclin G-luciferase (26), and an empty vector (pCMV-Neo-BamHI). Hdmx vectors were pcDNA3.1 
human HA-hdmx, pcDNA3.1 human wt hdmx, HA-hdmx-C (amino acids (aa) 1–318 followed by 25 alternative 
aa), hdmx-D (aa 1–206 followed by 13 alternative aa), HA-hdmx-G (Δ27–124 aa). Hdmx deletion mutants were 
Myc-tagged hdmx ΔN (aa 101–490) and hdmx p53 binding domain (p53 BD)-His-Myc (aa 1–153). The Tyr to Phe 
substitutions within Hdmx were generated by using the QuikChange site-directed in vitro mutagenesis kit 
(Stratagene) on the full-length and the p53 BD hdmx forms. For the production of GFP-c-Abl lentivirus, the 
following vectors were used; GFP-c-Abl was cloned into SIN18.hEF1-WPRE vector using SmaI and XbaI sites, 
pCMV_R8.91-packaging construct, and pMD2.VSVG envelope construct. For the production of lentivirus these 
three vectors were co-transfected into HEK293T cells, and lentivirus was collected from the supernatants after 48 
h. For the production of si-3_UTR-Hdmx lentivirus (MISSION Library Sigma-Aldrich) the manufacturer’s 
instructions were followed.  
Antibodies―Anti-Hdmx antibodies used were: rabbit polyclonal sera p55, p56 (27), and 1328 (P. de Graaf and 
A. G. Jochemsen, unpublished data), mouse monoclonal antibodies 6B1A, 11F4D, and 12G11G (28), and mouse 
monoclonal MX-82 antibody (Sigma MX-82). Anti-c-Abl antibodies used were the rabbit polyclonal K-12 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and the monoclonal Abl-148 antibody (Sigma); the anti-
phospho-Hdmx antibodies were phospho-Tyr-55 (Sigma PH-MDMX-55) and phospho-Tyr-99 monoclonal 
antibodies (Sigma PH-MDMX-169) and anti-phospho-Ser-367 rabbit polyclonal antibody (29). Additional 
antibodies used were: anti-human p53 monoclonal antibodies PAb1801 and DO1; anti-p53 goat polyclonal 
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antibody (FL-393 Santa Cruz Biotechnology); anti-p53 rabbit polyclonal antibody (FL-393, Santa Cruz 
Biotechnology); anti-phospho-p53 Ser-20 antibody (Cell Signaling Technology, Inc., Danvers, MA); anti-Hdm2 
SMP14 and 2A9 monoclonal antibodies, anti-GFP (Roche Applied Science), anti-phosphotyrosine 4G10 (Upstate 
Biotechnology, Lake Placid, NY), anti-14-3-3 tau (BIOSOURCE, Camarillo, CA), horseradish peroxidase-
conjugated affinity-purified goat anti-mouse IgG (Jackson Immuno-Research Laboratories, Inc., West Grove, PA), 
and EnVision peroxidase anti-mouse or anti-rabbit IgG antibodies (DAKO Corp., Glostrup, Denmark).  
Immunoblotting, Immunoprecipitation, in Vivo Kinase Assay and Nickel Pulldown Assay― 
Western blot analysis and immunoprecipitation assay were performed as previously described (26), whereas the 
lysis buffer for immunoprecipitation consisted of 50 mM Tris, pH 8.0, 150–300 mM NaCl, 5 mM EDTA, 0.5% 
Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 4 mM NaF, and 1 mM sodium 
orthovanadate. Nickel pulldown and in vivo kinase assay were performed as described previously (24).  
Luciferase Assay―This assay was done essentially as previously described (24). 
Detection of Phosphorylated Tyr by Mass Spectrometry―Phosphorylated and non-phosphorylated 
Hdmx proteins were derived from in vivo kinase assay using wt or kinase-defective c-Abl. The proteins were 
digested using Asp N enzyme, and mass spectrometry was carried out with Qtof2 (Micromass, England) using 
nanospray attachment (30). Data analysis was done using the biolynx package (Micromass, England), and data 
base searches were performed with the Mascot package (Matrix Science). 
 
 
RESULTS 
Interaction between c-Abl and Hdmx 
To determine whether the protection of p53 by c-Abl involves relief from Hdmx, we 
examined a possible interaction between c-Abl and Hdmx proteins in cultured cells. 
HEK293 cells were transfected with expression plasmids for HA-Hdmx either alone or 
together with wt or a KD c-AblK290H mutant of c-Abl. Forty-eight hours post-transfection, 
cell extracts were subjected to immunoprecipitation (IP) using anti-c-Abl Abl-148 antibody 
followed by immunoblotting (IB) with anti-Hdmx antibodies. 
As shown in Fig. 1A, Hdmx was efficiently co-precipitated only in the presence of c-Abl, 
demonstrating an interaction between the two proteins in cultured cells. The interaction 
between Hdmx and the KD mutant of c-Abl appeared to be weaker. To further establish the 
interaction between Hdmx and c-Abl, we performed a reversal experiment where IP was 
done with anti-Hdmx 6B1A antibody and IB with anti-c-Abl antibody. Hdmx efficiently 
co-precipitated c-Abl (Fig. 1B). These results demonstrate an interaction between the two 
proteins in cultured cells. Next, we investigated whether endogenous Hdmx interacts with 
endogenous c-Abl. To answer this question, we performed co-immunoprecipitation 
experiments using MCF-7 cell line expressing relatively high endogenous Hdmx levels. c-
Abl was immunoprecipitated from cell extracts using anti-c-Abl K-12 antibody followed by 
immunoblotting with anti-Hdmx antibody. As shown in Fig. 1C, Hdmx protein was co-
immunoprecipitated by c-Abl, providing evidence for an interaction between the two 
endogenous proteins. 
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FIGURE 1. Hdmx interacts with c-Abl in vivo. A, B, E, and F, HEK293 cells were transfected with 
expression plasmids for c-abl or c-ablKD(K290H; panel A only) either alone or together with the indicated hdmx 
expressing plasmids. Forty-eight hours post-transfection cell extracts were subjected to IP analysis using the 
following antibodies: anti-c-Abl monoclonal ABL-148 antibody (A), anti-Hdmx 6B1A antibody (B), anti-c-Abl K-
12 polyclonal antibody (E and F). IP was followed by IB with anti-Hdmx antibody (MX-82) (A and F) or 6B1A 
(E) or with anti-c-Abl antibody (ABL-148) for B. c-Abl levels were monitored by blotting with anti-c-Abl 
antibody (ABL-148). C, MCF-7 cells were subjected to IP analysis as described for F. Note that shorter exposure 
for Hdmx is presented in input panel as compared with co-immunoprecipitation panel. D, schematic representation 
of the Hdmx deletion mutants used in this study. All the mutants were found to bind c-Abl. Amino acid 
composition of the mutants is indicated on the right; note that mutant C and D contains an additional 25 or 13 
residues, respectively. 
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Both c-Abl and Hdmx interact with p53 and Hdm2 (19). We, therefore, investigated 
whether the c-Abl/Hdmx interaction is mediated by p53 and/or Hdm2. To address this 
question, HEK293 cells were transfected with expression plasmids for c-Abl in combination 
with different Hdmx deletion mutants. First, we tested the involvement of p53 by using 
Hdmx-G, a product of an alternative splice variant that lacks amino acids 27–124 
encompassing the p53 binding domain of Hdmx (Ref. 15 and Fig. 1D). Twenty-four hours 
posttransfection cell extracts were subjected to immunoprecipitation assay. As shown in 
Fig. 1E, Hdmx-G (ΔN) bound efficiently to c-Abl, suggesting that p53 is not essential for c-
Abl-Hdmx interaction under these conditions. Next we investigated the contribution of 
Hdm2 to the interaction by using another Hdmx alternative splice variant, Hdmx-D, which 
lacks the C terminus (amino acids 207–490) including the Hdm2 binding region and 
contains an additional 13 alternative amino acids after amino acid 206 (Fig. 1D). As shown 
in Fig. 1F, Hdmx D (ΔC) efficiently co-precipitated with c-Abl, implying that the Hdm2 
binding domain is not critical for c-Abl-Hdmx interaction. To further define the interaction 
region of c-Abl within Hdmx, a series of additional deletion mutants of Hdmx (Fig. 1D) 
were tested using the same assay. All the Hdmx deletion mutants tested were able to bind c-
Abl (supplemental Fig. S1), implying that c-Abl may bind Hdmx at more than one site 
and/or that additional proteins are involved in the interaction with some of these mutants. 
 
c-Abl Phosphorylates Hdmx within the p53 Binding Domain 
Because c-Abl is a tyrosine kinase, we asked whether Hdmx is phosphorylated by c-Abl. 
There are nine Tyr residues within Hdmx, five of which are clustered within the p53 BD 
(Fig. 2A) and are conserved among mice, rat, and human (Fig. 2B). In view of the possible 
link to p53 regulation, we examined the ability of c-Abl to phosphorylate an Hdmx deletion 
mutant containing the N-terminal p53 BD (amino acids 1–153) in an in vivo kinase assay. 
HEK293 cells were transfected with expression plasmids for the Myc- and His-tagged 
hdmx p53 BD either alone or in combination with wt or c-Abl KD. Twenty-four hours post-
transfection Hdmx was isolated from cell extracts using nickel resin, and Tyr 
phosphorylation of Hdmx was monitored with anti-phosphotyrosine antibody. As shown in 
Fig. 2C, Tyr phosphorylation of Hdmx p53 BD was detected only in the presence of wt c-
Abl, supporting a role for c-Abl in Tyr phosphorylation of Hdmx within the p53 BD. 
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FIGURE 2. c-Abl-dependent 
tyrosine phosphorylation of Hdmx. 
A, schematic representation of the 
tyrosine residues in Hdmx. The cluster of 
the tyrosine residues within p53 binding 
domain of Hdmx is highlighted. B, 
alignment of the Mdmx amino acid 
sequence from rat, mouse, and human. 
The conserved tyrosine residues within 
Mdmx are highlighted. C, HEK293 cells 
were transfected with expression 
plasmids for c-abl or c-abl KD either 
alone or together with His- and Myc-
tagged hdmx p53 BD (binding domain; 
amino acids 1-153). Twenty-four hours 
post-transfection cells were harvested, 
and Hdmx p53 BD was isolated from cell 
extracts using nickel resin. 
Phosphorylation was detected with anti-
phosphotyrosine antibody (4G10), and 
Hdmx levels were monitored by blotting 
(IB) with anti-Myc antibody. The 
expression level of c-Abl was 
monitored with anti-c-Abl antibody 
(ABL-148). 
 
 
Tyr-99 and Tyr-55 Are the Major Sites within the p53 BD of Hdmx 
To identify the c-Abl Tyr phosphorylation site(s) within the p53 BD of Hdmx, we 
employed mass spectrometric analysis along with site-directed mutagenesis. Hdmx p53 BD 
was phosphorylated in vivo by c-Abl (Fig. 2C) and then subjected to mass spectrometry 
analysis. Tyr-55 was identified as a potential Tyr phosphorylation site (data not shown). 
Additionally, we generated substitution mutants from Tyr(Y) to Phe(F) for each Tyr residue 
in the p53 BD of Hdmx, either alone or in various combinations. The effect of these 
substitutions on Hdmx phosphorylation by c-Abl was measured in phosphorylation assays 
in vivo. HEK293 cells were transfected with expression plasmids for wt hdmx p53 BD or 
phosphorylation mutants together with wt c-Abl or c-Abl KD. Twenty-four hours 
posttransfection, Hdmx was precipitated, and Tyr phosphorylation analysis revealed that 
substitutions of Y99F and Y55F, but not the other Tyr residues within the p53 binding 
domain, reduced the extent of Hdmx phosphorylation (Fig. 3A and data not shown). Tyr 
phosphorylation was almost abolished in the Hdmx Y55F,Y99F double mutant (Fig. 3A), 
supporting the notion that Tyr-55 and Tyr-99 are the major c-Abl phosphorylation sites 
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within the p53 BD of Hdmx. Among these two sites, Y99F substitution had a greater effect 
on Hdmx phosphorylation (Fig. 3A); hence, it was assumed to be a more dominating site. 
To further verify the phosphorylation of Hdmx on Tyr-99 and Tyr-55, anti-phospho-
monoclonal antibodies were raised. To determine the specificity of these antibodies, 
HEK293 cells were transfected with expression plasmids for the Myc and His-tagged hdmx 
p53 BD in combination with wt c-Abl or c-Abl KD. Specific c-Abl-induced Hdmx 
phosphorylations on Tyr-55 and Tyr-99 were detected with the corresponding anti-phospho 
antibodies (Fig. 3B). A similar result was obtained when the experiment was repeated with 
full-length non-tagged wt Hdmx (Fig. 3C).  
 
 
 
FIGURE 3. c-Abl phosphorylates Hdmx on Tyr-99 and Tyr-55 in vivo. A, HEK293 cells were 
transfected with the indicated plasmids. Twenty-four hours later Hdmx p53 BD was isolated by nickel resin from 
cell extracts, and the protein complex was subjected to Western blotting (IB) using the indicated antibodies as 
described in Fig. 2C. B and C, HEK293 cells were transfected with the indicated plasmids. Twenty-four (B) or 
forty-eight (C) hours later cell extracts were analyzed by Western blotting using anti-phospho-Tyr-55 antibody and 
anti-phospho-Tyr-99 antibody. Total Hdmx levels were monitored by blotting with anti-Hdmx 1328 polyclonal 
antibody. The position of Tyr-55 and Tyr-99-phosphorylated Hdmx and total Hdmx is indicated. A dividing line in 
B indicates that lanes were merged from different parts of the same gel.  
 
 
Phospho-Tyr-99 Affects the Phosphorylation of Tyr-55 
Because the phosphorylation sites reside within the same domain of Hdmx, it was of 
interest to test a potential dependence between the two sites. To examine this possibility, 
HEK293 cells were transfected with expression plasmids for Myc and His-tagged wt hdmx 
p53 BD or phosphorylation mutants either alone or in combination with wt c-Abl or c-Abl 
KD. The phosphorylation of Tyr-99 was detected in wt Hdmx and the Y55F substitution 
mutant (Fig. 4A), suggesting that the Tyr-99 phosphorylation is independent of Tyr-55 
phosphorylation. Interestingly, the phosphorylation of Tyr-55 was reduced not only in the 
Y55F mutant but partially also in the Y99F mutant (Fig. 4B). A similar effect was observed 
with full-length non-tagged Hdmx (Fig. 4C). This suggests that phosphorylation on Tyr-99 
is required at least partially for an efficient phosphorylation of Tyr-55. An alternative 
explanation is that the Y99F substitution impairs the interaction between Hdmx and c-Abl. 
To test this possibility HEK293 cells were transfected with expression plasmids for c-Abl 
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either alone or together with Myc-His-tagged wt or Y99F hdmx p53 BD mutant. Hdmx was 
immunoprecipitated using anti-Myc antibody, and the amount of co-precipitated c-Abl was 
determined by IB using anti-c-Abl antibody (Fig. 4D). As shown in Fig. 4D, the Y99F 
substitution did not reduce the c-Abl-Hdmx interaction but, rather, increased it.  
 
 
 
FIGURE 4. Tyr-99 is required for the efficient phosphorylation of Tyr-55, and both tyrosine 
phosphorylations are independent of Ser-342 and Ser-367 phosphorylation. A-C, HEK293 cells 
were transfected with the indicated plasmids. Twenty-four (A and B) or forty-eight hours (C) later cell extracts 
were subjected to Western blotting using either anti-phospho-Tyr-55 antibody (B and C) or anti-phospho-Tyr-99 
antibody (A and C). Total Hdmx levels were monitored using anti-Hdmx 1328 polyclonal antibody. The position 
of Tyr-55 and Tyr-99-phosphorylated Hdmx and total Hdmx is indicated. Hdmx p53 BD mutant was described in 
Fig. 2C. D, HEK293 cells were transfected with the expression plasmid for c-abl alone or together with Myc and 
His-tagged hdmx p53 BD either wt or Y99F mutant. Twenty-four hours post-transfection Hdmx was 
immunoprecipitated using anti-Myc antibody. The level of the co-precipitated c-Abl was monitored by blotting 
with anti-c-Abl antibody (ABL-148). The expression level of the Hdmx was investigated by using anti-Myc 
antibody. E, HEK293-T cells were transfected with expression vectors for HA-tagged hdmx or hdmx-S342/367A or 
empty vector together with c-abl. Cells were either non-treated or treated with 3 mm H2O2 for 45 min together 
with tyrosine phosphatase inhibitor sodium orthovanadate (Na3VO4; 1 mm) for 5 h before harvest. Twenty-nine 
hours post-transfection cell extracts were subjected to IP with anti-HA rabbit polyclonal antibody.  
Immunoprecipitates were analyzed by Western blotting with anti-phospho-Tyr-55-Hdmx, anti-phospho-Y99-
Hdmx, and anti-Hdmx MX-82 to monitor total Hdmx levels. To show the absence of Ser-367 phosphorylation of 
the mutant, the same protein extracts were used in immunoprecipitation with anti-HA monoclonal antibody, and 
immunoprecipitates were analyzed on Western blot with anti-phospho-Ser-367-Hdmx or anti-Hdmx antibody 
(BL1258).  
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Interplay between c-Abl-mediated Phosphorylation of Hdmx and the DNA Damage-induced 
Hdmx Phosphorylation on Ser-342, Ser-367, and Ser-403 and 14-3-3 Binding 
It has been shown that Hdmx is independently phosphorylated on Ser-342, Ser-367, and 
Ser-403 in response to double strand breaks by ATM (ataxia telangiectasia mutated) or by 
its target Chk2 (29, 31). Each of these phosphorylations contributes to the increased 
ubiquitination and degradation of Hdmx afterDNAdamage, caused by dissociation of the 
herpes virus-associated ubiquitin-specific protease (HAUSP) from both Hdmx and Hdm2 
and promotion of nuclear accumulation of Hdmx (12, 32). Phosphorylation of Ser-342 and 
Ser-367 was shown to be essential for creating a binding site for several isoforms of the 14-
3-3 protein, leading to nuclear localization of Hdmx, and promoting the degradation of 
Hdmx (29, 33, 34). Because c-Abl is also a target for ATM-dependent phosphorylation 
after DNA damage, a possible interdependence between the serine and tyrosine 
phosphorylations on Hdmx was studied. Initially, we asked whether phosphorylation of 
Hdmx Tyr-55 and Tyr-99 depends on the phosphorylation of Hdmx-Ser-342 and Ser-367. 
The extent of c-Abl-mediated phosphorylation of Hdmx-Tyr-55 and Hdmx-Tyr-99 was 
compared between Hdmx S342A/S367A mutant and wild-type Hdmx. We found that the 
S342A/S367A mutant was still phosphorylated on both Tyr-55 and Tyr-99, indicating that 
the Tyr-55 and Tyr-99 phosphorylations are independent of Ser-342/Ser-367 
phosphorylation (Fig. 4E). 
 
Next, we investigated if phosphorylation of Ser-367 depends on phosphorylation of Hdmx-
Tyr-99. To this end, Ser-367 phosphorylation was compared between wild-type Hdmx and 
Hdmx-Y99F mutant. As can be seen, no significant difference was observed in the Ser-367 
phosphorylation between wildtype and Y99F mutant of Hdmx (supplemental Fig. S2A).  
Another way of approaching this question is to measure whether the Y99F and Y55F 
substitutions would affect the increased interaction between Hdmx and 14-3-3 proteins 
upon induction of double strand break by neocarzinostatin. This interaction is dependent on 
Ser-367 and Ser-342 phosphorylation (29). We found that both Hdmx-Y55F and Y99F 
mutants were able to bind 14-3-3tau and show increased binding similar to wt Hdmx after 
DNA damage, whereas Hdmx-S367A was unable to interact with 14-3-3tau as previously 
shown (supplemental Fig. S2B). These results are further supported by the preliminary 
observation that the Y55F and Y99F mutants indeed accumulate in the nucleus, as does 
wild-type Hdmx, upon treatment of cells with neocarzinostatin (data not shown). Together 
these result show that phosphorylation of Hdmx-Ser-367 is independent of Hdmx-Tyr-55 
and -Tyr-99 phosphorylation. 
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FIGURE 5. Phosphorylation of Hdmx 
on Tyr-99 inhibits its interaction with 
p53. H1299 cells were transfected with the 
indicated plasmids. Twenty-four hours later 
cell extracts were subjected to 
immunoprecipitation analysis using anti-p53 
antibody (goat FL-393-Ac). The expression 
level and the amount of the 
immunoprecipitated p53 were detected by 
using anti-p53 antibodies (PAb1801 and 
DO1) (A) or anti-p53 rabbit antibody (FL-
393) (B). The level of Hdmx was monitored 
with anti-Hdmx MX-82 antibody. The extent 
of phosphorylated Tyr-99 and Tyr-55 was 
investigated by blotting with anti-phospho-
Tyr-99 or anti-phospho-Tyr-55 Hdmx 
antibodies, respectively. The very same 
exposures are presented for the input and 
immunoprecipitated fractions, which were 
run on the same gel. The expression levels of 
GFP were used to monitor the efficiency of 
transfection (A). A dividing line in A 
indicates that lanes were merged from 
different parts of the same gel. C, MCF-7 
lines stably expressing the indicated HA-
tagged Hdmx proteins were subjected to IP 
analysis using anti-p53 antibody (FL-393) 
followed by immunoblotting with anti-HA 
antibody for monitoring the Hdmx levels. 
DM, double Y55,99F mutant.  
 
 
 
Phosphorylation of Hdmx on Tyr-99 but Not on Tyr-55 Impairs Its Interaction with p53 
The location of Tyr-99 and Tyr-55 within the p53 binding domain of Hdmx begged the 
question as to whether the phosphorylation of these tyrosines modulates the p53-Hdmx 
interaction. To address this question, H1299 cells, lacking p53 expression, were transfected 
with expression plasmids for p53, either alone or together with hdmx p53 BD and c-Abl. 
Twenty-four hours after transfection, cell extracts were subjected to IP using anti-p53 
antibody followed by immunoblotting with either specific anti-phospho- antibodies or anti-
Hdmx antibodies. As expected, p53 interacts efficiently with Hdmx. By marked contrast, 
p53 interaction with the Tyr-99 phosphorylated form of Hdmx was not detected, even after 
very long exposure of the film (Fig. 5A). This result suggests that Tyr-99 phosphorylation 
inhibits the interaction of Hdmx with p53. In contrast to Tyr-99, the phosphorylation of 
Tyr-55 did not impair its interaction with p53 (Fig. 5B) and in some experiments even 
enhanced it (supplemental Fig. S3). To further establish these findings, we monitored the 
effect of Hdmx tyrosine phosphorylations at more physiological levels of expression. We 
have generated MCF-7 stable lines expressing the following full-length HA-tagged Hdmx 
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proteins: wt, Y99F, Y55F, and Y55F,Y99F. To eliminate the effect of endogenous Hdmx 
on p53 interaction, endogenous Hdmx was downregulated by short hairpin RNA targeting 
the 3’-untranslated region (data not shown). Using this set of cell lines we examined the 
interaction between equivalent levels of Hdmx proteins and endogenous p53. p53 was 
immunoprecipitated (FL-393 antibody), and the amount of bound Hdmx protein was 
monitored with anti-HA antibody. Our results (Fig. 5C) revealed a slightly enhanced 
interaction between p53 and Y99F mutant, which is consistent with the above results (panel 
A). Interestingly, the interaction between p53 and Y55F and especially Y55F,Y99F mutants 
was reduced. These results strengthen the impact of these phosphorylation sites on the 
interaction between Hdmx and p53 (see “Discussion”).  
 
 
 
FIGURE 6. Structural model; phosphorylation of Hdmx on Tyr-99 is expected to strongly 
interfere with its binding to p53. A, structure of the Mdmx protein (humanized zebrafish Mdmx; shown as a 
ribbon) bound to the p53 peptide (residues 15-37, shown as a stick model). Tyr-96 in the zebrafish protein is 
equivalent to Tyr-99 in human Mdmx. B, same structure as in panel A but with modelled phosphotyrosine (green). 
C, a close-up view of the interaction region with the van der Waals surface added. D, same as in panel C but with 
modelled phosphotyrosine (green).  
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Effect of Stress on Hdmx Phosphorylations by c-Abl 
Because c-Abl is activated upon stress, we examined the effect of stress conditions on Tyr-
99 phosphorylation as a major c-Abl target site. HEK293 cells were transfected with 
expression plasmids for wt or Y55F,Y99F hdmx mutant, either alone or in combination 
with wt c-Abl or KD c-Abl. Cells were either left untreated or treated with a combination of 
H2O2 with tyrosine phosphatise inhibitor, sodium orthovanadate (Na3VO4), to activate c-
Abl and prevent Hdmx dephosphorylation, respectively (36). Twenty-seven hours post-
transfection Hdmx was immunoprecipitated, and protein complexes were analyzed by 
immunoblotting using anti-phospho-Tyr-99 Hdmx antibody. As shown in Fig. 7A, c-Abl-
induced phosphorylation of Tyr-99 increased in response to these stress conditions. The 
H2O2/Na3VO4 treatment also induced a shift in the electrophoretic mobility of Hdmx. The 
reason for this shift is not clear, but it has been reported earlier that the DNA damage-
induced mobility shift is dependent on phosphorylation of serine 403 (e.g. Ref. 29). To 
corroborate that the observed stress-induced Hdmx phosphorylation is not cell type-
specific, we confirmed these results in p53/mdm2 double KO mouse fibroblasts (2KO 
174.2) and in MCF-7 breast cancer cells (supplemental Fig. S4). Furthermore, to examine 
whether endogenous c-Abl can mediate Hdmx Tyr-99 phosphorylation, HEK293-T cells 
were transfected with expression plasmid for hdmx. Cells were either left untreated or 
treated with H2O2/Na3VO4 before being subjected to a phosphorylation assay. As shown in 
Fig. 7B, Tyr-99 phosphorylation was detected even in the absence of transfected c-Abl but 
only after H2O2/Na3VO4 treatment to activate endogenous c-Abl. Of note, this 
phosphorylation was not detected in cells expressing a kinase-defective mutant of c-Abl 
(Fig. 7A), which is due to the dominant negative effect of this mutant over endogenous c-
Abl. The detection of endogenous Hdmx phosphorylation by endogenous c-Abl was 
unsuccessful, primarily due to the low expression levels ofHdmxafter exposure to stress. 
Our findings of a potential dependence of Tyr-55 phosphorylations on Tyr-99 together with 
the differential effect of these phosphorylation sites on p53 interaction raised the possibility 
that these two phosphorylation sites may be regulated differently. To test this possibility, 
HEK293 cells were infected with c-Abl-GFP expressing lentivirus and then transfected 
with hdmx p53 BD expression plasmid. Cells were exposed at different time points to the 
genotoxic agent doxorubicin for 1 h, washed, and harvested at the same time (Fig. 7C, 
upper panel). As shown in Fig. 7C, phosphorylations of both Tyr-55 and Tyr-99 increased 
after genotoxic stress, with a slightly earlier onset for Tyr-99 phosphorylation. Notably, 
with time after exposure to stress, the increase in phosphorylation of Tyr-55 was more 
intense relative to the increase in Tyr-99 phosphorylation. These results show that Tyr-55 
and Tyr-99 phosphorylations are elevated by DNA damage, but the kinetics of their 
regulation may differ. 
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FIGURE 7. Stress induces 
Hdmx phosphorylations by 
c-Abl. HEK293 (A) or 
HEK293-T cells (B) were 
transfected with the indicated 
plasmids. Cells were either left 
untreated or were treated with 3 
mm H2O2 together with tyrosine 
phosphatase inhibitor sodium 
orthovanadate (Na3VO4; 1 mm) 
for 20 min before harvest. 
Twenty-four hours post-
transfection Hdmx was 
immunoprecipitated from cell 
extracts using anti-Hdmx 
antibody. 6B1A antibody was 
used in A, and a mixture of 
rabbit polyclonal anti-Hdmx 
antibodies (p55, p56, and 1328) 
was used in B. Hdmx 
phosphorylated on Tyr-99 was 
detected with anti-phospho-Tyr-
99 antibody, and total Hdmx 
level was monitored with 6B1A 
(A) or MX-82 (B) anti-Hdmx 
antibody. C, HEK293 cells were 
infected with c-Abl-GFP 
lentivirus. Seventy-two hours 
later cells were transfected with 
His and Myc-tagged hdmx p53 
BD plasmid. Forty-eight hours 
post-transfection, cells were 
either left untreated or were 
treated at different time points 
with doxorubicin 2.5 μg/ml for 1 
h. All the cells were harvested at 
the same time point. The time 
course of the experiment is 
shown in the upper panel. Hdmx 
p53 BD was isolated from cell extracts as described in Fig. 2C, and the protein complex was subjected to Western 
blotting using either anti-phospho-Tyr-55 antibody or anti-phospho-Tyr-99 antibody. Total Hdmx levels were 
monitored by blotting with anti-Hdmx antibody (MX-82). Stress-induced activation of p53 was followed by using 
anti-phospho-Ser20 antibody.  
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DISCUSSION 
p53 protein levels and activity are tightly regulated under normal and stress conditions. The 
negative regulation of p53 is governed largely by the Mdm proteins (for review, see Ref. 
37). Deregulation of either Mdm proteins can be sufficient to suppress p53, as seen in 10–
20% of human cancer cases bearing wt p53 (6). In normal cells the release of p53 from the 
inhibitory effects of the Mdm proteins is essential for the proper accumulation and 
activation of p53 (17). This relief involves a spectrum of posttranslational modifications of 
p53 and the Mdm2 proteins (for review, see Refs. 38 and 39). Additionally, recent studies 
show that Mdmx is also subjected to a spectrum of posttranslational modifications (for 
review, see Ref. 2). These include basal phosphorylation of Mdmx by CDK2/Cdc2(p34) 
proposed to regulate Mdm2 localization (40) and phosphorylation by CK1-α stimulating the 
Mdmx-p53 interaction (41). Additionally, Akt1 mediates Hdmx phosphorylation, leading to 
Hdmx stabilization and induced 14-3-3 binding (42). Upon stress, Mdmx is modified by 
key regulators of biological response to DNA damage like checkpoint kinases 1 and 2 
(Chk1, Chk2) and ATM (for review, see Refs. 2 and 43). Furthermore, ATM-dependent 
phosphorylations of Mdmx are required for the efficient damage-induced Mdmx 
degradation, at least partially by affecting binding to herpes virus-associated ubiquitin-
specific protease (HAUSP) (44), and also by stimulating the interaction with 14-3-3 
proteins, which contributes to nuclear accumulation and degradation of Hdmx under DNA-
damage conditions (29, 31). The degradation of Hdmx in response to stress is critical for 
p53 activation (for review, see Ref. 17). An additional important arm of the ATM stress 
response is the activation of c-Abl. We have previously shown that p53 activation by c-Abl 
requires the neutralization of the inhibitory effects of Mdm2 (22, 23). c-Abl interacts with 
and phosphorylates Hdm2, thereby impairing its E3 ligase activity toward p53 (24, 25). In 
addition, c-Abl stabilizes the interaction of p53 tetramer with certain promoters, such as 
p21 (45, 46). 
In this study we explored a new pathway by which c-Abl regulates p53. We found that c-
Abl interacts with Hdmx and phosphorylates it in cultured cells. Specifically, we identified 
Tyr-55 and Tyr-99 as c-Abl phosphorylation sites. These phosphorylations are independent 
of Hdmx phosphorylation by ATM or Chk2, and they do not affect 14-3-3/Hdmx binding. 
Importantly, however, both tyrosines reside within the p53 binding region. We found that 
phosphorylation of Tyr-99 inhibits the interaction between Hdmx and p53 (Fig. 5A). This 
finding is highly supported by a recent study describing the crystal structure of the N- 
terminus of Mdmx bound to a p53 peptide. This study highlighted Y96 (humanized 
zebrafish Mdmx equivalent to Tyr-99) as a critical residue for p53 binding (35). The 
addition of phosphorylated Tyr-99 to the modelled structure reveals the expected inhibition 
of p53 binding (Fig. 6). Because a physical interaction is required for the inhibition of p53 
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by Hdmx (47), interference with this interaction provides an efficient mechanism by which 
to modulate the Hdmx-p53 regulation. Our results imply that in response to stress, c-Abl 
protects p53 also by modulating the Hdmx-p53 interaction through Tyr-99 phosphorylation. 
This defines the first phosphorylation of Hdmx, which inhibits its interaction with p53. 
Consequently, it is predicted that this phosphorylation would impair the inhibitory effect of 
Hdmx on p53. To test this prediction we measured the effect of Y99F substitution on the 
inhibitory effect ofHdmxon p53 transcriptional activity using a luciferase reporter assay. 
Although the substitution mutant consistently inhibited more efficiently than wt Hdmx, the 
effect was very modest (supplemental Fig. S5). Why is this effect so small? First, we 
assume that only a fraction of Hdmx molecules undergo tyrosine phosphorylation, to which 
the phosphorylation mutant is compared. Second, it needs to be stressed that in this type of 
experiments c-Abl is an efficient activator of p53 (22–24). It is, therefore, difficult to 
achieve an optimal stoichiometry between Hdmx, c-Abl, and p53 that distinguishes the 
direct effect of c-Abl on p53 from the indirect effect via the Mdm proteins.  
 
The phosphorylation of Hdmx on Tyr-55 did not impair its interaction with p53, and in 
some experiments it even seemed to enhance this interaction (supplemental Fig. S3). 
Moreover, interaction of endogenous p53 with Y55F and especially with Y55F,Y99F 
Hdmx was reduced as compared with wt and Y99F Hdmx (Fig. 5C), emphasizing the role 
of Tyr-55 in the p53-Hdmx interaction. Thus, c-Abl phosphorylates two tyrosines within 
the p53 binding region of Hdmx, which differently affect its interaction with p53. How 
could this observation be reconciled? In an attempt to understand this observation, we 
monitored the pattern of these phosphorylations in response to DNA damage, a stress signal 
known to activate c-Abl and p53. Although the phosphorylation of both sites was enhanced 
in response toDNAdamage, the pattern of phosphorylation of the two sites differed. The 
extent of Tyr-99 phosphorylation increased moderately, with a possible temporary 
reduction at around 8–9 h after damage. On the other hand, Tyr-55 phosphorylation 
appeared with a short delay after Tyr-99 phosphorylation but continued to increase stronger 
with time after exposure (Fig. 7C and data not shown). Furthermore, Tyr-55 
phosphorylation was impaired in the absence of Tyr-99, suggesting a potential sequential 
phosphorylation where Tyr-99 precedes Tyr-55 (Fig. 4). On the basis of these findings we 
propose a scenario whereby Tyr-99 phosphorylation occurs early after exposure to DNA 
damage, preventing Hdmx-p53 interaction, thereby contributing to p53 activation. 
Subsequent phosphorylation of Hdmx on Tyr-55 may counteract the effect of Tyr-99 on 
p53 interaction, thereby contributing to the recovery of p53 from stress-induced activation. 
Overall, we show here that c-Abl not only targets Hdm2, but also targets Hdmx, which 
contributes to its role in p53 regulation. 
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Supplementary Figures 
 
Supplementary Figure S1: Hdmx N- and C-terminal deletion mutants interact with c-Abl in 
vivo. HEK 293 cells were transfected with indicated plasmids. Forty-eight hours post-transfection cell extracts 
were subjected to immunoprecipitation (IP) using anti-c-Abl K-12 polyclonal antibody. IP was followed by 
immunoblotting (IB) with anti-Hdmx MX-82 monoclonal antibody (A) or anti-Hdmx 6B1A monoclonal antibody 
(B). c-Abl levels were monitored by blotting with anti-c-Abl monoclonal antibody (ABL-148). Schematic 
representation of the Hdmx deletion mutants used in this study is presented in Fig. 1B. Dividing lines in A and B 
indicate that lanes were grouped from different parts of the same gel. 
 
 
Chapter 3 
- 66 - 
 
 
Supplementary Figure S2: Phosphorylation of Hdmx Y99 is not necessary for phosphorylation 
of Hdmx S367 or for binding of 14-3-3 to Hdmx. (A) HEK293-T cells were transfected with expression 
vectors for hdmx or hdmx-Y99. Cells were treated with 3 mM H2O2 for 20 min, together with tyrosine phosphatase 
inhibitor sodium orthovanadate (Na3VO4; 1 mM) for 4 hrs, either with or without treatment with 20 6M protease 
inhibitor MG132. Twenty-eight hrs post-transfection cells were harvested and extracts were analysed by Western 
blotting using anti-phospho-S367-Hdmx antibody. Total Hdmx levels were monitored by incubating with anti-
Hdmx antibody (BL1258). (B) MCF7 cells were transfected with expression vectors for hdmx, hdmx-Y55F, hdmx-
Y99F or hdmx-S367A. Cells were either non-treated or treated with Neocarzinostatin (NCS) (500 ng/ml) for 5 hrs 
before harvesting. Twenty-nine hours post-transfection cell extracts were subjected to immunoprecipitation (IP) 
using a mixture of rabbit anti-Hdmx antibodies p55, p56 and 1328. Immunoprecipitates were analysed by 
immunoblotting (IB) with anti-14-3-3tau antibody or anti-Hdmx antibody. Hdmx and 14-3-3tau levels in total 
extracts were investigated by immunoblotting with anti-Hdmx (BL1258) antibody and anti-14-3-3tau antibody, 
respectively. 
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Supplementary Figure S3: c-Abl-dependent phosphorylation of Hdmx on Y55 enhances its 
binding to p53. H1299 cells were transfected with expression plasmids for hdmx p53 BD wt or Y55,99F 
phosphorylation mutant either alone or in combination with p53 and c-abl. Twenty-four hours later cell extracts 
were subjected to immunoprecipitation analysis using anti-p53 393-Ac antibody. The level of Hdmx was 
monitored with anti-Hdmx 1328 antibody. The extent of phosphorylated Y55 was monitored by blotting with anti-
phospho-Y55 Hdmx antibody. The very same exposures are presented for the input and immunoprecipitated 
fractions which were run on the same gel. 
 
 
 
 
 
 
Supplementary Figure S4: Hdmx is phosphorylated upon stress by c-Abl on Tyr-99 in different 
cell types. 2KO 174.2 (mdm2/p53 double knock-out MEFs) and MCF7 cells were transfected with expression 
plasmids for hdmx with or without c-abl. Cells were either non–treated or treated with 3 mM H2O2 together with 
tyrosine phosphatase inhibitor sodium orthovanadate (Na3VO4; 1 mM) for 20 min before harvest. Twenty-four hrs 
post-transfection Hdmx was immunoprecipitated from cell extracts using a mixture of rabbit polyclonal anti-Hdmx 
antibodies (p55, p56 and 1328). Hdmx phosphorylated on Y99 was detected with anti-phospho-Y99 antibody and 
total Hdmx level was monitored with anti-Hdmx antibody (MX-82). 
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Supplementary Figure S5: c-Abl-dependent phosphorylation of Hdmx at Y99 slightly inhibits 
Hdmx ability to inhibit p53. H1299 cells were transfected with the p53-reporter plasmid (Cyclin G-luc) 
either alone or in combination with p53 and c-abl with or without addition of wt or mutant hdmx p53 BD. Twenty-
six hours later cell extracts were subjected to luciferase assay using Promega luciferase kit. Cells were treated with 
tyrosine phosphatase inhibitor sodium orthovanadate (Na3VO4; 0.3 mM) for 4.5 hours before harvesting. 
  
Chapter 4   
 
 
Oncogenic functions of hMDMX in in vitro 
transformation of primary human fibroblasts 
and embryonic retinoblasts 
 
Kristiaan Lenos*, Job de Lange*, Amina Teunisse, Kirsten Lodder, Matty Verlaan-de 
Vries, Eliza Wiercinska, Marja van der Burg, Karoly Szuhai, Aart G Jochemsen 
 
 
Department of Molecular Cell Biology, Leiden University Medical Center, P.O. Box 9600, 
2300 RC Leiden, The Netherlands  
 
*These authors contributed equally to this work 
 
 
 
 
 
 
Mol. Cancer 2011 Sep 12;10(1):111
Chapter 4 
- 70 - 
Background 
In around 50% of all human cancers the tumor suppressor p53 is mutated. It is generally 
assumed that in the remaining tumors the wild-type p53 protein is functionally impaired. 
The two main inhibitors of p53, hMDM2 (MDM2) and hMDMX (MDMX/MDM4) are 
frequently overexpressed in wild-type p53 tumors. Whereas the main activity of hMDM2 is 
to degrade p53 protein, its close homolog hMDMX does not degrade p53, but it represses 
its transcriptional activity.  Here we study the role of hMDMX in the neoplastic 
transformation of human fibroblasts and embryonic retinoblasts, since a high number of 
retinoblastomas contain elevated hMDMX levels. 
Methods 
We made use of an in vitro transformation model using a retroviral system of RNA 
interference and gene overexpression in primary human fibroblasts and embryonic 
retinoblasts. Consecutive knockdown of RB and p53, overexpression of SV40-small t, 
oncogenic HRasV12 and HA-hMDMX resulted in a number of stable cell lines 
representing different stages of the transformation process, enabling a comparison between 
loss of p53 and hMDMX overexpression. The cell lines were tested in various assays to 
assess their oncogenic potential.    
Results 
Both p53-knockdown and hMDMX overexpression accelerated proliferation and prevented 
growth suppression induced by introduction of oncogenic Ras, which was required for 
anchorage-independent growth and the ability to form tumors in vivo. Furthermore, we 
found that hMDMX overexpression represses basal p53 activity to some extent. 
Transformed fibroblasts with very high levels of hMDMX became largely resistant to the 
p53 reactivating drug Nutlin-3. The Nutlin-3 response of hMDMX transformed retinoblasts 
was intact and resembled that of retinoblastoma cell lines.  
Conclusions 
Our studies show that hMDMX has the essential properties of an oncogene. Its constitutive 
expression contributes to the oncogenic phenotype of transformed human cells. Its main 
function appears to be p53 inactivation. Therefore, developing new drugs targeting 
hMDMX is a valid approach to obtain new treatments for a subset of human tumors 
expressing wild-type p53.   
Oncogenic functions of hMDMX in in vitro transformation  
- 71 - 
Background 
In approximately 50% of all human cancers mutations are found in the TP53 gene, 
encoding the tumor suppressor protein p53 [1, 2], whereas it is assumed that in tumors 
expressing wild-type p53 the tumor suppressing activity of p53 is attenuated [3]. Normal, 
non-stressed cells maintain relatively low p53 protein levels. Upon various stress signals 
like DNA damage or oncogenic stress, p53 is stabilized and activated.  Activated p53 
affects various processes, including cell cycle progression, DNA repair, senescence and 
apoptosis [4]. Two main negative regulators of p53 are MDM2 and MDMX, also called 
hMDM2 and hMDMX. MDM2, an E3 ubiquitin ligase, inhibits p53 via poly-ubiquitination 
[5] and by binding to p53’s N-terminus, thereby shielding its transcription activation 
domain. Since the MDM2 gene is also a p53 target, a negative feedback-loop is established 
[6]. The importance of MDM2 in p53 regulation was best shown by the p53-dependent 
embryonic lethality of MDM2 -/- mice [7, 8]. Similarly, MDMX -/- mice are embryonic 
lethal in a p53-dependent manner [9-11], indicating that both MDM2 and MDMX fulfil an 
essential, non-redundant function in p53-regulation. Despite great structural similarities 
between MDM2 and MDMX [12], including the RING finger domain needed for MDM2 
E3 ligase activity, MDMX has no detectable E3 ligase activity. MDMX functions mostly 
by inhibiting p53 activity through interaction with its transcription activation domain [13, 
14]. Furthermore, MDMX and MDM2 dimerize via their RING finger domains [15], 
thereby stabilizing MDM2 and promoting its E3 ligase activity towards p53 [16, 17].  
 
hMDM2 is overexpressed in 5-10% of all human tumors, revealing hMDM2 as an 
oncogene [18]. Similar observations were made regarding hMDMX. A study of common 
tumor types showed increased hMDMX mRNA expression in 20% of these tumors [19], 
and a subset of gliomas contained hMDMX gene amplification [20]. Furthermore, Ramos et 
al. showed upregulated or aberrant hMDMX expression in a large number of human tumor 
cell lines, mostly correlating with wild-type p53 status [21]. A particularly high proportion 
of retinoblastomas contain hMDMX gene amplification [22]. hMDMX knockdown in p53 
wild-type tumor cells has been shown to induce p53-dependent growth inhibition [19, 22]. 
 
The first evidence for direct oncogenic activity of MDMX was provided by Danovi et al. 
[19]. MDMX overexpression in early cultures of mouse embryonic fibroblasts resulted in 
immortalization and neoplastic transformation when combined with HRasV12 
overexpression. This suggests that MDMX overexpression is sufficient to inactivate the p53 
tumor suppressor pathway. However, such an oncogene function of hMDMX has not yet 
been directly shown in human cells.  
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Human primary cells require a specific set of genetic changes for neoplastic transformation. 
By expression of the human Telomerase reverse transcriptase subunit (hTERT), oncogenic 
HRasV12, and the early region of SV40, encoding the viral large and small T antigens (LT 
and st), primary human cells can be immortalized and transformed. LT is needed to 
inactivate RB and p53, since functional loss of both genes is required for tumor formation 
[23, 24]. By combining this transformation model with specific RNA interference, the 
tumor-suppressive functions of p14ARF and p16INK4A were assessed by Voorhoeve and 
Agami [25]. They also showed that directly targeting p53 and RB could replace LT 
expression. Here we use a retroviral system of RNA interference and gene overexpression 
to establish an in vitro transformation model for assessing the contribution of hMDMX to 
the transformation of human primary cells.  
 
Results  
Generation of transformed human skin fibroblasts and human embryonic 
retinoblasts, including hMDMX as a potential oncogene  
To investigate whether hMDMX can function as an oncogene in the transformation of 
human primary cells, we applied a previously described in vitro transformation model [25] 
to two different cell types: human foreskin fibroblasts (VH10) and human embryonic 
retinoblasts (HER). 
 
The generation of the VH10 transformation model is depicted in Fig. 1A. Sequential 
retroviral transductions resulted in a panel of stable polyclonal cell lines, representing 
different stages of the transformation process. This enabled a pair-wise comparison 
between hMDMX overexpression and p53-knockdown. Stable cell lines with shRB-HA-
hMDMX, or shRB alone, could not be established, suggesting that RB reduction is growth 
limiting in these cells. Oncogenic HRasV12 without concomitant p53-knockdown or HA-
hMDMX overexpression induced a senescent-like crisis blocking proliferation of most 
cells, followed by expansion of single colonies. This suggests the occurrence of additional 
selection bypassing the HRasV12-induced senescence. RB knockdown was not sufficient to 
rescue HRasV12-induced growth inhibition. Therefore, the cell lines VH10-shRB-
HRasV12 and VH10-HRasV12 could not be established. We monitored the effectiveness of 
the transductions by western blotting (Fig. 1B) and found strong overexpression of 
hMDMX, somewhat increased HRas levels and marked reductions of p53 and RB, 
correlating with the respective transductions. Interestingly, endogenous HRas level was 
slightly increased upon p53-knockdown or hMDMX overexpression, correlating with 
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accelerated growth. HRasV12 has been reported to induce p16-dependent senescence in 
human fibroblasts [4, 25, 26]. Indeed, HRasV12-transformed as well as p53-knockdown 
cells expressed higher p16 protein levels (Fig.1B), although we observed no signs of 
senescence. This suggests that during the transformation process the pathway downstream 
of p16 is somehow impaired. Alternatively, p53 inactivation may prevent HRasV12-
induced senescence, which was indeed described for hMDMX overexpression [27]. 
 
For HER transformation, we initially used a comparable approach. However, HRasV12-
transformed cells could not be established without p53-knockdown or HA-hMDMX 
overexpression, which prompted us to modify the scheme (Fig. 1C). Transformation of 
HER-hTERT-shRB or HER-hTERT cells with an empty puromycin vector and subsequent 
puromycin selection resulted in initial colony formation, but these colonies eventually 
stopped growing. This suggests that in HER cells, in contrast to VH10, inactivation of p53 
is essential for establishing immortalized cell lines. Protein levels of RB, hMDMX, p53 and 
HRas correlated with the applied transductions (Fig. 1D), although the RB depletion was 
less efficient in HA-hMDMX cells (lane 4 and 5). Similar to the observations in VH10 
cells, HRasV12 expression induced p16 protein levels in HER cells. This did not affect 
growth of RB-knockdown cells, whereas HER cells without RB-knockdown eventually 
stopped proliferating upon HRasV12 overexpression. Likely, HRasV12 activated a p16- 
and RB-dependent mechanism resulting in growth suppression (also illustrated by large, 
flattened cells, Fig. 2C), which could not be rescued by p53-knockdown or hMDMX 
overexpression. Therefore, these cells could not be used in further experiments. 
 
hMDMX overexpression and p53-knockdown were analyzed with qRT-PCR, showing 
approximately 90% reduction of p53 and 10-fold increase of hMDMX mRNA expression in 
VH10 cells (Table 1 and not shown). Expression of p53 target genes p21, PUMA and 
hMDM2-p2 was significantly decreased upon p53-knockdown in VH10 and HER cells, and 
also hMDMX overexpression slightly decreased basal levels of some of these genes (Table 
1 and Fig. 5B). Reduced p21 protein levels upon p53-knockdown (Fig. 1B and 1D), in line 
with the qRT-PCR data, indicate impaired basal p53 activity. hMDMX overexpression did 
slightly reduce basal p21 protein levels in VH10 cells (Table 2), In addition, in HA-
hMDMX cells the protein levels of p53 were slightly increased, most likely by protein 
stabilization. 
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Figure 1. Generation of 
panels of transformed 
human skin fibroblasts 
and human embryonic 
retinoblasts. 
A. Schematic representation of 
transformation process. Primary 
human fibroblasts (VH10) were 
immortalized with human 
Telomerase (hTERT). In 
subsequent rounds of retroviral 
infection using the indicated 
constructs, followed by 
selection, several stable cell 
lines were created. B. Total cell 
extracts from all transformed 
fibroblast cell lines were 
analyzed by immunoblotting 
with the indicated antibodies. 
C. Human Embryonic 
Retinoblasts (HER) were 
similarly transformed according 
to the scheme. D. Total cell 
extracts from all transformed 
HER cell lines were analyzed 
by immunoblotting with the 
indicated antibodies. 
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Table 1. mRNA expression levels in VH10 and HER cell lines 
VH10 p21 hMDM2-p2 PUMA 
VH10 wt 1.00 ± 0.16 1.00 ± 0.17 1.00 ± 0.23 
shp53 0.24 ± 0.03 0.20 ± 0.03 0.49 ± 0.11 
HRasV12-shp53 0.15 ± 0.03 0.32 ± 0.07 0.44 ± 0.15 
shRB-HRasV12-shp53 0.63 ± 0.11 0.41 ± 0.15 1.54 ± 0.32 
HA-hMDMX 0.47 ± 0.09 0.61 ± 0.08 0.41 ± 0.08 
HRasV12-HA-hMDMX 0.76 ± 0.12 1.05 ± 0.17 0.53 ± 0.14 
shRB-HRasV12-HA-hMDMX 1.05 ± 0.12 1.14 ± 0.15 0.28 ± 0.07 
HER p21 hMDM2-p2 PUMA 
HER wt 1.00 ± 0.16 1.00 ± 0.15 1.00 ± 0.19 
shp53 0.11 ± 0.03 0.01 ± 0.01 0.46 ± 0.13 
shRB-shp53 0.23 ± 0.05 0.02 ± 0.00 0.36 ± 0.06 
shRB-HRasV12-shp53 0.05 ± 0.02 0.01 ± 0.00 0.15 ± 0.04 
HA-hMDMX 1.51 ± 0.26 1.43 ± 0.28 0.67 ± 0.30 
shRB-HA-hMDMX 1.01 ± 0.16 0.62 ± 0.13 0.34 ± 0.11 
shRB-HRasV12-HA-hMDMX 2.52 ± 0.70 0.61 ± 0.17 0.60 ± 0.17 
Total RNA of each cell line was isolated and expression levels of the indicated genes were determined by 
qRT-PCR and normalized for the housekeeping genes CAPNS1 and TBP; levels are shown relative to 
wild-type cells. 
 
 
Table 2. Protein levels, relative to untreated VH10 wt cells, corrected for HAUSP 
expression. 
Cell line Nutlin-3 treatment (h) p53 p21 hMDM2 
 0 1.00 1.00 1.00 
 VH10 wt 6 4.96 6.68 82.32 
  24 7.82 11.16 149.60 
 0 0.35 0.20 0.27 
shp53  6 0.87 0.65 0.30 
  24 1.25 2.26 4.54 
 0 0.28 0.03 0.33 
 HRasV12-shp53 6 0.30 0.09 0.78 
  24 0.44 0.33 0.74 
 0 0.45 1.01 2.51 
shRB-HRasV12- shp53 6 0.49 1.24 4.55 
 24 0.74 2.85 9.17 
 0 6.99 0.56 0.87 
HA-hMDMX  6 9.72 2.86 47.81 
  24 11.70 2.10 17.19 
 0 1.63 0.63 0.69 
 HRasV12-HA-hMDMX 6 4.13 2.88 36.75 
  24 5.01 3.07 29.42 
 0 1.07 1.45 2.79 
shRB-HRasV12-HA-hMDMX 6 2.38 5.37 132.80 
  24 1.76 4.28 79.91 
Band intensities shown in figure 3B were quantified using the Odyssey 2.1 analysis software 
(LI-COR Biosciences) and the relative protein levels were calculated using HAUSP expression 
as an internal control. Basal protein levels in VH10 wild-type cells were set at 1.0. 
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Immunofluorescence analysis revealed abundant GFP throughout the entire cell in all 
established HER and VH10 cell lines, which confirmed SV40-st expression (Add. File 1A 
and 1C).  
Exogenous hMDMX showed mainly cytoplasmic localisation in VH10 cells, but nuclear 
hMDMX was also observed (Add. File 1A). In HER cells, the main localization was 
nuclear (Add. File 1B). High levels of cytoplasmic hMDMX were reported to prevent p53 
nuclear localization [28]. However, we found no alterations in p53 localization upon 
hMDMX overexpression (Add. File 1B and 1D). hMDM2 protein, irrespective of hMDMX 
levels, was detected in the nucleus, although it could be observed in the cytoplasm as well. 
The cytoplasmic signal of hMDM2 is relatively underrepresented since the protein is 
diffused throughout the relatively large cytoplasmic surface, but is certainly present, as 
reported before [29] (Add. File 1B and D). 
 
Since p53 contributes to the maintenance of genomic stability [4], the various cell lines 
were analyzed for chromosomal abnormalities using COBRA-FISH [30]. Wild-type 
VH10hTERT cells (Add. File 2A) showed a normal 46,XY karyogram in 20% of the 
analyzed cells. The remaining cells harboured a Robertsonian translocation [31], which 
results in loss of the short arms of two acrocentric chromosomes. As these contain the 
ribosomal gene cassettes, this translocation has no further consequences at the cellular 
level. The observed rob(13;22) chromosome was lost during the transformation process. 
The transformed VH10 cell lines showed heterogeneous populations of mainly diploid and 
chromosomal stable cells, with low percentage random translocations or polyploidy. The 
HER cells showed more chromosomal aberrations and translocations (Add. File 2B). Most 
notably, loss of chromosome 13, harbouring the RB gene, was found in four out of six cell 
lines. The fact that it was not found in the HA-hMDMX and shRB-HA-hMDMX-HRasV12 
cell line suggests that loss of this chromosome occurred independently in those four cell 
lines (see Fig. 1C for transformation scheme). Two unlinked cell lines (shp53 and shRB-
HA-hMDMX-HRasV12) lost one X-chromosome, whereas loss of chromosome 22 and 
gain of chromosome 8 in shRB-shp53 and shRB-shp53-HRasV12 is likely to have been 
passed on from their shared parental cell line. In addition, several random translocations 
and fusions were observed, however, none was found in more than one cell line. In 
conclusion, transformation of VH10 and HER cells did not induce wide-spread genomic 
instability and aneuploidy.  
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Alterations in morphology and proliferation rate during transformation process 
Cell morphology changed during the transformation process. Whereas normal 
VH10hTERT cells are extended, fibroblastic cells aligning orderly in the dish, during the 
sequential transformation stages the cells became apparently smaller and rounder (Fig. 2A). 
HRasV12 induced a disordered way of growing and showed loss of contact inhibition. 
hMDMX-overexpressing and p53-knockdown cells showed similar morphology changes. 
Both shp53- and HA-hMDMX cells obviously proliferated faster than wild-type 
VH10hTERT cells, a property that was not further enhanced by additional HRasV12 
expression. This was confirmed in short-term growth (WST-1) assays (Fig. 2B), suggesting 
that hMDMX overexpression is sufficient to inhibit p53-dependent growth control, similar 
to p53-knockdown. 
 
Morphology changes in transformed HER cells were comparable to those observed in 
VH10 cells (Fig. 2C). In addition, both p53-knockdown and hMDMX overexpression 
accelerated growth as compared to wild-type HER cells (Fig. 2D). HRasV12 even further 
enhanced growth rate in shRB-shp53 cells, but not in shRB-HA-hMDMX cells.  
 
Effect of hMDMX overexpression on anchorage-independent growth  
Anchorage-independent growth is a vital feature of tumorigenic cells. Therefore, we 
investigated the growth potential of the different cell lines in soft agar (Fig. 3A). 
Control VH10hTERT cells did not grow, but both p53-knockdown and hMDMX 
overexpression induced formation of some small colonies. HRasV12 expression clearly 
increased the size and the number of colonies. However, this was more pronounced in p53-
knockdown cells than in hMDMX-overexpressing cells. Interestingly, hMDMX 
overexpression did not prevent the growth inhibitory effect of Nutlin-3, in contrast to 
experiments in 2D-culture (see below). These findings suggest that hMDMX cannot fully 
inhibit the function of p53 in soft agar growth. 
 
Untransformed HER cells did not grow at all in soft agar, and neither hMDMX 
overexpression nor p53-knockdown alone was able to induce colony formation (not 
shown). Although additional RB knockdown induced formation of very small colonies, 
only HRasV12 expression dramatically increased colony size and number (Fig. 3B). 
Similar to the observations in VH10 cells, colony formation was more efficient in p53-
knockdown cells than in hMDMX-overexpressing cells. Furthermore, Nutlin-3 inhibited 
colony formation of hMDMX-overexpressing cells, whereas p53-knockdown cells were 
unaffected. 
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Figure 2. Transformation alters cell morphology and growth rate.  
Phase-contrast photographs of the transformed VH10 (A) and HER (C) cell lines (10x magnification, Olympus 
CKX41) showing morphology changes during the transformation process. Growth rates of VH10 (B) and HER (D) 
cell lines were measured using WST-1 proliferation assays.  
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Figure 3. hMDMX overexpression promotes anchorage-independent growth and tumor growth 
in vivo. A, B. Various VH10hTERT and HER cell lines were embedded in 0.3 % agarose on a 0.6% agarose 
bottom-layer, with additional normal growth medium or growth medium containing 10 µM Nutlin-3 on top of the 
agarose. Colony outgrowth was monitored and pictures were taken 18 days (VH10) and 4 weeks (HER) after 
seeding.  Representative pictures of several independent experiments are shown. C. Schedule for investigating in 
vivo growth of parental and transformed VH10 cells using the shell-less chicken CAM model. At embryonic 
development day (EDD) 7, 2.5 million cells were grafted onto a chicken CAM. Tumors were harvested at EDD17. 
D. Representative pictures of GFP-positive tumors, P-Histone-3 staining and vimentin staining. E. Tumor volumes 
of VH10hTERT control (N=5), shRB-HRasV12-shp53 (N=4) and shRB-HRasV12-HA-hMDMX (N=5). F. 
Quantification of the number of mitotic (P-Histone-3 positive) cells. Statistical analysis was performed by one-
way ANOVA followed by Bonferroni's Multiple Comparison Test. P<0.05 was considered statistically significant. 
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Role of hMDMX in tumorigenicity in vivo. 
We tested the in vivo tumorigenic potential of the transformed VH10 cells by subcutaneous 
injection into Balb/c nu/nu mice. Unfortunately, no tumor formation could be detected. The 
lack of tumor growth could possibly be explained by the immune response still present in 
nu/nu mice; however, similar results were obtained in NOD/SCID mice. Therefore, we 
switched to the shell-less chick CAM assay [32] (Fig. 3C-F). Ten days after grafting both 
shRB-HRasV12-HA-hMDMX- and shRB-HRasV12-shp53 tumors were significantly 
larger (4-5 fold) than those formed by wild-type VH10 cells (P < 0.05, Bonferroni’s 
Multiple Comparison Test; Fig. 3D left and E). Interestingly, the transformed cell lines 
showed equal tumor volumes, indicating that hMDMX overexpression and p53-knockdown 
have similar effects on tumor growth. Moreover, tumors from the transformed cells 
contained significantly (P<0.05) more mitotic cells than wild-type tumors as revealed with 
P-Histone-3 staining, with no detectable difference between hMDMX-overexpressing and 
p53-knockdown cells (Fig. 3D middle and 3F). Staining with fibroblast marker vimentin 
showed the fibroblastic origin of the tumors (Fig 3D right).  
 
The in vivo growth capacity of transformed HER cells was tested in a previously described 
murine model [33], by injection into the anterior eye chamber of Balb/c nu/nu mice. Both 
tested cell lines showed similar, but limited in vivo growth potential. The hMDMX-
expressing cells showed growth in 2/5 cases, but growth stopped when the eye chamber 
was filled up to 50% with tumor cells. The p53-knockdown cells started tumor growth in 
4/5 cases, but stopped when the eye chamber was filled up to 20% (2x), 30% (1x) or 50% 
(1x). Altogether, it is clear that hMDMX overexpression promotes in vivo tumor growth 
and in that respect largely mimics p53-knockdown in the same cells. 
 
hMDMX overexpression inhibits the Nutlin-3 induced p53 response in VH10 skin 
fibroblasts. 
We next investigated whether hMDMX overexpression prevents p53 activation in VH10 
cells. The various cell lines were treated with the small-molecule p53-activator Nutlin-3 
[34]. Nutlin-3 reduced survival of normal human fibroblasts (Fig. 4A), whereas p53-
knockdown cells were not affected. hMDMX overexpression also prevented Nutlin-3 
induced growth inhibition. In wild-type VH10hTERT cells, the Nutlin-3 response is marked 
by increased p53, hMDM2 and p21 and decreased hMDMX protein levels (Fig. 4B). This 
response was diminished upon p53-knockdown, reaching levels slightly above basal 
expression in wild-type cells (Table 2). HA-hMDMX overexpression also attenuated the 
induction of p53 and its target genes. Notably, exogenous HA-hMDMX levels remained 
relatively high, despite some Nutlin-3 induced degradation. Levels of the p53-responsive  
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Figure 4. hMDMX overexpression inhibits Nutlin-3 mediated p53 activation in human 
fibroblasts. 
A. Various VH10hTERT cell lines were continuously treated with 10 μM Nutlin-3 and proliferation was measured 
after 96 hours using a WST-1 assay. Relative cell numbers are displayed as survival relative to untreated cells. B. 
Various VH10hTERT cell lines were treated for the indicated times with 10 µM Nutlin-3, and protein levels were 
analyzed with immunoblotting using the indicated antibodies. C. qRT-PCR analysis of cells treated as in B. 
Expression levels of hMDM2-p2, p21, PUMA and SURVIVIN are shown as the fold induction relative to untreated 
wild-type VH10 cells.  
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transcripts of hMDM2-p2, p21 and PUMA correlated with protein levels (Fig. 4C). 
Furthermore, hMDMX overexpression partially rescued the reduction of the anti-apoptotic 
gene SURVIVIN by Nutlin-3 [35]. Table 3 shows fold changes of p53, hMDM2, hMDMX 
and the p53 targets hMDM2-p2, p21, PUMA, GADD45-alpha and SURVIVIN, for each cell 
line separately. As expected, p53 and hMDMX mRNA levels did not significantly change 
upon Nutlin-3 treatment.  
 
hMDMX overexpression in HER cells is not sufficient to inhibit the Nutlin-3 induced 
p53 response.  
Similar to the observations in VH10, in HER cells Nutlin-3 increased p53, hMDM2 and 
p21 and reduced hMDMX protein levels, which was efficiently blocked by p53-knockdown 
(Fig. 5A). Surprisingly however, hMDMX overexpression hardly rescued these effects. 
Although at the mRNA level (Fig. 5B) the inductions of p53 targets hMDM2-p2, p21 and 
PUMA were indeed slightly attenuated, this appeared to be insufficient to prevent Nutlin-3 
induced growth inhibition, as illustrated by reduced survival (Fig. 5C) and S-phase 
depletion (Fig. 5D).  
 
To explain the differences between the hMDMX-overexpressing VH10 and HER cells in 
their Nutlin-3 response, we compared protein and mRNA levels side-by-side (Fig. 5E and 
F). Strikingly, HA-hMDMX was clearly higher expressed in VH10 cells than in HER cells, 
while endogenous p53, hMDM2 and p21 levels were comparable. As Nutlin-3 not only 
binds hMDM2 but also hMDMX, albeit with much lower affinity [22], the levels of 
hMDMX may affect Nutlin-3 sensitivity. In HER cells, the remaining hMDMX levels after 
Nutlin-3 treatment may not be sufficient to prevent p53 activity. Importantly, we found that 
hMDMX levels in transformed HER cells were comparable to the levels in retinoblastoma 
cell lines Y79 and Weri1 (Fig. 5G). We have previously shown that in these retinoblastoma 
cells p53 is inhibited via high hMDMX expression, and that they are sensitive to Nutlin-3 
[22]. These findings indicate that the transformed retinoblasts provide a representative 
model for retinoblastoma. 
 
The response to Nutlin-3 may also be determined by E2F1 activity, which activates p73. 
Kitagawa et al. [36] reported that Nutlin-3-induced downregulation of E2F1 correlates with 
relative Nutlin-3 resistance, and they suggested that cells lacking RB activity are much 
more prone to entering Nutlin-3-induced apoptosis. Therefore, we compared RB and E2F1 
levels in a selected panel of VH10 and HER cell lines (Fig. 5E). As reported before [37], 
Nutlin-3 decreased total and hyper-phosphorylated (upper band) RB. However, the amount 
of hypo-RB (lower band) was hardly affected. Moreover, after Nutlin-3 treatment, the  
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Figure 5. hMDMX overexpression in HER cells is not sufficient to prevent the Nutlin-3 induced 
p53-activation, which resembles retinoblastoma cell lines.  
A. The various HER cell lines were treated with 10 µM Nutlin-3 for 24 hours, and protein levels were analyzed 
with immunoblotting using the indicated antibodies. B. qRT-PCR analysis of cells treated as in A. Expression 
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levels of hMDM2-p2, p21 and PUMA are shown as the fold induction relative to untreated wild-type HER cells. C. 
The various HER cell lines were continuously treated with 10 μM Nutlin-3 and proliferation was measured after 
120 hours using a WST-1 assay. Relative cell numbers are displayed as survival relative to untreated cells. D. 
Cells were treated with 10 μM Nutlin-3 for 24 hours and analyzed by flow cytometry. Percentages of cells in S-
phase are displayed as indicative for cell proliferation. E. Parental and shRB-HRasV12-HA-hMDMX (RRHX) 
transformed VH10 and HER cells were treated with 10 μM Nutlin-3 for 24 hours and analyzed with 
immunoblotting using the indicated antibodies. F. Quantification of the indicated protein levels using Odyssey 2.1 
analysis software (LI-COR Biosciences) for at least two different exposures. Relative protein levels were 
calculated using Vinculin expression as an internal control and indicated as fold induction relative to untreated 
cells. G. Parental and RRHX transformed HER cells and the retinoblastoma cell lines Y79 and Weri1 were treated 
with 10 μM Nutlin-3 for 24 hours, and analyzed with immunoblotting using the indicated antibodies. 
 
hypo-RB levels in normal and RB-knockdown cells were comparable, and the differences 
between VH10 and HER cells were rather small.  E2F1 reduction at the protein (Fig. 5E) 
and mRNA level (Add. File 3A, upper panel) as observed in the parental VH10 and HER 
cells was attenuated in the transformed cells. The mRNA levels of the E2F1 target gene 
CDC25a followed a similar pattern. Nutlin-3 also reduced the expression of both total p73 
(Add. File 3A, lower panel) and TA-p73 (not shown) in the parental cells. Strikingly, basal 
p73 expression was strongly reduced upon transformation. However, transformed VH10 
and HER cells showed comparable E2F1 regulation and p73 expression, so this cannot 
explain the observed differences in Nutlin-3 sensitivity. Therefore, these dissimilarities are 
more likely the result of different HA-hMDMX levels. 
 
hMDMX overexpression in VH10 cells also inhibited p53 activation by 5-FU and etoposide 
on both mRNA and protein level (Add. File 3B and C), similar as observed with Nutlin-3 
treatments. However, reduced proliferation in response to these drugs occurred mainly 
through p53-independent pathways, because neither p53-knockdown nor hMDMX 
overexpression did not rescue the growth inhibitory effect (Add. File 3D). Nevertheless, 
FACS analysis showed different responses between wild-type, hMDMX-overexpressing 
and p53-knockdown VH10 cells (data not shown). Upon etoposide treatment, wild-type and 
hMDMX-overexpressing cells showed a two-fold reduction of G1 phase and an increased 
G2 fraction. The G2 arrest in p53-knockdown cells was much more severe, with less than 
10% remaining in G1. 5-FU induced S-phase accumulation and G2 reduction in wild-type 
and HA-hMDMX expressing cells, whereas p53-knockdown cells strongly accumulated in 
G1. 
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Table 3. Fold induction mRNA per cell line after Nutlin-3 treatment. 
Cell line 
Nutlin-3 
treatment 
(h) 
p53 p21 hMDM2 hMDM2-p2 hMDMX  PUMA GADD45a SURVIVIN 
  0 1.00 ± 0.19 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.17 1.00 ± 0.16 1.00 ± 0.23 1.00 ± 0.38 1.00 ± 0.16 
VH10 wt 6 1.10 ± 0.18 9.36 ± 1.34 28.62 ± 5.40 43.93 ± 6.93 1.38 ± 0.21 4.90 ± 1.06 5.17 ± 1.45 0.90 ± 0.14 
  24 0.79 ± 0.18 11.98 ± 2.09 26.42 ± 5.42 66.60 ± 11.19 0.95 ± 0.16 4.49 ± 1.25 4.89 ± 1.79 0.02 ± 0.00 
0 1.00 ± 0.09 1.00 ± 0.11 1.00 ± 0.25 1.00 ± 0.09 1.00 ± 0.09 1.00 ± 0.23 1.00 ± 0.11 1.00 ± 0.13 
shp53 6 0.85 ± 0.17 2.24 ± 0.24 1.56 ± 0.31 4.26 ± 0.43 0.91 ± 0.17 1.84 ± 0.35 1.46 ± 0.28 1.18 ± 0.14 
  24 0.63 ± 0.54 5.36 ± 0.45 4.08 ± 0.92 9.46 ± 0.73 1.00 ± 0.12 3.29 ± 0.54 1.28 ± 0.12 0.85 ± 0.11 
HRasV12- 
shp53  
0 1.00 ± 0.35 1.00 ± 0.27 1.00 ± 0.32 1.00 ± 0.28 1.00 ± 0.29 1.00 ± 0.41 1.00 ± 0.28 1.00 ± 0.23 
6 0.81 ± 0.24 1.34 ± 0.33 1.29 ± 0.39 1.97 ± 0.56 1.09 ± 0.41 1.19 ± 0.40 1.14 ± 0.30 0.99 ± 0.22 
24 0.84 ± 0.28 2.11 ± 0.50 1.44 ± 0.36 2.37 ± 0.66 1.18 ± 0.30 1.53 ± 0.47 1.37 ± 0.32 1.06 ± 0.22 
shRB-HRasV12- 
shp53 
0 1.00 ± 0.24 1.00 ± 0.18 1.00 ± 0.22 1.00 ± 0.48 1.00 ± 0.19 1.00 ± 0.18 1.00 ± 0.18 1.00 ± 0.18 
6 0.88 ± 0.24 1.54 ± 0.30 1.16 ± 0.30 2.61 ± 0.97 1.22 ± 0.24 1.22 ± 0.54 1.49 ± 0.63 1.00 ± 0.20 
24 0.98 ± 0.27 2.49 ± 0.67 1.68 ± 0.66 6.32 ± 2.59 1.18 ± 0.38 1.35 ± 0.35 1.76 ± 0.48 0.59 ± 0.16 
0 1.00 ± 0.17 1.00 ± 0.22 1.00 ± 0.03 1.00 ± 0.08 1.00 ± 0.34 1.00 ± 0.14 1.00 ± 0.09 1.00 ± 0.58 
HA-hMDMX 6 0.74 ± 0.23 4.14 ± 0.67 3.47 ± 1.26 11.83 ± 1.00 1.42 ± 0.36 3.05 ± 0.49 1.25 ± 0.58 1.52 ± 0.64 
  24 1.63 ± 0.25 6.86 ± 1.71 11.92 ± 1.36 18.14 ± 2.03 1.80 ± 0.58 5.45 ± 1.00 2.88 ± 0.93 0.48 ± 0.20 
HRasV12- 
HA-hMDMX  
0 1.00 ± 0.14 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.16 1.00 ± 0.22 1.00 ± 0.29 1.00 ± 0.14 1.00 ± 0.16 
6 0.90 ± 0.16 6.78 ± 1.16 9.01 ± 1.83 17.33 ± 2.97 1.09 ± 0.22 3.09 ± 0.91 1.27 ± 0.21 0.79 ± 0.22 
24 0.79 ± 0.10 10.38 ± 2.76 12.08 ± 1.58 26.21 ± 2.95 0.74 ± 0.11 3.50 ± 0.85 1.69 ± 0.19 0.26 ± 0.03 
shRb-HRasV12- 
HA-hMDMX 
0 1.00 ± 0.10 1.00 ± 0.05 1.00 ± 0.09 1.00 ± 0.07 1.00 ± 0.05 1.00 ± 0.26 1.00 ± 0.05 1.00 ± 0.06 
6 1.04 ± 0.13 4.57 ± 0.46 6.46 ± 1.61 13.53 ± 2.08 1.01 ± 0.13 3.10 ± 0.63 1.73 ± 0.26 0.81 ± 0.13 
24 0.99 ± 0.14 5.76 ± 0.92 6.55 ± 0.94 15.36 ± 2.04 0.96 ± 0.14 5.33 ± 1.27 1.71 ± 0.28 0.23 ± 0.03  
VH10 cells were treated with 10 μM Nutlin-3 for the indicated times and analyzed using qRT-PCR. Expression 
was normalized for the housekeeping genes CAPNS1 and TBP. The induction of mRNA expression upon Nutlin-3 
treatment per cell line is shown for p53, p21, hMDM2, hMDM2-p2, hMDMX, PUMA, GADD45alpha and 
SURVIVIN. For each cell line the basal mRNA expression is set at 1.0. 
 
 
Discussion  
In this study, we analyzed the putative oncogenic function of hMDMX in the neoplastic 
transformation of normal human skin fibroblasts (VH10) and Human Embryonic 
Retinoblasts (HER). We chose retinoblasts since hMDMX is frequently overexpressed 
and/or amplified in retinoblastoma development. Retinoblastomas, like most other human 
tumors with increased hMDMX levels, retain wild-type p53 [19-22], suggesting that the 
oncogenic function of hMDMX is primarily based upon p53 inhibition. After RB 
inactivation, E2F1 is activated resulting in elevated p14ARF levels, repression of hMDM2 
and activation of p53. Since hMDMX is not inhibited by p14ARF, hMDMX-
overexpressing cells escape the p53-mediated cell death [38]. 
 
Indeed, we find that constitutive expression of hMDMX in foreskin fibroblasts functionally 
strongly resembles p53-knockdown cells. In combination with other defined genetic 
changes, hMDMX expression contributes to neoplastic transformation. In transformed 
cells, hMDMX overexpression reduces basal mRNA and protein levels of p53 targets, with 
exception of hMDM2 protein levels which are increased most likely via hMDMX-mediated 
stabilization. Vice versa, the expression of p53-repressed genes, like SURVIVIN, is 
increased. The ultimately obtained transformed cells show anchorage-independent growth, 
and can form tumors in an in vivo model. 
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Similarly, hMDMX-expressing HER cells largely resemble p53-knockdown HER cells 
regarding transformed properties, although hMDMX is less able to counteract the 
oncogenic HRas-induced growth inhibition, even in RB-knockdown cells. The ultimately 
obtained transformed cells, with either hMDMX overexpression or p53-knockdown, show 
in vivo growth capacity, although limited. 
 
Our results support the idea that the hMDMX overexpression, which is found in a subset of 
human tumors [19-22], is an important step in the development of that tumor, and that its 
main function is to inactivate p53. Interestingly, recently two transgenic mouse models 
have been described that widely overexpress MDMX [39, 40]. Surprisingly, the phenotypes 
were very different. Whereas mice from the Lozano lab spontaneously developed tumors 
upon MDMX overexpression [39], no spontaneous tumor formation nor cooperation with 
Eµ-Myc-induced tumors was observed in the mice from the Marine lab [40]. In both cases 
the MDMX-overexpressing MEFs or thymocytes showed an attenuated p53 response upon 
Nutlin-3 and IR treatment, respectively, suggesting the expression of a functional MDMX 
protein. It will be important to carefully examine these two mouse models to understand the 
distinct phenotype. This might teach us more about functions of MDMX in tumorigenesis.  
 
In line with these studies, we find that hMDMX overexpression attenuates the Nutlin-3 
mediated p53 activation and growth inhibition in skin fibroblasts. Nutlin-3 has a much 
lower affinity for hMDMX compared to hMDM2 [22, 41], so the effect of hMDMX 
overexpression is probably caused by direct p53 inhibition. Similarly, hMDMX 
overexpression reduces p53 activation by etoposide and 5-FU.  
More strikingly, the hMDMX-overexpressing HER cells are still sensitive to Nutlin-3. The 
p53-response is hardly affected, both regarding regulation of p53 target genes and 
inhibition of cell proliferation. This difference with hMDMX-transformed VH10 cells is 
probably due to the lower hMDMX levels in HER-hMDMX cells, which are even further 
reduced by Nutlin-3. In that respect, the Nutlin-3 response of the transformed retinoblasts 
resembles that of retinoblastoma cell lines. As we have shown before, these retinoblastoma 
cell lines are still sensitive to Nutlin-3 and even show an apoptotic response, despite high 
levels of hMDMX [22].  
 
High hMDMX expression has been reported to attenuate the Nutlin-3 response [42-44]. In a 
study by Patton and colleagues [43], human embryonic lung fibroblasts were transformed 
using hTERT, E1A, and oncogenic Ras, with either hMDMX or hMDM2 overexpression, 
or p53-knockdown, and Nutlin-3 sensitivity was assessed. They found that hMDMX 
overexpression, in contrast to hMDM2, prevented p53 activation upon Nutlin-3 treatment, 
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which fits most of our data. Nutlin-3 did not inhibit soft agar growth of hMDMX-
overexpressing cells in their study. By contrast, we found partial inhibition of soft agar 
growth by Nutlin-3, whereas growth in a monolayer was not affected at all. Possibly, in 3D 
additional stress is posed upon the cells, causing super-activation of p53 that cannot be 
completely counteracted by hMDMX proteins. 
The discussed fibroblast models also show a different Nutlin-3 response: IMR-90 cells 
entered apoptosis, whereas in VH10 cells Nutlin-3 mainly inhibited cell growth without 
induction of apoptosis (data not shown). Notably, IMR-90 cells are embryonic lung cells; 
embryonic cells are less differentiated and can be more easily transformed. Furthermore, 
Patton et al. used adenovirus E1A for RB inactivation, but E1A proteins have additional 
growth affecting functions, including attenuation of the p53 response by interacting with 
p300/CBP [45, 46]. Therefore, a clean appreciation of the effects of hMDMX on the p53 
response in the presence of E1A is difficult.  
 
Beside hMDMX levels, also other factors may be involved in determining the outcome of 
Nutlin-3 treatment. Kitagawa et al. [36] have shown that RB status and E2F1 activity are 
important contributors. However, we found only minor changes in E2F1 activity in our 
model, which cannot explain the differences in Nutlin-3 sensitivity. Interestingly, the E2F1 
target TA-p73 was dramatically decreased upon transformation. This might be a result of 
HRasV12 activity; oncogenic Ras has been described to switch the expression from TA-
p73 to the antagonistic ΔN-p73, an important step during transformation. TA-p73 was 
reported to prevent anchorage-independent growth via activation of KCNK1 [47]. 
However, since transformed fibroblasts as well as retinoblasts express low levels of p73, 
this does not provide an explanation for the differential Nutlin-3 responses. 
 
Conclusions  
In conclusion, we find that hMDMX overexpression can replace loss of p53 during the 
transformation process of human fibroblasts and embryonic retinoblasts. In addition, very 
high hMDMX levels, as observed in VH10 cells, can prevent p53 activation by Nutlin-3. 
However, lower hMDMX levels like in the HER cells can no longer inhibit p53 after 
Nutlin-3 treatment, because hMDMX protein is mostly degraded by elevated hMDM2 
levels, as previously shown in other tumor cells [48]. The Nutlin-3 response of the 
transformed HER cells resembles that of retinoblastoma cell lines, indicating that this is a 
physiologically relevant model. A combination therapy using Nutlin-3 and a specific 
hMDMX inhibitor, possibly a low dose of a DNA damaging agent leading to hMDMX 
degradation, might result in more effective treatment of tumors expressing wild-type p53 
and high levels of hMDMX. 
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Table 4. List of used antibodies. 
Protein Name/ cat. # Company 
hMDMX A300-287A Bethyl Laboratories, Montgomery TX, USA 
hMDMX 6B1A [50] 
HA-tag HA.11 Covance, Princeton, New Jersey, USA 
HA-tag ab9110 Abcam, Cambridge, UK 
p53 ° DO-1 / sc-126 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
p53 ° PAb 1801 / sc-98 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
p53 FL-393 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
hMDM2 * /MDM2 4B2 [51] 
hMDM 2 * SMP14 sc-6965 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
p21 CP74 / 05-655 Upstate Biotechnology, Lake Placid, NY, USA 
RB G3-245 / 554136 BD Pharmingen, Franklin Lakes, New Jersey, USA 
HRas Y13-259 [52] 
HAUSP/USP7 A300-033A Bethyl Laboratories, Montgomery TX, USA 
HAUSP/USP7 7G9 [53] 
p21 CP74 / 05-655 Upstate Biotechnology, Lake Placid, NY, USA 
γ-tubulin GTU-88 / T6557 Sigma-Aldrich, St Louis, MO, USA 
Antibodies used in this study are listed in table 4, together with name or category number and the 
name of the company. For detection of human p53 we used a mix of DO-1 and 1801 (°), for 
detection of human Hdm2 we used a mix of 4B2 and SMP14 (*).  
Table 5. Primer sequences  
hMDM2-P2 Fw 5’-acgcacgccactttttctct- 3’ 
hMDM2-P2 Rv 5’-tccgaagctggaatctgtgag- 3’ 
P53 Fw 5’-ctctccccagccaaagaagaa- 3’ 
P53 Rv 5’-tccaaggcctcattcagctct- 3’ 
hMDMX Fw 5’-aggtgcgcaaggtgaaatgt- 3’ 
hMDMX Rv 5’-ccatatgctgctcctgctgat- 3’ 
PUMA Fw 5’-gacctcaacgcacagta- 3’ 
PUMA Rv 5’-ctaattgggctccatct- 3’ 
p21 Fw 5’-agcagaggaagaccatgtgga- 3’ 
p21 Rv 5’-aatctgtcatgctggtctgcc- 3’ 
SURVIVIN Fw 5’-gagacagaatagagtgatagg- 3’ 
SURVIVIN Rv 5’-gacagatgtgaaggttgg- 3’ 
GADD45A Fw 5’-gcgacctgcagtttgcaata- 3’ 
GADD45A Rv 5’-atcccccaccttatccatcct- 3’ 
CAPNS1 Fw 5’-atggttttggcattgacacatg- 3’ 
CAPNS1 Rv 5’-gcttgcctgtggtgtcgc- 3’ 
TBP Fw 5’-cacgaaccacggcactgatt- 3’ 
TBP Rv 5’-ttttcttgctgccagtctggac- 3’ 
RPS11 Fw 5’-aagcagccgaccatctttca- 3’ 
RPS11 Rv 5’-cgggagcttctccttgcc- 3’ 
SRPR Fw 5’-cattgcttttgcacgtaaccaa- 3’ 
SRPR Rv 5’-attgtcttgcatgcggcc- 3’ 
CDC25A Fw 5’-ctccgagtcaacagattcagg- 3’ 
CDC25A Rv 5’-ttcaaggttttctttactgtccaa- 3’ 
Sequences of qRT-PCR primers used in this study.
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Methods 
 
Generation of stably transformed human cell lines 
Primary human fibroblasts (VH10) and Human Embryonic Retinoblasts (HER) were immortalized by introducing 
human Telomerase (hTERT). Cells were maintained in DMEM supplemented with 10% FBS, 1% glutamine, 
antibiotics, amino-acids, glucose and vitamins. Stably transformed cell lines were generated in subsequent 
retroviral infection rounds according to the transformation schemes in Fig. 1A and 1C. pRetroSuper-shRB-Hygro 
and pRS-Hygro [25] were used for RB-knockdown or control cell lines, followed by hygromycin selection (50 
µg/ml). pMSCV-blast-Ras or pMSCV-blast [25] were used for HRasV12 overexpression or control cell lines, 
followed by blasticidin selection (5 µg/ml). pBABE-HA-hMDMX-puro or pRS-shp53-puro [25] were used for 
hMDMX overexpression or p53-knockdown, both combined with pMSCV-GFP-st [25] for SV40-small-t 
expression, followed by puromycin selection (0.5 µg/ml). Cell lines were maintained under selection pressure. 
Immunoblotting 
Cells were lysed in Giordano 250 buffer (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM 
EDTA), with protease- and phosphatase inhibitors. Proteins were separated by SDS-PAGE, transferred onto 
polyvinyldene difluoride membranes (Immobilon-P, Millipore) and incubated with the appropriate primary (listed 
in Table 4) and HRP-conjugated secondary antibody (Jackson Laboratories). Bands were visualized by enhanced 
chemiluminescence (Super Signal; Pierce). Alternatively, membranes were incubated with secondary antibodies 
coupled to IRdye-680 and IRdye-800 near Infrared dyes (LI-COR Biosciences), and analyzed with the Odyssey 
Infrared Imager (LI-COR Biosciences). Signals were quantified using the Odyssey 2.1 analysis software (LI-COR 
Biosciences). 
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.2 % Triton X-100 for 10 min, 
blocked with 5% Normal Goat Serum (NGS) for 1 hour and incubated with primary antibodies for 1.5 hours and 
anti-mouse-Rhodamine secondary antibody (Jackson Laboratories) for 30 min. Coverslips were mounted onto 
microscope slides using DAPI-DABCO mounting solution. 
RNA isolation, qRT-PCR 
RNA was isolated using the SV Total RNA isolation kit (Promega, Madison, WI). cDNA was synthesized using 
1.0 μg RNA in Reverse Transcriptase reaction mixture (Promega). Samples were analyzed in triplicate using 
SYBR Green mix (Roche Biochemicals, Indianapolis, IN) in a 7900ht Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA). For normalization the geometric mean of at least two housekeeping genes was used. 
Primer sequences are available in Table 5. 
Growth assay, soft agar assay 
For growth assays, 1000 cells were seeded in triplicate in 96-wells plates; treatments were started 24 hours after 
seeding. Cells were incubated with WST-1 reagent (Roche) for 1-4 hours and absorbance (450 nm) was measured 
in a microplate reader (Victor3 Multilabel Counter 1420-042, Perkin-Elmer).   
Soft agar assays were performed in 96-well plates (VH10) or 6-well plates (HER) coated with a 0.6 % agarose 
bottom-layer. Per well, 5000 VH10 or 20.000 HER cells were seeded in 0.3 % agarose. Colony outgrowth was 
monitored (10x magnification, Olympus CKX41) and pictures were taken at several time points. 
Flow cytometry 
Cells were harvested, washed with PBS and fixed ice-cold 70 % ethanol. Cells were washed in PBS and incubated 
in PBS containing 50 µg/ml propidium iodide and 50 µg/ml RNase. Flow cytometry was performed in a BD LSR 
II system (BD Biosciences). 
Cytogenetic methods and combined binary ratio fluorescence in situ hybridization (COBRA-
FISH)  
Culturing, harvest conditions and karyotyping were performed according to standard protocols [49]. Slides with 
metaphase chromosomes were hybridized using a multicolor FISH approach. Staining, digital imaging, and 
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analysis were performed as described previously [30]. Hybridizations with individual libraries labeled with single 
fluorochromes were used to confirm the detected rearrangements. Chromosomal breakpoints were assigned by 
using inverted images counterstained with 4’,6-diamidino-2-phenylindole (DAPI; Downers Grove, IL) together 
with the information derived from the short- and long-arm specific hybridization during COBRA-FISH. 
Karyotypes were described according to ISCN 2009. 
Shell-less Chicken Chorioallantoic Membrane (CAM) assay  
Fertilised chicken eggs were incubated at 37C in humidified atmosphere. After 4 days they were cracked open 
into plastic dishes. At day 7, two-and-half million cells transduced with turbo-GFP lentiviral construct (SHC003, 
Sigma-Aldrich) were mixed with 50 µl basement membrane matrix (BD Biosciences) and grafted onto the CAM. 
At day 17, tumors with surrounding CAM were removed and the size was measured. GFP-positive tumors were 
photographed using a fluorescence stereomicroscope. Tumors were embedded in paraffin, sectioned and stained 
with anti-Vimentin, clone V9 (Santa Cruz) and anti-phospho-Histone-3 (Upstate, Millipore). Percentage of 
proliferating cells was calculated by quantifying phospho-Histone-3 positive nuclei of on average 500 nuclei from 
5 random pictures per sample. 
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Additional files 
 
Additional File 1. Overexpressed HA-hMDMX is localised both nuclear and cytoplasmic and 
does not alter p53 and hMDM2 localisation. 
Localisation of hMDMX, hMDM2 and p53 in various VH10 (A, B) and HER (C, D) cell lines was determined by 
immunofluorescence using the indicated antibodies. DAPI staining was used to visualise nuclei, GFP signal 
represents SV-40 small-t expression. 
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Additional File 2. Karyotyping of VH10 and HER cell lines. 
Karyotypes of transformed VH10 (A) and HER (B) cell lines using combined binary ratio labeling-fluorescence in 
situ hybridization (COBRA-FISH). Representative karyograms after COBRA-FISH hybridization are shown for 
each cell line.  
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Additional File 3. hMDMX overexpression inhibits p53 response but does not rescue the growth 
inhibition induced by 5-fluoro-uracil or etoposide in human fibroblasts.  
A. The indicated VH10 and HER cell lines were treated with 10 μM Nutlin-3 for 24 hours and analyzed with qRT-
PCR. Expression levels of E2F1, CDC25a (upper panel) and p73 (lower panel) were normalized for housekeeping 
genes RPS11 and CAPNS1. B. Indicated VH10 cell lines were treated for 24 hours with 25 µM 5-FU, 5 µM 
etoposide or mock treated, and analyzed with qRT-PCR. Expression levels of hMDM2-p2 and p21 were 
normalized for housekeeping genes CAPNS1 and SRPR. C. Protein levels of cells treated as in B were analyzed 
with immunoblotting using the indicated antibodies. D. Cell growth was monitored using WST-1 proliferation 
assays. 24 hours after seeding the cells were treated for 24 hours with the indicated drugs. Cell proliferation was 
measured at day 0, 2 and 4 after treatment. 
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Abstract 
 
Tumour suppressor p53 is functionally attenuated in virtually all human tumours. In 
osteosarcoma, only ~20% of tumours contain a p53 mutation and 10-35% has amplification 
of p53-inhibitor HDM2 (MDM2), suggesting alternative p53-inhibiting mechanisms in the 
remaining tumours, such as overexpression of another p53 inhibitor, HDMX 
(MDMX/MDM4). An oncogenic function of HDMX in other tumour types has been 
shown. Expression of an alternative HDMX splice variant (HDMX-S) is correlated with 
worse survival and high tumour grade in several tumour types. In this study we analyzed 
HDMX expression and alternative splicing in high-grade osteosarcomas and osteosarcoma 
cell lines. We found increased HDMX-S expression in a high number of osteosarcoma, 
correlating with shorter disease-specific survival and increased occurrence of metastases. 
Analysis of osteosarcoma cell lines showed a clear association of high HDMX-S expression 
with mutant or inactivated p53 and low HDMX protein expression. These findings were 
confirmed and validated in two independent panels of tumour cell lines, the NCI60 and a 
set of breast cancer cell lines. The clinical meaning of these findings was emphasized by 
the better prognostic value of the HDMX-S / HDMX-FL ratio than p53 mutational status in 
a cohort of soft tissue sarcoma patients.  
Using RNAi techniques to reduce HDMX levels in osteosarcoma cell lines, we observed a 
largely p53-independent growth inhibition and p53-dependent increased Nutlin-3-
sensitivity. Furthermore, relatively high levels of full-length HDMX protein may be 
associated with cisplatin and doxorubicin resistance of osteosarcoma cells. Our results 
indicate a p53-independent role for HDMX in osteosarcomagenesis, whereas in later stage 
and clinically aggressive tumours a switch occurs towards the splice-variant HDMX-S, 
thereby reducing HDMX-FL protein levels. This altered ratio may serve as a new predictive 
biomarker for p53 inhibition in diverse tumour types. 
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Introduction 
 
Osteosarcoma is the most common primary bone malignancy in children and adolescents, 
occurring mostly in patients between 10 and 25 years and found in the rapid growth areas 
of the long bones [Raymond et al., 2002].The vast majority of osteosarcoma arises without 
clear hereditary setting, while a small subset occurs in the context of Li-Fraumeni 
syndrome or progeria syndromes. Overall survival for patients with non-metastatic 
osteosarcomas has been increased from 10 to 65% over the past 20 years, due to improved 
surgical techniques and multidrug chemotherapy, but further improvement is lacking 
[Lewis et al., 2007]. However, 25-50% of the patients will have a relapse or will present 
metastasis and survival for metastatic osteosarcomas is only 10-20% [Buddingh et al., 
2010; Gelderblom et al., 2011]. Alternative therapeutic targets are required to complement 
the existing treatments to increase the survival of osteosarcoma patients.  
 
In approximately 50% of all human cancers mutations are found in the TP53 gene, 
encoding the tumour suppressor protein p53 [Hollstein et al., 1991; Hainaut and Hollstein, 
2000; Goh et al., 2011] and its activity is attenuated in many wild-type p53 tumours 
[Vogelstein et al., 2000]. Only 20% of high-grade osteosarcoma have p53 mutations 
[Yokoyama et al., 1998; Park et al., 2004; Wunder et al., 2005], while DNA of the negative 
regulator of p53, HDM2, an E3 ubiquitin ligase for p53 [Kawai et al., 2003; Meulmeester et 
al., 2003], was found to be amplified in 10-35% of osteosarcoma and mutations in p53 and 
HDM2 amplification were mutually exclusive [Yokoyama et al., 1998; Park et al., 2004; 
Wunder et al., 2005; Ito et al., 2011]. In many studies on p53 as a prognostic marker for 
osteosarcoma, HDM2 analysis was not included, thereby possibly underestimating the 
influence of p53 inactivation on prognosis. Even more, p53 activity might also be inhibited 
by HDMX, the near homolog of HDM2, which also functions as an essential inhibitor of 
p53 [Shvarts et al., 1996; Marine and Jochemsen, 2005]. Not much is known about the 
HDMX status in osteosarcoma, whereas for several other tumour types it has been reported 
that HDMX does exert an oncogenic function. Overexpression and amplification of HDMX 
has been shown both in tumour samples [Riemenschneider et al., 2003; Danovi et al., 2004] 
and tumour cell lines, mostly correlating with wild-type p53 status [Ramos et al., 2001]. 
Strikingly, retinoblastoma and Ewing sarcoma, tumour types that mostly retain wild-type 
p53, show very frequently increased HDMX expression [Laurie et al., 2006; Pishas et al., 
2010]. 
Recently, HDMX amplification was reported in soft tissue sarcomas (16%) and 
osteosarcomas (35%) [Ito et al., 2011]. Earlier, Bartel et al. already found an association in 
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soft tissue sarcomas between HDMX gene amplification (in 17% of soft tissue sarcomas) 
and poor prognosis [Bartel et al., 2005]. Furthermore, mRNA expression of an alternative 
splice variant of HDMX, HDMX-S, was found to be upregulated in 14% of STS samples 
and the increased HDMX-S/HDMX-FL ratio correlated with tumour grade and decreased 
patient survival, independent of HDMX-FL levels. This ratio was also found to be increased 
in high-grade glioblastomas [Riemenschneider et al., 2003] and papillary thyroid 
carcinomas [Prodosmo et al., 2008]. The HDMX-S transcript contains an internal deletion 
of 68 nucleotides caused by skipping of exon 6 [Rallapalli et al., 2003], resulting in 26 
unique C-terminal amino acids and a premature stop codon (Fig.1A). The HDMX-S protein 
consists mainly of the p53 binding domain and was shown in overexpression studies to bind 
and inhibit p53 more efficiently than HDMX-FL. HDMX-S expression was found increased 
in transformed- and serum-stimulated normal cells [Rallapalli et al., 1999]. Although these 
studies suggest an oncogenic role for HDMX-S, hardly any data are available on the level 
and function of the endogenous HDMX-S protein.  
 
In this study we analyzed clinical osteosarcoma samples and osteosarcoma cell lines for 
HDMX mRNA expression and splicing, and manipulated HDMX protein levels in a set of 
osteosarcoma cell lines to investigate a putative oncogenic role of HDMX in osteosarcoma. 
We found an association between elevated HDMX-S mRNA levels and inactivated or 
mutant p53, which predicted a worse survival and enhanced risk for metastasis formation in 
osteosarcoma. Importantly, the correlation between the p53 functionality and alternative 
HDMX splicing was confirmed in two independent sets of tumour cell lines, the NCI60 
panel and a set of 39 breast cancer cell lines. Analysis of a set of soft tissue sarcoma 
revealed that the relatively enhanced HDMX-S expression is a better prognostic marker than 
p53 mutational status, indicating the clinical relevance of the HDMX-splicing.  
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Materials and Methods 
 
Patient Material 
Clinicopathological data of a group of 51 high-grade osteosarcoma patients are shown in 
Table 1. The majority of the tumors were of the osteoblastic histological subtype and 82% 
of the patients was between 10 and 25 years old at diagnosis. Part of the samples was 
previously described [Buddingh et al., 2011]. Biopsies were taken before pre-operative 
chemotherapeutics were administered. Difference in response to chemotherapy was 
classified as good or poor response, using the Huvos criteria [Huvos, 1991]. All tissue 
samples were handled according to the National Ethical Guidelines (‘Code for Proper 
Secondary Use of Human Tissue in The Netherlands’, Dutch Federation of Medical 
Scientific Societies). Soft tissue sarcoma patient material was described previously [Bartel 
et al., 2005]. 
 
Cell Culture and Reagents 
Cell lines were maintained in RPMI supplemented with 10% fetal bovine serum and 
antibiotics. Most of the osteosarcoma cell lines have been described previously [Ottaviano 
et al., 2010] and recently characterized with regard to phenotype and metastatic behaviour 
in vivo [Mohseny et al., 2011]. Osteosarcoma cell lines L2531, L2635, L2792, L2826, 
L2857 and L2962 were recently established at the Dept. of Molecular Cell Biology, 
LUMC in the lab of Dr. Szuhai. Normal osteoblasts were obtained as described previously 
[Cleton-Jansen et al., 2009]. Cells were treated with Nutlin-3 (Cayman Chemical, Ann 
Arbor, MI, USA), doxorubicin (Sigma-Aldrich, St Louis, MO, USA ) or cisplatin (Sigma-
Aldrich, St Louis, MO, USA) for the indicated times and concentrations.  
 
Plasmids, Lentiviral Transduction  
The construction of lentiviral vectors expressing specific shRNAs and the production of 
lentivirus particles have been described recently [Lam et al., 2010]. Information and 
sequences of shRNAs are available in Supplementary Information.  
 
Proliferation assay, Colony Forming assay, FACS analysis 
For proliferation assays 2000-2500 cells were seeded in a 96-wells plate, and the assays 
were performed as described earlier [Lam et al., 2010]. For colony forming assays 3000-
4000 cells were seeded in duplicate per condition in 6-wells plates; cells were treated for 
three days with 3 µM Nutlin-3 or mock treated and fixated and stained eight days after 
seeding. Colonies were quantified with the Odyssey Infrared Imager and Odyssey 2.1 
analysis software (LI-COR Biosciences, Lincoln, Nebraska USA). 
For FACS analysis 100,000 cells were seeded in 6-cm dishes 24 hours before mock or 
Nutlin-3 treatment. Cells and medium were harvested after 48 hours of treatment, fixated 
and analyzed on the Flow cytometer (Beckton Dickinson, Franklin Lakes, NJ USA) using 
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FACS DIVA software after incubation in PBS with 50 µg/ml propidium-iodide (PI) and 50 
µg/ml RNase. 
 
RNA isolation, Reverse Transcription, Semi-Quantitative PCR and Q-RT-PCR  
RNA was isolated using the SV Total RNA Isolation System (Promega) according to the 
manufacturer’s protocol, followed by cDNA synthesis following standard protocols. Semi-
Quantitative PCR was performed according to standard protocols; primer sequences are 
available in Supplemental Information. Band intensities were quantified using Odyssey 2.1 
analysis software (LI-COR Biosciences, Lincoln, Nebraska USA). Quantitative-Real-Time 
PCR (q-RT-PCR) amplification of cDNA derived from frozen osteosarcoma material and 
manipulated cell lines was performed on the ABI 7900HT thermocycler, using FastStart 
Universal SYBR-Green Master (ROX) mix (Roche Biochemicals, Indianapolis, IN, USA). 
Details and primer sequences are available in Supplemental Information.  
The cDNAs for NCI60 cell lines panel were obtained from National Cancer Institute 
(NCI)/NIH Developmental Therapeutics Program. qRT-PCR amplification of all cell line 
cDNA was performed in triplicate duplex reactions with Applied Biosystem 7500 detector 
according to manufactures recommendations using FAM labelled TaqMan probes (Applied 
Biosystems), HDMX-FL (Hs00967241_m1; exon 5-6) and HDMX-S (custom made 
HDMX-S_F: 5’-GCCCTCTCTATGATATGCTAAGAAAGAATC-3’; HDMX-S_R: 5’-
TTCTGTAGTTCTTTTTCTGGAAGTGGAA-3’; HDMX-S_M FAM: 5’-
CTGCACTTTGCTGTAGTAGC-3’). Relative gene expression was normalized according 
to expression of GAPDH measured in same reaction with VIC labelled TaqMan probe 
(4326317E, Applied Biosystem). 
Measurements of HDM2 transcript levels were performed by qRT-PCR using 
commercially available RoboGene®MDM2 cDNA quantification module, with ABI 
PRISM 7000 Sequence Detection System. HDM2 measurements were normalised to 
GAPDH transcript levels.  
 
Protein extraction, Western blotting and Antibodies 
Protein extraction and immunoblotting were performed as described previously [Lam et al., 
2010]. The antibodies are described in Supplementary Information.  
 
Statistical Analysis 
Data are presented as the mean±S.D. of duplicates or triplicates, and represent at least two 
independent experiments. Differences between various groups were evaluated either by 
one-way ANOVA followed by Bonferroni's Multiple Comparison Test or two-tailed 
unpaired Student’s t-Test. P<0.05 was considered as statistically significant. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. Survival analysis was done using the Kaplan-Meier 
and the Cox's multivariate proportional hazards regression model with GraphPad software. 
Patients who were alive at the time of the last follow-up were included as censored data 
into the survival analyses. 
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Table 1. Clinicopathological data of 51 high grade osteosarcoma patients 
Patient 
ID Age Sex 
Histological 
subtype Tumour Location Huvos ToM ToD ToF Origin 
L3446 174 M Giant cell rich left distal femur 4 0, 16 27 27 WWU 
L3447 162 M Osteoblastic left proximal humerus 2 16 21 21 WWU 
L3448 170 M Osteoblastic left distal femur 3 0, 22  46 WWU 
L3449 133 F Fibroblastic left distal femur 1 10  28 WWU 
L3431 81 F Osteoblastic humerus 1 5 11 11 WWU 
L3432 144 M Chondroblastic tibia 2 30  37 WWU 
L3433 204 F Osteoblastic left femur 1 9 33 33 WWU 
L3434 181 M Sclerosing right proximal tibia 1 25  25 WWU 
L3435 200 M Osteoblastic right proximal femur 1 0, 13 30 30 WWU 
L3436 205 M Chondroblastic left distal femur 3 9 35 35 WWU 
L3437 183 M Osteoblastic distal femur 2 0, 21 27 27 WWU 
L3438 220 M Osteoblastic right proximal tibia 4 0, 18  26 WWU 
L3439 385 M Chondromyxoid fibroma like right humerus 1 10 18 18 WWU 
L3440 264 M Osteoblastic femur 1 10  36 IOR 
L3441 228 M Osteoblastic femur 3 24  123 IOR 
L3442 144 F Osteoblastic femur 3 44 110 110 IOR 
L3443 204 F Fibroblastic humerus 2   63 IOR 
L3444 264 M Fibroblastic humerus 1   60 IOR 
L3445 696 F Telangiectatic tibia    60 IOR 
L1386 101 M Osteoblastic diaphysis femur left 1   105 LUMC 
L2295 487 F Anaplastic proximal femur left 2   97 LUMC 
L2611 242 F Osteoblastic distal femur right 3   91 LUMC 
L2281 212 M Osteoblastic proximal fibula left 2 36 64 64 LUMC 
L2298 244 F Anaplastic distal femur right 3   94 LUMC 
L2300 217 M Osteoblastic proximal fibula right 3   87 LUMC 
L2297 137 F Osteoblastic proximal tibia left 2   77 LUMC 
L2292 136 M Osteoblastic proximal tibia left 3   78 LUMC 
L2613 181 M Osteoblastic proximal tibia right 3   40 LUMC 
L2614 165 M Osteoblastic distal femur left 2 0 29 29 LUMC 
L2615 261 M Osteoblastic proximal tibia left 3   35 LUMC 
L2616 218 M Osteoblastic proximal fibula left 2 24  32 LUMC 
L2617 181 F Osteoblastic proximal tibia left 4   32 LUMC 
L2618 96 M Osteoblastic distal femur left 2 0  31 LUMC 
L1368 177 M Osteoblastic distal femur left 4 0  95 LUMC 
L1369 212 F Osteoblastic distal femur right 2 17 83 83 LUMC 
L1370 216 M Osteoblastic distal femur left 3   246 LUMC 
L1016 200 M Osteoblastic proximal tibia left 1 6 10 10 LUMC 
L2619 128 F Osteoblastic distal femur right 1 0 25 25 LUMC 
L1372 200 M Telangiectatic distal femur right 1 0 25 25 LUMC 
L2620 217 M Osteoblastic distal femur left 2   219 LUMC 
L428 192 F Osteoblastic proximal tibia right 2   193 LUMC 
L436 37 F Osteoblastic proximal tibia left 4   194 LUMC 
L1376 164 F Telangiectatic proximal tibia right 1 18 40 40 LUMC 
L1378 197 F Fibroblastic, MFH-like distal femur left 2  14 14 LUMC 
L2294 205 F Osteoblastic distal femur left 1   147 LUMC 
L2289 136 M Fibroblastic distal femur left 2   135 LUMC 
L2290 440 M Fibroblastic distal femur left 2 10 13 13 LUMC 
L2301 304 M Osteoblastic proximal ibia left 2 27 47 47 LUMC 
L1382 175 M Osteoblastic distal tibia right 2   143 LUMC 
L2302 229 F Chondroblastic proximal humerus right 2   120 LUMC 
L1385 200 M Osteoblastic proximal humerus left  0 11 11 LUMC 
Time: all shown in months; ToM: time of detection metastasis, measured from diagnosis; ToD: time of death, 
measured from diagnosis; ToF: time of follow up, measured from diagnosis; WWU: Westfälische 
Wilhemsinversität, Münster, Germany; IOR: Instituti Ortopedici Rizzoli, Bologna, Italy; LUMC: Leiden 
University Medical Centre, The Netherlands. 
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Results 
 
HDMX-S mRNA is relatively high expressed in osteosarcoma 
Clinical data of 51 fresh frozen osteosarcoma biopsies are shown in Table 1.  
Evaluation of HDMX mRNA expression of osteosarcoma samples, normal osteoblasts and 
MCF-7 cells revealed predominant HDMX-S expression in 75% (38/51) of osteosarcoma 
samples, whereas in normal osteoblasts and MCF-7 cells mainly HDMX-FL is expressed 
(Fig. 1B and Table 2).  
 
Table 2. Ratio between HDMX-S and HDMX-FL mRNA in 51 osteosarcomas samples. 
# 
Sample 
ID 
Ratio 
S:FL  # 
Sample 
ID 
Ratio 
S:FL 
1 L1368 0.90  28 L2292 1.00 
2 L1376 2.17  29 L2613 0.80 
3 L2290 1.13  30 L2615 0.69 
4 L1385 0.38  31 L2616 1.74 
5 L2295 0.72  32 L2618 3.42 
6 L2611 1.77  33 L3446 3.72 
7 L2300 1.17  34 L3447 2.24 
8 L2614 4.86  35 L3448 2.92 
9 L2617 1.19  36 L3449 n.d.* 
10 L1369 1.25  37 L3431 4.07 
11 L1370 0.85  38 L3432 1.29 
12 L1016 3.18  39 L3433 1.56 
13 L2619 0.84  40 L3434 3.29 
14 L1372 1.19  41 L3435 1.89 
15 L2620 2.77  42 L3436 2.06 
16 L436 1.39  43 L3437 1.44 
17 L428 0.83  44 L3438 2.89 
18 L1378 1.12  45 L3439 1.20 
19 L2294 1.15  46 L3440 2.30 
20 L2289 0.44  47 L3441 2.02 
21 L2301 1.00  48 L3442 2.63 
22 L1382 0.91  49 L3443 n.d.* 
23 L2302 1.88  50 L3444 1.80 
24 L1386 0.82  51 L3445 2.80 
25 L2281 0.68   OB 0.18 
26 L2298 0.85   MCF7 0.15 
27 L2297 1.30     
PCR bands representing HDMX-FL and HDMX-S shown in 
Fig.1B were quantified with densitometry and the ratio 
HDMX-S / HDMX-FL for each sample was calculated.  
* Upper band below detection limit 
 
To find out if this ratio showed any correlation with sensitivity to pre-operative 
chemotherapy, the ratio was compared between good (Huvos grades 3 and 4, ≥90% 
necrosis after chemotherapy) and bad responders, but no significant difference was found 
(Supp. Fig. 1A). However, in the group of patients that express mainly HDMX-FL, there is 
a significantly longer disease specific survival compared to the HDMX-S group (104 vs. 58 
months, P= 0.0153, Unpaired t test, for patients died within or followed at least for 3 years) 
(Table 3).  
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Table 3. Analysis of clinicopathological data and HDMX mRNA expression. 
Ratio HDMX-FL / HDMX-S HDMX-FL > HDMX-S HDMX-S ≥ HDMX-FL 
 Total 13 38 
  Male/Female 5/8 23/15 
Response Huvos 1 2 12 
 Huvos 2 5 14 
 total bad response 7 (54%) 26 (68%) 
    
 Huvos 3 4 7 
 Huvos 4 1 4 
 total good response 5 (38%) 11 (29%) 
  unknown 1 (7.7%) 1 (2.6%) 
  HDMX-FL > HDMX-S HDMX-S ≥ HDMX-FL 
 3 year cut-off    
 free  8 11 
 metastasis 4 24 
 deceased 2 13 
 not deceased 10 15 
    HDMX-FL > HDMX-S HDMX-S ≥ HDMX-FL 
 5 year cut-off   
 free  7 11 
 metastasis 4 25 
 deceased 2 15 
  not deceased 9 14 
Calculated mRNA ratios between HDMX-S and HDMX-FL were compared 
between different groups within the group of 51 osteosarcoma samples.  
 
Results of Kaplan-Meier analysis for overall survival indicated a trend for high HDMX-S 
levels associating with worse survival (Supp. Fig. 1B).  Furthermore, Cox multivariate 
regression survival analysis (Supp. Fig. 1C), that was adjusted for tumour stage, showed a 
significant difference between the high and low HDMX-S group (P = 0.036). Interestingly, 
the group of patients that developed metastases within a follow-up time of 3 years, show a 
significantly higher HDMX-S /HDMX-FL ratio, (1.6 fold; P = 0.013, Unpaired t test) (Table 
3 and Supp. Fig. 1D). Confirming, q-RT-PCR analysis revealed no significant increase in 
HDMX-FL levels (P= 0.99, Unpaired t test) in patients with metastasizing tumours, whereas 
total HDMX mRNA is significantly higher (P= 0.0199, Unpaired t test). Therefore, the 
increase in total HDMX mRNA must be caused by increased HDMX-S levels (Supp. Fig. 
1D). These observations were confirmed in the Kaplan-Meier analysis for metastasis free 
survival, which shows clear significant differences between the high, medium and low 
HDMX-S groups (p=0.002; Fig. 1C). Cox multivariate regression survival analysis (Fig. 
1D) supported these differences (P = 0.002), indicating HDMX-S as an independent 
prognostic factor for metastasis-free survival in these tumours. 
 
No significant differences in mRNA levels of p53, HDM2, HDMX-FL, total HDMX and 
p21 between bad or good responders were found (data not shown). Only 6% of the samples 
showed increased mRNA HDM2 and HDMX expression, suggesting a low number of 
HDM2 and HDMX amplification (data not shown). 
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Figure 1. Analysis of HDMX-S mRNA expression in osteosarcoma biopsies 
Fig. 1A Schematic drawing of HDMX protein structure (upper), containing the p53 Binding Domain (p53-BD), 
Acidic Domain (AD), Zinc-finger (Zn) and RING Domain. Structure of HDMX-FL and HDMX-S mRNA is 
depicted below. Arrows indicate the start and stop codon in both mRNA structures. Exon 6 is spliced out in 
HDMX-S resulting in 26 novel amino acids and a premature stop codon. Fig. 1B Expression pattern of HDMX-FL 
and HDMX-S mRNA in 51 osteosarcoma biopsies, normal osteoblasts and breast cancer cell line MCF7. Results of 
semi-quantitative PCR with HDMX primers in exon 3 (FW) and exon 8 (Rev), resulting in bands for both HDMX-
FL and -S. Fig. 1C Kaplan-Meier analysis of metastasis free survival of osteosarcoma patients (n=51) using high, 
medium and low HDMX-S/HDMX-FL ratio as prognostic factors. Patients that were alive, but not followed for the 
complete time-of-follow up are indicated as censored (P = 0.002, Mantel-Cox). Patients that already developed 
metastases before the beginning of observation time were excluded from the analysis (n=6). Fig. 1D Results 
analyzed in Fig. 1C were confirmed by Cox multivariate regression survival analysis, controlled for tumour 
staging (P= 0.004). 
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Analysis of osteosarcoma cell lines 
A number of established and freshly cultured osteosarcoma cell lines, of which a subset was 
recently characterized regarding p53 status/expression, HDM2 gene amplification and 
protein expression [Ottaviano et al., 2010], were analyzed for p53, HDM2 and HDMX 
protein/mRNA expression. Results are summarized in Table 4.  
 
Table 4. Summary of p53 status, HDM2 and HDMX levels in 22 osteosarcoma cell 
lines. 
  Protein Levels  mRNA Levels  
# name p53 HDM2 HDMX 
Rel. 
Quant. 
HDMX
 HDMX splicing
Ratio 
S/FL 
Rel. 
Quant. 
HDMX-FL
Rel. 
Quant. 
HDMX-S
Nutlin-3 
response group 
0 Osteoblast wt n.a n.a. n.a.  FL 0.18 n.a. n.a. n.a. n.a. 
1 U2OS wt + high 1.89  FL/S 0.71 0.80 0.57 + 1 
2 KPD wt + high 2.03  FL/S 1.16 0.55 0.64 + 1 
3 MHM wt(high) high low 0.18  S 1.31 0.54 0.70 + 3 
4 OSA/SJSA1 wt high low 0.22  S 1.40 0.55 0.77 + 3 
5 L2792 wt high very low 0.01  S 1.83 0.25 0.46 + 3 
6 L2962 wt (low) very low low 0.29  FL 0.61 0.58 0.36 + 2 
7 OST mt low low 0.24  S 2.31 0.48 1.10 - 2 
8 HOS mt(high) low high 0.84  S 1.27 0.75 0.95 - 1 
9 HOS-143b mt(high) low low 0.11  S 2.34 0.34 0.80 - 2 
10 HOS-MNNG mt(high) low low 0.51  S 1.77 0.33 0.59 - 2 
11 IOR/OS15 mt(high) low low 0.30  S 2.63 0.40 1.04 - 2 
12 HAL mt low high 3.44  FL 0.39 1.45 0.56 - 1 
13 IOR/OS18 neg + low 0.67  S 1.56 0.70 1.09 - 2 
14 MG-63 neg low + 2.18  S 1.46 0.85 1.24 - 1 
15 ZK58 neg low + 1.30  S 1.51 0.41 0.62 - 1 
16 HOS58 neg + low 0.45  S 1.56 0.84 1.31 - 2 
17 IOR/OS9 neg low low 0.27  S 2.05 0.76 1.56 - 2 
18 SaOS2 neg low low 0.18  S 2.78 0.39 1.09 - 2 
19 L2531 neg low low 0.52  S 2.07 0.56 1.16 - 2 
20 L2857 neg low + 0.76  S 1.31 0.48 0.62 - 1 
21 L2826 neg low very low 0.00  S 3.18 0.39 1.23 - 2 
22 L2635 neg low + 0.71  S 1.32 1.50 1.97 - 1 
Result of p53 pathway analysis of 22 osteosarcoma cell lines is shown in Table 4. P53 status was deducted 
from results of protein analysis, RNA analysis and Nutlin-3 response. Protein levels of both HDM2 and 
HDMX as shown in fig. 2A were quantified using densitometry, and normalized to USP7 expression. 
HDMX mRNA levels as shown in Fig. 2B were quantified, normalized to GAPDH expression and ratio 
HDMX-S/ HDMX-FL was calculated. Nutlin-3 response was analyzed by western blotting as shown in 
Supp. Fig 2A. Cell lines were named Nutlin-3 responsive when an induction of p53 protein levels and it 
target genes was observed, indicating the presence of functional, wild type p53. Cell lines were divided in 3 
groups, as indicated by number. Group 1 has relatively high HDMX, low HDM2, group 2 low HDMX and 
low HDM2 and group 3 has low HDMX and high HDM2 protein levels.  
 
P53 status 
P53 status was analyzed by immunoblotting of protein extracts of untreated cells and cells 
treated with Nutlin-3, a small molecule inhibitor of the p53-HDM2 interaction [Vassilev et 
al., 2004], which activates p53. Out of 22 cell lines, only 6 lines had detectable p53 protein 
levels and showed a functional p53 response. A huge overexpression of p53 was observed 
in 4 out of 22 cell lines, whereas no p53 response was observed upon Nutlin-3 treatment, 
suggesting the expression of a mutant p53. No or very weak p53 protein expression was 
found in 12 out of 22 cell lines, of which some were previously reported to contain a wild-
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type p53 gene (IOR/OS9, ZK-58 and MG-63) [Ottaviano et al., 2010] (Table 4 and Supp. 
Fig. 2A). The p53 response of p53 wild-type cell line KPD is shown in Figure 4.  
 
HDM2 and HDMX status 
Three of the six wild-type p53 cell lines, MHM, OSA and L2792, express very high HDM2 
protein levels, caused by HDM2 gene amplification ([Ottaviano et al., 2010] and Szuhai et 
al., personal communication, 2011) and two express high levels of HDMX (U2OS and 
KPD; Fig. 2A). Proliferation assays and FACS experiments (Supp. Fig. 2B and C) clearly 
showed that high HDM2 expression correlates with a strong, apoptotic Nutlin-3 response, 
as reported previously [Xia et al., 2008]. HDMX overexpressing cells were relatively 
resistant to Nutlin-3 treatment, but stopped proliferating. 
 
Ratio HDMX-S / HDMX-FL 
Out of 22 analyzed osteosarcoma cell lines, 17 (77%) have a ratio HDMX-S/HDMX-FL 
≥1.3 (Fig. 2B and Table 4). Strikingly, in p53 wild-type cells this ratio is significantly lower 
(P=0.0146, Unpaired t test). These results were confirmed using quantitative RT-PCR using 
probes designed to detect the specific transcripts. Specifically, as the HDMX-S splice 
variant excludes exon 6 (Fig. 1A), we used a probe that covers the exon 5/6 boundary to 
detect HDMX-FL and a probe that covers the exon 5/7 boundary to detect HDMX-S. Based 
on HDMX and HDM2 protein expression levels, 3 groups of cell lines were made, shown 
in Table 4. Group 1 (High HDMX, low HDM2) and group 2 (Low HDMX, low HDM2) 
differ significantly in average HDMX-FL mRNA expression (1.5-fold higher in group 1, 
P=0.034, Unpaired t test), as well as the ratio between HDMX-S and HDMX-FL (P=0.0034, 
Unpaired t test), correlating with HDMX protein levels. In group 3 (Low HDMX, High 
HDM2), the high HDM2 protein expression most likely is responsible for the low HDMX 
protein levels [de Graaf P. et al., 2003]; although HDMX-FL is still moderately expressed, 
the level of HDMX protein is very low. 
 
Functional p53 inhibition associates with elevated HDMX-S levels in a diverse cell line 
panel. 
The results from the analysis of the HDMX transcripts in the osteosarcoma cell panel 
suggest that p53 inactivation is associated with an increase in HDMX-S transcript and an 
increase in the HDMX-S/HDMX-FL ratio. In order to further validate these observations in 
a second, independent cell panel and possibly extend these results to cancer cell lines 
derived from cancers other than osteosarcoma, we measured levels of the HDMX-FL and 
HDMX-S transcripts in the NCI60 cell line panel which consist of 59 cell lines from 9 
distinct tumour types (Supplemental Table 1): non-small cell lung cancer (9), breast cancer 
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(5), central nervous system cancers  (6), colon cancer (7), leukaemia (6), melanoma (9), 
ovarian cancer (7), prostate cancer (2) and renal cancer (8) [Shoemaker, 2006]. Of the 59 
cell lines, 14 are known to have wild type p53, while 36 cell lines have either mutated or 
deleted p53 and for 9 cell lines the p53 status is inconclusive [Caron de Fromentel and 
Soussi, 1992; Berglind et al., 2008]. To measure the HDMX-FL and HDMX-S transcripts, 
we used quantitative RT-PCR using the probes described above. Interestingly and similar to 
the associations in the osteosarcoma cell panel, HDMX-S levels in mutant p53 are on 
average 2 fold higher than in cells with wild type p53 (Table 5). Specifically, cells with 
wild type p53 had on average delta CT measurements of 11.38 for the HDMX-S variant 
compared to average delta CT measurements of 10.43 in cells with mutant p53 (p= 0.0398, 
Unpaired t test). No significant differences in HDMX-FL were noted (p= 0.21, Unpaired t 
test). Therefore, as expected and predicted by the osteosarcoma cell panel data, the HDMX-
S/HDMX-FL ratio is also significantly lower in cells with wild type p53 compared to the 
average ratio in cells with mutant p53 (p= 0.0063, Mann-Whitney test).  
As mentioned above, another mechanism that cancers like osteosarcoma use to inhibit p53, 
other than somatic p53 mutation, is the overexpression of HDM2. We, therefore, were 
interested to explore if p53 inhibition by HDM2 overexpression, without p53 mutation, 
would also associate with elevated HDMX-S levels. To do this, we measured HDM2 
transcript levels in cell lines that have retained wild type p53. Strikingly, we found the 
levels of the HDMX-S transcript positively correlated with HDM2 levels (correlation 
coefficient 0.763, Spearman, p= 0.001). Indeed, this correlation results in a 2-fold increase 
in HDMX-S expression those 5 cells with wild type p53 and the highest levels of HDM2 
compared to those 5 cells with wild type p53 and the lowest HDM2 levels (p= 0.019, 
Unpaired t test, Table 5). No significant differences in HDMX-FL were noted (p= 0.907, 
Unpaired t test). Therefore, as expected, the HDMX-S/HDMX-FL ratio is also significantly 
higher in cells with wild type p53 and the highest HDM2 levels compared to the average 
ratio in cells with wild type p53 and the lowest HDM2 levels (p= 0.0487, Unpaired t test).  
These results could be confirmed by quantification of the specific HDMX bands resulting 
from semi-quantitative PCR amplification (Suppl. Fig. 3A and Suppl. Table 2). Overall, 
when we compared the HDMX-S/HDMX-FL ratio of cells with functional active p53 (wild-
type p53 and low HDM2) with that of cells that have either mutant p53 or high HDM2 
levels, we found a 5-fold increase in the cells with functionally inactivated p53 (P = 0.07, 
Unpaired t test) and observed a significant increase of HDMX-S levels (P =0.002, Unpaired 
t test). 
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Figure 2.  Analysis of 22 osteosarcoma cell lines 
Protein and RNA was extracted from 22 asynchronically growing osteosarcoma cell lines. Fig. 2A Protein levels 
were analyzed with immunoblotting using the indicated antibodies. USP7 expression was analyzed as loading 
control. Fig. 2B 22 osteosarcoma cell lines and 1 osteoblast sample were examined for HDMX-FL and HDMX-S 
mRNA expression using primers for HDMX exon 3 (Fw) to exon 8 (Rev). GAPDH mRNA expression was 
examined as an internal control. 
 
Table 5. Functional p53 inactivation is associated with elevated HDMX-S levels in the 
NCI60 
    
Reciprocal Ratio  
delta CT S/FL  HDMX-FL* HDMX-S* 
p53 
wt (n=14) 0.90 10.18 11.38 
mut (n=36) 1.05 10.77 10.43 
p value 0.0063** 0.2139*** 0.0398*** 
wt p53  
low HDM2 (n=5) 0.78 10.54 12.39 
high HDM2 (n=5) 0.95 10.71 10.53 
p value 0.0487*** 0.907*** 0.019*** 
Q-RT-PCR analysis was performed on cDNAs of the NCI60 cell line panel, using specific probes for HDMX-
FL and HDMX-S, as described in Material and Methods section. Delta CT values were calculated using 
GAPDH as a housekeeping gene. Delta CT and the reciprocal ratios delta CT HDMX-S/HDMX-FL are 
displayed for p53 wild-type or mutant cell lines and for high or low HDM2 expressing p53 wild-type cells. P-
values of differences between groups were calculated using unpaired T-Test or Mann-Whitney test, as 
indicated. * average delta CT; ** Mann-Whitney test; *** Unpaired t test 
 
p53 inactivation associates with elevated HDMX-S levels in a breast cancer cell line 
panel. 
To further validate these observations, we analysed the HDMX-FL and HDMX-S mRNA 
expression in a set of 39 breast cancer cell lines, previously described [Hollestelle et al., 
2009] (Supp. Fig. 3B and Supp. Table 3). Again we found a significantly higher HDMX-
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S/HDMX-FL ratio in cell lines that were indicated as mutant p53 (2.5-fold, P= 0.014, 
Unpaired t test), with significantly lower HDMX-FL levels in mutant p53 cells. Moreover, 
wild-type p53 cells showed significantly higher HDMX protein expression than mutant p53 
cells (5-fold, P = 3*10-7 Unpaired t test).  
 
The mRNA ratio HDMX-S/HDMX-FL is a better prognostic factor than p53 
mutational status.  
To find out more about the clinical meaning of these results, we re-analysed the data of a 
set of soft tissue sarcomas, which were previously analysed for HDMX-S expression and 
p53 status [Bartel et al., 2005]. Preliminary data indicate that the ratio HDMX-S/HDMX-FL 
is a better prognostic factor for overall survival than p53 mutation status. Kaplan-Meier 
analysis for overall survival using p53 mutation as a prognostic factor yields only small 
differences (P = 0.509, Kaplan-Meier) (Supp. Fig. 3C), whereas using high, medium or low 
HDMX-S/HDMX-FL ratio clearly separates the three groups (P= 0.013, Kaplan-Meier). 
Cox multivariate regression survival analysis confirms these results (P= 0.005, Cox) (Supp. 
Fig. 3D).  
 
HDMX inhibits basal expression of p53 targets in the osteosarcoma cell line KPD.  
To elucidate a possible role of HDMX in osteosarcoma cells retaining wild-type p53, we 
performed HDMX-knockdown experiments in the osteosarcoma cell line KPD, which has a 
relatively high HDMX protein expression. To be able to assess a function for p53-
regulation upon HDMX knockdown, initially a stable p53-knock-down KPD-derivative 
was generated, with the appropriate control. Subsequently, these cells were transduced with 
either HDMX- or a non-targeting control knockdown virus, and the effects of decreased 
HDMX levels on cell proliferation and response to stress were assessed. Knockdown of 
HDMX was performed with two short hairpin RNA constructs, sh-HDMX#1 and sh-
HDMX-3’-UTR. Either alone or combined the HDMX knockdown constructs resulted in a 
relative good knockdown (Fig. 3A). Confirming the role of HDMX as an inhibitor of p53, 
decreasing HDMX resulted in increased mRNA levels of HDM2-P2, p21 and GADD45-
alpha, all transcriptional targets of p53 (data not shown). Accordingly, protein levels of 
HDM2, p21 and p53 are slightly induced, whereas in p53 knockdown cell-lines these 
effects are strongly diminished (Fig. 3A). 
 
HDMX knockdown inhibits growth of osteosarcoma cell lines independent of p53. 
To assess the effects of HDMX knockdown on cell proliferation and survival, both short- 
and long-term growth assays were performed. In a short-term growth assay, HDMX-
knockdown significantly inhibited cell growth (P<0.0001), resulting in a relative survival 
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between 50 and 60% three days after seeding (Fig. 3B). Surprisingly, the observed growth 
inhibition appeared to be independent of p53 (P<0.0001 for p53-knockdown cells). 
Accordingly, this was not only observed in KPD cells, which express high levels of 
HDMX, but also in U2OS cells (Supp. Fig. 4A), OSA, MHM cells and in two cell lines 
with inactive or mutant p53, OST and HAL, respectively (Supp. Fig. 4B). In long-term 
growth assays (colony formation), knocking down HDMX in KPD cells results in a rather 
strong reduction in the number of colonies formed (P<0.0001), which appears to be partly 
p53-dependent (Fig. 3C).   
FACS analyses showed a slight decrease of the number of cells in S-phase, which was 
accompanied by a small increase of cells in G2/M and sub-G1 phase upon HDMX 
knockdown. In cells with reduced p53 levels, this G2 arrest was even somewhat enhanced, 
again indicating a p53-independent function of HDMX in these cells (Fig. 3D). 
 
Reducing HDMX levels sensitizes the osteosarcoma cell line KPD for Nutlin-3 induced 
growth inhibition.  
HDMX inhibits p53 transcriptional activity in a similar way as HDM2, but has a much 
lower affinity for Nutlin-3 [Laurie et al., 2006]. Therefore, Nutlin-3 treatment might be less 
effective in tumours with high HDMX levels.  
Control- and HDMX- knockdown KPD cells were treated with Nutlin-3, leading to a p53 
response. Consequently, protein and mRNA levels of p53 targets HDM2 and p21 increased 
and HDMX protein levels slightly decreased after 48 hrs of treatment; all these effects are 
strongly reduced in p53-knockdown cells. When HDMX levels are reduced, no significant 
differences in changes of HDM2 and p21 at the protein and RNA level upon Nutlin-3 
treatment are observed (Fig. 4A and B). However, the pro-apoptotic protein PUMA, is 
somewhat stronger upregulated in the cells with reduced HDMX levels (Fig. 4A). 
Consistently, HDMX knockdown sensitizes KPD cells for Nutlin-3-mediated growth 
inhibition, observed both in short-term (P<0.01) and long-term assays (P<0.01) (Fig. 4C-E). 
Furthermore, FACS analysis of cell cycle distribution showed that HDMX knockdown 
enhances the loss of S-phase cells and the number of G2/M cells in Nutlin-3 treated cells, 
which is diminished by concomitant p53 knockdown (Fig. 4F). Importantly, reducing 
HDMX levels strongly sensitizes the KPD cells for Nutlin-3 induced apoptosis as 
illustrated by the strong increase in sub-G1 cells, in a p53-dependent manner.  
In conclusion, the relatively high HDMX levels in the KPD osteosarcoma cell line do 
significantly impact on the efficacy of Nutlin-3 mediated growth-inhibition, most likely by 
attenuation of the p53-mediated apoptotic response. 
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Figure 3. HDMX inhibits basal p53 activity and stimulates the growth of the 
osteosarcoma cell line KPD, independent of p53  
Stable control- and p53-knockdown KPD cell lines were established and lentiviral transduced with either control-, 
two different HDMX knockdown constructs or a combination of both knockdown vectors. Cells were counted four 
days post-infection and seeded for various experiments. Fig. 3A Two days after seeding, protein was extracted and 
analyzed with immunoblotting using the indicated antibodies. USP7 expression was analyzed as loading control. 
Fig. 3B Proliferation of control- and p53-knockdown cells transduced with a control- or one of two HDMX 
knockdown vectors was measured 72 hours after seeding and is depicted as relative survival to the corresponding 
control cell line. Fig. 3C Colony formation of transduced cells was measured eight days after seeding and 
displayed as relative to the corresponding control cells. Fig. 3D FACS analysis was performed five days post-
infection on stable control- or p53-knockdown KPD cells, transduced with either control- or two distinct HDMX 
knockdown constructs; representative pictures for HDMX knockdown are shown. Indicated are percentages of 
cycling cells in G1, S or G2/M phase and percentages of single cells in SubG1. Differences between various 
groups were evaluated by one-way ANOVA followed by Bonferroni's Multiple Comparison Test. P<0.05 was 
considered as statistically significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Figure 4. HDMX plays a minor role in the Nutlin-3 induced p53 activation in U2OS 
cells Stable control- and p53-knockdown KPD cells were lentiviral transduced with control- or a combination of 
two different HDMX knockdown constructs. At day 5 post-infection, cells were either mock- or Nutlin-3 (10 µM) 
treated for 24 and 48 hours. Protein extracts were isolated and analyzed with immunoblotting using the indicated 
antibodies. USP7 expression was analyzed as loading control. Representative blots are shown in Fig. 4A.  
Fig. 4B mRNA expression levels of HDM2-P2 and p21 of mock- and 24 hours Nutlin-3 (10 µM) treated cells 
were quantified using q-RT-PCR and are shown as normalized relative mRNA levels. Fig. 4C Proliferation of 
cells treated for 24 hours with 10 µM Nutlin-3 was measured 72 hours after start of treatment and is depicted as 
relative survival to the corresponding mock-treated cells. Differences between various groups were evaluated by 
one-way ANOVA followed by Bonferroni's Multiple Comparison Test. P<0.05 was considered as statistically 
significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Fig. 4D At day 4 post-infection, cells were seeded 
for colony forming assays. Cells were treated with Nutlin-3 (3 µM) for 24 hours one day after seeding and colony 
formation was monitored eight days later. Colonies were quantified and displayed as relative colony formation to 
mock-treated cells. Representative pictures of the formed colonies are shown in Fig. 4E. Fig. 4F FACS analysis 
was performed on KPD cells transduced with the indicated knockdown constructs, mock- or Nutlin-3 (10 µM) 
treated for 48 hours. Indicated are percentages of cycling cells in G1, S or G2/M phase and percentages of single 
cells in SubG1. Figures shown of mock-treated cells are the same as shown in figure 3D. 
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Full length HDMX stimulates the growth of osteosarcoma.  
To investigate the role of HDMX-S in the growth of osteosarcoma cells, we performed 
either total HDMX- or full-length specific HDMX knockdown, using a target sequence in 
exon 6 of the HDMX mRNA, which is not present in HDMX-S mRNA. For this experiment 
we used not only KPD but also OST cells, the latter expressing predominantly HDMX-S 
mRNA (Fig. 2B). It is important to note that despite the high HDMX-S mRNA levels in 
OST cells, only full length HDMX protein could be detected (Fig. 5A). Reducing HDMX-
FL in OST cells affected cell proliferation slightly, but significantly, similar to the effect of 
total HDMX knockdown (Fig. 5B (left panel)). Since the OST cell line contains a mutant 
p53 and does not respond to Nutlin-3 treatment (Table 4, Fig. 5A), no differences in growth 
between control cells and cells with reduced full-length or total HDMX were observed 
when treated with Nutlin-3 (Fig. 5B (right panel)).   
 
The reduction of either HDMX-FL or total HDMX in KPD cells (Fig. 5C) resulted in a 
comparable inhibition of cell growth (Fig. 5D (left panel) and colony formation (Fig. 5E 
(left panel)), correlating with the knockdown efficiency, which was somewhat lower for the 
HDMX-FL specific knockdown. Consistently, total and HDMX-FL specific knockdown 
had comparable effects on basal and Nutlin-3 induced protein levels (Fig. 5C) and Nutlin-3 
sensitivity in cell proliferation and colony formation assays (Fig. 5D and E (right panels)). 
In conclusion, our data indicate that the growth inhibition of osteosarcoma cell lines caused 
by HDMX knockdown is mainly through loss of HDMX-FL. 
  
HDMX knockdown sensitizes KPD cells for cisplatin and doxorubicin.   
Control and HDMX-knockdown KPD cells were treated with either cisplatin or 
doxorubicin and the growth/survival response was analyzed. The growth of control KPD 
cells is not affected by this rather low dose of cisplatin (1 µM), but reducing HDMX levels 
sensitized for cisplatin treatment, independent of p53 (P<0.01 for control- and P<0.05 for 
p53-knockdown cells) (Fig. 6A (left panel)). Accordingly, cisplatin did not significantly 
induce p53, p21 and HDM2 protein levels. Only a minor reduction of HDMX protein in 
KPD cells is observed (Fig. 6B), most likely due to enhanced degrading activity of HDM2, 
since HDMX mRNA levels remain constant (Fig. 6C). HDMX knockdown in KPD cells 
increased the cisplatin-induced mRNA levels of the pro-apoptotic p53 targets PUMA 
(P<0.01) and GADD45-alpha (P<0.05), whereas the induction of cell-cycle regulator p21 
and of HDM2-P2 is not significantly altered (Fig. 6D).  
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Figure 5. Full length HDMX stimulates the growth of osteosarcoma. 
OST and KPD cells were lentiviral transduced with control-, total HDMX- or full length-specific HDMX-exon 6 
knockdown constructs. At day 5 post-infection, cells were treated with 10 µM Nutlin-3 for the indicated times or 
mock-treated and protein extracts were isolated. Fig. 5A Protein extracts of transduced OST cells were analyzed 
with immunoblotting using the indicated antibodies. The MX-82 anti-HDMX antibody is able to detect both full 
length HDMX and HDMX-S. USP7 expression was analyzed as loading control. * indicates an a-specific band, 
FL indicates size of full length HDMX, S indicates the region HDMX-S protein was expected to be detected. 
Transduced OST cells were seeded for a proliferation assay and mock- or Nutlin-3 treated for 24 hours. 
Proliferation was measured 72 hours after start treatment. Proliferation of mock treated cells (left panel) is 
displayed as survival relative to control infection of the corresponding cell line. The effect of Nutlin-3 on the 
proliferation (right panel) is displayed as survival relative to the corresponding mock-treated cells.  
Fig. 5C Transduced KPD cells were treated with 10 µM Nutlin-3 or mock treated one day after seeding and 
protein extracts were isolated 24 hours later. Protein extracts were analyzed with immunoblotting using the 
indicated antibodies; USP7 expression was analyzed as loading control. Fig. 5D Transduced KPD cells were 
seeded for a proliferation assay, mock- or Nutlin-3 (10 µM) treated for 24 hours, and proliferation was measured 
72 hours after start treatment. Proliferation of mock-treated cells (left) is displayed as survival relative to control 
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infection of the corresponding cell line. The effect of Nutlin-3 on the proliferation (right) is displayed as survival 
relative to the mock-treated cells of the same transduction. Fig. 5E Transduced KPD cells were seeded for colony 
forming assays, mock- or Nutlin-3 (3 µM) treated for 24 hours and colony formation was quantified 8 days later. 
Colony formation is displayed relative to control infection (left) or mock-treated cells of the same infection (right). 
Differences between various groups were evaluated by one-way ANOVA followed by Bonferroni's Multiple 
Comparison Test. P<0.05 was considered as statistically significant. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001.  
 
Whereas cisplatin caused no growth inhibition in control cells, treatment of KPD cells with 
0.5 µM doxorubicin for 24 hours resulted in dramatic, partially p53-dependent growth 
inhibition. Nevertheless, HDMX-knockdown cells are even more sensitive for doxorubicin 
(P<0.0001) (Fig. 6A (right panel)) and the enhanced sensitivity is partially p53-dependent 
(P<0.1 for p53-knockdown cells). This concentration of doxorubicin causes highly 
increased p53 protein levels, good induction of HDM2 and p21 levels on both protein and 
RNA level and degradation of HDMX protein (Fig. 6B and D). Interestingly, we also 
observed a decrease in HDMX-FL mRNA levels, accompanied with increasing HDMX-S 
expression (Fig. 6C). The induced protein levels of p53 and HDM2 are similar in the 
control and HDMX-knockdown cells, whereas p21 protein levels are slightly higher in 
HDMX-knockdown cells, correlating with mRNA levels (P<0.05 for p21) (Fig. 6D). 
Furthermore, in HDMX-knockdown cells we observe higher doxorubicin-induced levels of 
PUMA (P<0.01) and GADD45-alpha (P<0.05).  
 
In conclusion, reducing HDMX protein levels in the KPD osteosarcoma cell line does 
slightly, but significantly enhance the sensitivity for cisplatin and doxorubicin.  
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Figure 6. HDMX knockdown slightly sensitizes osteosarcoma cells for cisplatin or 
doxorubicin treatment 
Stable control and p53 knockdown KPD cells were lentiviral transduced with control- or HDMX-knockdown 
constructs. At day 5 post-infection, cells were treated with 1 µM cisplatin or 0.5 µM doxorubicin for 24 hours or 
mock treated. Fig. 6A Survival of cisplatin- (left) or doxorubicin- (right) treated cells was measured 72 hours after 
start of the treatment and depicted as relative survival compared to the corresponding mock-treated cells. Fig. 6B 
Protein extracts were analyzed with immunoblotting using the indicated antibodies; USP7 expression was 
analyzed as loading control. Fig. 6C mRNA was isolated and analysed using semi-quantitative RT-PCR using 
primers in HDMX exon 3 (Fw) to exon 8 (Rev), resulting in bands for both HDMX-FL (FL) and HDMX-S (S). 
mRNA expression of GAPDH was investigated as an internal control. Fig. 6D mRNA expression levels of p21, 
HDM2-P2, PUMA and GADD45-alpha were quantified using q-RT-PCR and are shown as normalized relative 
mRNA levels. Differences between control- and HDMX-knockdown cells were evaluated by two-tailed unpaired 
Student’s t-Test. P<0.05 was considered as statistically significant. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
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Discussion  
 
In this study, the putative oncogenic role of the p53 inhibitor HDMX in osteosarcoma was 
investigated. A role for HDMX in osteosarcoma formation was suggested by the relatively 
low frequency of p53 mutations and HDM2 amplification in this type of tumours 
[Yokoyama et al., 1998; Park et al., 2004; Wunder et al., 2005; Ito et al., 2011]. In several 
tumour types, amplification and overexpression of HDMX was correlated with p53 wild-
type status [Riemenschneider et al., 1999; Danovi et al., 2004; Laurie et al., 2006; Pishas et 
al., 2010], tumour grading [Riemenschneider et al., 2003] and worse prognosis [Bartel et 
al., 2005]. Furthermore, a number of studies report increased mRNA expression of HDMX-
S in various cancers [Riemenschneider et al., 1999; Bartel et al., 2005; Prodosmo et al., 
2008]. Interestingly, many tumours that showed increased HDMX-S mRNA levels had 
down-regulated HDMX-FL, both on RNA as protein level [Bartel et al., 2005; Prodosmo et 
al., 2008], correlating with later tumour stage. This might indicate that HDMX expression 
loses its oncogenic function in highly aggressive tumours with p53 function impaired by 
other means than via inhibition by HDMX.  
Consistent with these findings, we recently suggested that the main function of increased 
HDMX-S/HDMX-FL ratio is to decrease HDMX-FL protein levels [Lenos and Jochemsen, 
2011]. We could show that even in cells expressing high and predominantly HDMX-S 
mRNA, only full length HDMX protein can be detected (Fig. 5A and [Lenos and 
Jochemsen, 2011]). Probably, the HDMX-S protein is very unstable or inefficiently 
translated and, therefore, most likely will not play an important, dominant role in cell 
proliferation. Furthermore, it was found that upon treatment with various drugs, the 
reduction of full length HDMX protein is accompanied by a shift from HDMX-FL to 
HDMX-S mRNA expression ([Lenos and Jochemsen, 2011] and this study).  
In this study we observed predominant overexpression of HDMX-S mRNA in a high 
number of osteosarcoma tissue samples (75%) and cell lines (77%). Especially, cells with 
inactive p53 and low HDMX protein levels express relatively high HDMX-S mRNA. 
Strikingly, predominant HDMX-S expression was correlated with a much worse patient 
survival and was significantly more frequent in clinically aggressive tumours that 
developed metastases within 3 years. Very recently, a subset of the cell lines mentioned in 
this study was analyzed for in vivo growth characteristics, including the capacity to 
metastasize [Mohseny et al., 2011]. One of the tested cell lines was found to produce 
metastases, HOS-143B, whereas the parental HOS cell line did not. Confirming our 
hypothesis, we find a dramatically increased HDMX-S/HDMX-FL ratio and significantly 
decreased HDMX protein levels in HOS-143B cells compared to HOS cells (Fig. 2A and 
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B). Survival analysis indicated an association between high HDMX-S expression and poor 
overall or metastasis-free survival. Our results in osteosarcoma were validated in 
independent sets of other cell lines derived from diverse tumour types, resulting again in an 
association between high HDMX-S expression and mutant or inactive p53. Furthermore, we 
could confirm a significantly higher HDMX-FL protein expression in wild-type p53 cells, 
whereas no expression of the shorter HDMX-S was found. 
 Preliminary data in a set of soft tissue sarcoma further indicated that the ratio between 
HDMX-S/HDMX-FL might serve as a better prognostic factor than p53 mutation. p53 
mutational status will not include p53 inactivation by other factors, such as HDM2 
amplification, whereas we show that a high ratio HDMX-S / HDMX-FL does take such 
factors into account.  
All in all, these data validate the significance of the observations made in the osteosaroma 
cell panel and extends it to other cancers. It also supports the model that inhibition of p53 
activity, by either p53 gene mutation or overexpression of HDM2, leads to elevated HDMX-
S levels in cells. Furthermore, we have shown that a high ratio HDMX-S/HDMX-FL may 
serve as a good new prognostic biomarker.   
 
Moreover, our results are in line with previous findings in other tumours and indicate a loss 
of function of HDMX-FL in more aggressive, advanced stage tumours with inactivated 
p53. The expression of full length HDMX protein is reduced by the prevalence for the 
alternative splice-variant HDMX-S, which is very inefficiently translated or produces a very 
unstable protein. A possible explanation for the apparent selection against HDMX 
expression might be that HDMX has growth inhibitory functions which are only obvious 
when the p53 pathway is not functional. This idea is supported by the Jones’ lab, which 
showed in a mouse model that in the absence of p21 or in p53-negative MEFs, MDMX has 
a growth suppressive role [Steinman et al., 2004; Steinman et al., 2005]. Later, it was 
demonstrated that MDMX suppresses transformation and tumourigenesis by promoting 
bipolar mitosis in p53 negative cells [Matijasevic et al., 2008].  
 
Whereas in fresh osteosarcoma tumours only a low frequency of p53 mutation is found, 
establishment of osteosarcoma cell lines is apparently accompanied by strong selection for 
loss of p53 expression. This selection might complicate the interpretation of the analysis of 
these cells and is not likely to reflect the clinical situation. Only six out of the 22 cell lines 
(27%) here analyzed, showed a p53-response upon Nutlin-3 treatment. Two of these 
express relatively high levels of HDMX (KPD, U2OS). Using these cell lines, we show in a 
comprehensive way that HDMX-FL overexpression may indeed play a subtle role in the 
inhibition of basal and activated p53 levels. When cells were treated with the p53 activating 
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agent Nutlin-3, HDMX expression inhibits the apoptotic response and reduction of HDMX 
resulted in enhanced increase of pro-apoptotic genes such as PUMA and GADD45-alpha 
when cells are treated with the DNA damaging drugs cisplatin and doxorubicin. 
Furthermore, HDMX seems to inhibit the basal levels of the p53 targets p21 and HDM2, 
thereby playing a role in normal cell cycle regulation.    
 
Interestingly, we found that HDMX also fulfils a p53-independent function in stimulating 
the proliferation of various (p53-negative and -positive) osteosarcoma cells, illustrated by 
the growth inhibition caused by HDMX knockdown. Apparently alternative growth 
suppressing processes are inhibited by high HDMX expression. Further research to 
elucidate the mechanism of this novel function of HDMX in osteosarcoma is required, 
since it might be an interesting drug target for a subset of these tumours. Interference with 
this inhibitory function of HDMX will reduce cell growth and might enhance the effect of 
chemotherapeutic agents in osteosarcomas that are relatively resistant to p53 reactivation. 
Currently, several p53 reactivation therapies are in development, like adenoviral restoration 
of wild-type p53, mutant p53 reactivation or p53 stabilisation, some already used in clinical 
trials, reviewed in [Vazquez et al., 2008]. Since HDMX overexpressing tumours have been 
reported to be more resistant to the p53 reactivating agent Nutlin-3, the use of recently 
discovered HDMX inhibitors [Bernal et al., 2010] might provide new ways for 
osteosarcoma treatment.  
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Supplemental Table 1. Summary of NCI60 cell line panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of NCI cell line panel, including name of cell line, origin of tumour, p53 status and Q-RT-PCR data on 
HDM2, HDMX-FL and HDMX-S. * = inconclusive. 
# name origin p53
zmol 
MDM2/ 
amol 
GAPDH
MDMX-
FL 
delta ct
MDMX-
S delta 
ct
Ratio 
deltaCT 
S/FL 
Reci-
procal 
Ratio 
deltaCT
S/FL 
# name origin p53
zmol 
MDM2/ 
amol 
GAPDH
MDMX-
FL 
delta ct
MDMX -
S delta 
ct
Ratio 
deltaCT 
S/FL 
Reci - 
procal 
Ratio 
deltaCT 
S/FL 
1 A549 NSCL wt 64.9 11.05 12.59 1.14 0.88 31 HT29 Colon mut 56.2 9.16 8.42 0.92 1.09 
2 NCI -H460 NSCL wt 145.9 8.65 11.81 1.37 0.73 32 KM12 Colon mut 33.7 10.10 13.15 1.30 0.77 
3 MCF7 Breast wt 171.0 7.47 9.16 1.23 0.82 33 SW-620 Colon mut 52.0 11.84 10.61 0.90 1.12 
4 HCT- 116 Colon wt 94.3 7.79 12.10 1.55 0.64 34 CCRF-CEM Leukemia mut 46.0 8.16 10.06 1.23 0.81 
5 SR Leukemia wt 109.0 9.91 11.68 1.18 0.85 35 HL-60(TB) Leukemia mut 35.2 10.58 9.41 0.89 1.12 
6 LOX IMVI Melanoma wt 79.7 10.81 13.71 1.27 0.79 36 K-562 Leukemia mut 149.5 10.70 8.37 0.78 1.28 
7 MALME- 3M Melanoma wt 280.2 10.74 10.64 0.99 1.01 37 RPMI-8226 Leukemia mut 88.8 9.67 8.06 0.83 1.20 
8 SK - MEL-5 Melanoma wt 82.3 9.51 11.62 1.22 0.82 38 M14 Melanoma mut 49.3 12.38 10.40 0.84 1.19 
9 UACC -257 Melanoma wt 549.7 12.94 9.80 0.76 1.32 39 MDA-MB-435 Melanoma mut 25.1 10.66 8.79 0.82 1.21 
10 UACC -62 Melanoma wt 81.6 13.58 11.93 0.88 1.14 40 SK-MEL-2 Melanoma mut 55.7 9.31 12.11 1.30 0.77 
11 A498 Renal wt 111.8 10.21 12.10 1.18 0.84 41 SK-MEL-28 Melanoma mut 60.5 13.71 10.80 0.79 1.27 
12 ACHN Renal wt 179.5 10.59 11.29 1.07 0.94 42 NCI/ADR-RES Ovarian mut 36.8 11.21 12.48 1.11 0.90 
13 CAKI -1 Renal wt 506.9 7.43 9.00 1.21 0.83 43 OVCAR-3 Ovarian mut 64.0 12.63 10.06 0.80 1.26 
14 UO - 31 Renal wt 421.7 11.84 11.92 1.01 0.99 44 OVCAR-8 Ovarian mut 43.0 10.41 12.92 1.24 0.81 
15 HOP - 62 NSCL mut 38.3 12.06 11.77 0.98 1.03 45 SK-OV-3 Ovarian mut 53.9 10.98 9.60 0.87 1.14 
16 HOP - 92 NSCL mut 44.3 11.48 9.92 0.86 1.16 46 DU-145 Prostate mut 41.8 11.63 10.46 0.90 1.11 
17 NCI - H23 NSCL mut 142.0 10.48 9.92 0.95 1.06 47 PC-3 Prostate mut 72.6 11.72 9.60 0.82 1.22 
18 NCI - H322M NSCL mut 82.8 11.51 11.20 0.97 1.03 48 RXF 393 Renal mut 28.3 11.32 11.92 1.05 0.95 
19 NCI -H522 NSCL mut 91.7 9.43 9.49 1.01 0.99 49 SN12C Renal mut 49.4 9.34 10.44 1.12 0.89 
20 BT- 549 Breast mut 47.4 10.20 8.56 0.84 1.19 50 TK-10 Renal mut 68.1 9.61 13.17 1.37 0.73 
21 HS 578T Breast mut 56.0 11.00 8.44 0.77 1.30 51 EKVX NSCL * 34.6 9.67 11.55 1.19 0.84 
22 MDA -MB -231 Breast mut 54.6 9.18 9.53 1.04 0.96 52 NCI-H226 NSCL * 344.0 11.03 12.45 1.13 0.89 
23 T - 47D Breast mut 440.6 7.63 8.51 1.11 0.90 53 SF-539 CNS * 74.5 9.48 8.08 0.85 1.17 
24 SF- 268 CNS mut 36.6 11.11 9.71 0.87 1.14 54 HCT-15 Colon * 75.6 9.13 13.06 1.43 0.70 
25 SF- 295 CNS mut 22.4 12.82 11.59 0.90 1.11 55 MOLT-4 Leukemia * 74.0 7.79 9.52 1.22 0.82 
26 SNB -19 CNS mut 36.7 11.83 10.58 0.89 1.12 56 IGR-OV1 Ovarian * 139.8 9.23 14.25 1.54 0.65 
27 SNB -75 CNS mut 50.2 11.64 10.24 0.88 1.14 57 OVCAR-4 Ovarian * 57.7 12.06 9.87 0.82 1.22 
28 U251 CNS mut 31.4 10.45 12.07 1.15 0.87 58 OVCAR-5 Ovarian * 69.1 8.44 12.02 1.42 0.70 
29 COLO 205 Colon mut 36.9 10.69 10.06 0.94 1.06 59 786-0 Renal * 27.3 12.94 11.37 0.88 1.14 
30 HCC - 2998 Colon mut 29.3 11.03 12.92 1.17 0.85
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Supplemental Table 2. Semi-Quantitative PCR analysis of NCI60 panel  
# Name  Rel. band intensity Ratio  # Name  
Rel. band 
intensity Ratio 
  p53 HDMX-FL 
HDMX-
S S/FL    p53 
HDMX-
FL 
HDMX-
S S/FL 
1 K-562 mt 302.5 2788.5 9.22  31 NCI-H322M mt 852.3 1195.9 1.40 
2 MOLT-4 mt 2176.1 254.6 0.12  32 NCI-H226 mt 1141.6 598.4 0.52 
3 CCRF-CEM mt 1769.3 366.8 0.21  33 NCI-H23 mt 1994.7 2575.9 1.29 
4 RPMI-8226 mt 714.4 2189.6 3.06  34 NCI-H460 wt 2282.5 438.9 0.19 
5 HL-60 (TB) mt 509.4 1526.8 3.00  35 NCI-H522 mt 1549.1 1396.3 0.90 
6 SR wt 1171.0 354.4 0.30  36 LOX IMVI wt 1423.3 518.2 0.36 
7 SF-268 mt 679.3 1542.4 2.27  37 M14 mt 383.0 2433.5 6.35 
8 SF-295 mt 611.1 1387.7 2.27  38 MALME-3M wt 1310.1 1631.5 1.25 
9 SF-539 mt 785.5 1924.1 2.45  39 SK-MEL-2 mt 2312.4 52.1 0.02 
10 SNB-19 mt 405.1 1065.9 2.63  40 SK-MEL-28 mt 150.8 2812.6 18.65 
11 SNB-75 mt 604.9 1467.3 2.43  41 SK-MEL-5 wt 2293.9 216.1 0.09 
12 U251 mt 1416.8 495.6 0.35  42 UACC-257 wt 179.4 2223.9 12.40 
13 BT-549 mt 796.6 1703.8 2.14  43 UACC-62 wt 481.3 1383.3 2.87 
14 HS 578T mt 563.6 1765.4 3.13  44 IGROV1 mt 2769.9 143.4 0.05 
15 MCF7 wt 2820.1 707.3 0.25  45 OVCAR-3 mt 379.4 2021.8 5.33 
16 NCI/ADR-RES mt 1253.7 425.1 0.34  46 OVCAR-4 mt 410.8 1644.2 4.00 
17 MDA-MB-231/ATCC mt 1517.0 1017.6 0.67  47 OVCAR-5 mt 2010.4 151.2 0.08 
18 MDA-MB-435 mt 638.4 1489.3 2.33  48 OVCAR-8 mt 1896.1 134.8 0.07 
19 T-47D mt 2636.3 1367.7 0.52  49 SK-OV-3 mt 649.4 1999.5 3.08 
20 COLO 205 mt 139.3 1303.7 9.36  50 DU-145 mt 717.5 1519.2 2.12 
21 HCC-2998 mt 1294.4 212.8 0.16  51 PC-3 mt 460.0 1508.5 3.28 
22 HCT-116 wt 2555.6 4.4 0.00  52 786-O mt 422.1 1427.9 3.38 
23 HCT-15 mt 1893.1 0.7 0.00  53 A498 wt 1608.7 271.4 0.17 
24 HT29 mt 1257.2 2434.1 1.94  54 ACHN wt 1274.8 644.4 0.51 
25 KM12 mt 1247.3 105.7 0.08  55 CAKI-1 wt 1832.5 775.4 0.42 
26 SW-620 mt 469.3 1325.4 2.82  56 RXF-393 mt 1057.6 894.5 0.85 
27 A549/ATCC wt 1904.0 352.0 0.18  57 SN12C mt 2178.2 898.0 0.41 
28 EKVX mt 1527.2 427.5 0.28  58 TK-10 mt 1791.6 93.2 0.05 
29 HOP-62 mt 644.0 864.8 1.34  59 UO-31 wt 640.5 1041.0 1.63 
30 HOP-92 mt 421.8 1493.4 3.54        
Summary of NCI cell line panel, including name of cell line, p53 status and RT-PCR data on HDMX-FL and 
HDMX-S. HDMX-FL and HDMX-S mRNA expression was determined with RT-PCR using primers for HDMX 
exon 3 (Fw) to exon 8 (Rev), showed in Supp. Fig. 2A. GAPDH mRNA expression was examined as an internal 
control. Bands were quantified with densitometry and the ratio HDMX-S / HDMX-FL for each sample was 
calculated.  
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Supplemental Table 3. Summary of breast cancer cell line panel 
    RT-PCR HDMX   Protein (FL) 
# Cell line rel FL rel S 
Ratio 
S/FL p53 status HDM2 rel HDMX 
1 BT20 1.03 1.14 1.11 mutant 18,24 1,91 
2 BT474 0.31 0.51 1.63 mutant 54,89 7,05 
3 BT549 0.78 2.07 2.67 mutant 27,14 0,97 
4 CAMA-1 2.45 1.22 0.50 mutant 26,87 17,24 
5 DU4475 0.82 0.41 0.50 wt 42,68 11,61 
6 EVSA-T 0.94 2.09 2.22 mutant 19,66 4,75 
7 HCC1937 0.63 1.43 2.25 mutant Trunc 17,12 1,15 
8 Hs578T 0.51 0.67 1.32 mutant 43,34 5,30 
9 MCF-7 2.25 0.81 0.36 wt 48,49 22,10 
10 MDA-MB-134VI 1.40 1.40 1.00 mutant 33,03 5,23 
11 MDA-MB-157 0.41 1.69 4.09 mutant Trunc 8,92 1,31 
12 MDA-MB-175VII 2.52 0.92 0.37 wt 77,58 20,31 
13 MDA-MB-231 1.37 1.35 0.99 mutant 46,34 16,38 
14 MDA-MB-330 0.90 1.98 2.20 mutant 21,10 2,45 
15 MDA-MB-361 0.21 0.70 3.27 mutant Trunc 10,65 0,12 
16 MDA-MB-415 0.21 0.41 1.98 mutant 12,43 1,32 
17 MDA-MB-435S 0.47 0.88 1.86 mutant 9,65 3,15 
18 MDA-MB-436 0.47 1.55 3.33 mutant Trunc 16,76 1,23 
19 MDA-MB-453 2.03 0.83 0.41 mutant Trunc 13,51 7,64 
20 MDA-MB-468 1.41 0.78 0.55 mutant 27,99 6,33 
21 MPE600 2.06 0.69 0.34 wt 35,45 12,16 
22 B: OCUB-F 1.42 0.62 0.43 mutant 8,12 2,31 
23 SK-BR-3 0.67 1.07 1.59 mutant 26,76 1,89 
24 SK-BR-5 0.30 1.03 3.40 mutant 26,05 1,17 
25 SK-BR-7 1.32 0.54 0.41 wt 34,71 13,81 
26 SUM44PE 0.67 0.51 0.76 mutant Trunc 9,57 3,91 
27 SUM52PE 0.30 1.30 4.35 mutant Trunc 83,74 0,48 
28 SUM149PT 0.42 0.70 1.66 mutant 15,53 1,15 
29 SUM159PT 0.64 0.45 0.69 mutant 19,75 5,85 
30 SUM185PE 0.62 0.55 0.90 mutant Trunc 13,87 5,68 
31 SUM190PT 0.24 0.18 0.74 mutant Trunc 6,45 1,74 
32 SUM225CWN 0.21 0.57 2.64 mutant n.d. n.d. 
33 SUM229PE 0.12 0.15 1.26 mutant 14,04 1,65 
34 SUM1315M02 1.08 0.56 0.52 mutant 3,07 0,25 
35 T47D 1.35 1.45 1.07 mutant 17,68 8,69 
36 UACC-812 0.24 0.63 2.59 wt 56,17 26,13 
37 UACC-893 0.83 1.94 2.33 mutant Trunc 40,46 0,57 
38 ZR75-1 2.00 0.23 0.12 wt 77,17 7,72 
39 ZR75-30 0.47 0.88 1.86 wt 35,91 43,04 
Summary of breast cancer cell line panel, including name of cell line, quantified levels of HDMX-FL and HDMX-S 
determined with RT-PCR amplification, p53 status and HDM2 and HDMX (full length) protein levels, as was 
published before [Hollestelle et al., 2009]. HDMX-FL and HDMX-S mRNA expression was determined with RT-
PCR using primers for HDMX exon 3 (Fw) to exon 8 (Rev), showed in Supp. Fig. 3B. GAPDH mRNA expression 
was examined as an internal control. Bands were quantified with densitometry and the ratio HDMX-S / HDMX-FL 
for each sample was calculated. HDMX-FL protein bands were quantified with densitometry and USP7 expression 
was used as an internal control. Light-grey = p53 wild-type; dark-grey = HDM2 amplification; n.d. = not 
determined.
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Supplemental Figures 
 
 
Supplemental Figure 1. Ratio HDMX-S / HDMX-FL is significantly higher in metastasizing 
tumours  
Supp. Fig. 1A Ratio HDMX-S/HDMX-FL as quantified from Figure 1B, plotted against good/bad response, as 
defined by Huvos grade. Supp. Fig. 1B Kaplan-Meier analysis of overall survival of osteosarcoma patients (n=51) 
using high, medium and low HDMX-S/HDMX-FL ratio as prognostic factor. Patients that were alive, but not 
followed for the complete time-of-follow up are indicated as censored (P = 0.231, Mantel-Cox). Patients that 
already developed metastases before the beginning of observation time were excluded from the analysis (n=6). 
Results were confirmed by Cox multivariate regression survival analysis, controlled for tumour staging (P= 0.029) 
Supp. Fig. 1C. Supp. Fig. 1D Ratio HDMX-S / HDMX-FL mRNA expression was divided into a significant 
different non-metastatic and a metastatic group. P = 0.0026 (left graph). Levels of total HDMX and HDMX-FL 
specific (resp. middle and right graph) mRNA were quantified with Q-RT-PCR, HDMX-S mRNA levels were 
calculated from this data and plotted into non-metastatic and a metastatic group. Total HDMX mRNA levels were 
significantly different in both groups (P=0.0152), whereas HDMX-FL mRNA levels did not significantly vary 
(P=0.1337). Differences between various groups were evaluated by one-way ANOVA followed by Bonferroni's 
Multiple Comparison Test.  
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Supplemental Figure 2. Nutlin-3 response in set of osteosarcoma cell lines  
Supp. Fig. 2A Indicated osteosarcoma cell lines were tested for Nutlin-3 responsiveness by treating the cells for 0, 
8 or 24 hours with 10 µM Nutlin-3, after which protein extracts were made and analyzed with immunoblotting 
using antibodies for HDM2, p53 and USP7. Supp. Fig 2B U2OS, KPD and OSA cells were mock- or Nutlin-3 (10 
µM) treated for 24 hours, proliferation was measured 72 hours later and displayed as relative survival compared to 
the untreated cells. Supp. Fig. 2C FACS analysis of mock- or Nutlin-3 (10 µM, 24 hours) treated KPD, U2OS, 
OSA and MHM cells. Indicated are percentages of cycling cells in G1, S or G2/M phase and percentages of single 
cells in SubG1.  
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Supplemental Figure 3. Ratio HDMX-S / HDMX-FL in NCI60 panel and panel of breast cancer 
cell lines; high HDMX-S/HDMX-FL ratio is a better prognostic factor for overall survival in soft 
tissue sarcoma than p53 mutational status. 
Supp. Fig. 3A Expression patterns of HDMX-FL and HDMX-S mRNA in a set of 59 cell lines from the NCI60 
panel, determined by semi-quantitative PCR amplification with HDMX primers from exon 3 to exon 8 resulting in 
bands for both HDMX-FL and -S. GAPDH expression was used for normalization of expression levels. P53 status: 
wt = p53 wild-type; m = p53 mutant; i = inconclusive p53 status; wt - = p53 wild-type with low HDM2 levels; wt + 
= p53 wild-type with high HDM2 levels. Supp. Fig. 3B Expression patterns of HDMX-FL and HDMX-S mRNA in 
a set of 39 breast cancer cell lines, determined by semi-quantitative PCR amplification with HDMX primers from 
exon 3 to exon 8 resulting in bands for both HDMX-FL and -S. Supp. Fig. 3C Kaplan-Meier analysis of overall 
survival of Soft Tissue Sarcoma (STS) patients using p53 status as a prognostic factor (P = 0.509). Supp. Fig. 3D 
Kaplan-Meier analysis of overall survival of Soft Tissue Sarcoma (STS) patients using high, medium and low 
HDMX-S/HDMX-FL ratio as prognostic factor (P= 0.013). Patients that were not followed for the complete time-
of-follow up are indicated as censored. Results were confirmed by Cox multivariate regression survival analysis, 
(P= 0.005). 
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Supplemental Figure 4. HDMX expression stimulates the growth of osteosarcoma cells 
Supp. Fig. 4A Stable control- or p53 knockdown U2OS cells were seeded for a proliferation assay 4 days post-
infection with either control- or HDMX-knockdown vectors; proliferation was measured 72 hours later. The effect 
of HDMX knockdown is displayed as the relative survival to the corresponding control cells. Differences between 
various groups were evaluated by one-way ANOVA followed by Bonferroni's Multiple Comparison Test. P<0.05 
was considered as statistically significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Supp. Fig. 4B MHM, 
OSA, OST and HAL cells were seeded for a proliferation assay 4 days post-infection with either control- or 
HDMX-knockdown vectors; proliferation was measured 72 hours later. The effect of HDMX knockdown is 
displayed as the relative survival to the corresponding control cells. 
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Supplemental Information 
 
sh-RNA targeting sequences 
shHDMX-ex1: 5’-GTTGCGGCTTCATTACT-3’ 
shHDMX-3’UTR: 5’-GTGCAGTGAGTCAAGATTG-3’ 
shHDMX-ex6#1: 5’-GGATCACAG TATGGATATT-3’ 
shHDMX-ex6#2: 5’-AGTCAAGCAACTGAAGC-3’ 
Additional plasmids used for lentiviral transduction were a non-targeting shRNA coding 
plasmid (SHC002, Sigma MISSION Library; Sigma-Aldrich), an HDMX 3’UTR targeting 
shRNA (TRCN0000003860, Sigma Mission Library) and an shRNA targeting human p53 
[Brummelkamp et al., 2002] or mouse mdmx [Lam et al., 2010], which does not target the 
HDMX mRNA.  
 
Semi-Quantitative RT-PCR primer sequences 
For detection of both HDMX-FL and HDMX-S: 
HDMX ex3 forward 5'-TGCATGCAGCAGGTGCG-3'  
HDMX ex8 reverse 5'-CATTACTTCTAGGTGTAT-3'  
 
For detection of the housekeeping gene GAPDH: 
GAPDH forward 5'-AATCCCATCACCATCTTCC-3’ 
GAPDH reverse 5'-ATGAGTCCTTCCACGATACC-3’ 
 
Q-RT-PCR  
Relative mRNA quantities were calculated using an internal standard curve of diluted 
pooled samples and normalized to a set of 3 control genes, CAPNS1, SRPR and TBP, with 
use of the SDS2.3 analysis program (Applied Biosystems).  
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q-RT-PCR Primer sequences 
HDM2-P2 Fw 5’-ACGCACGCCACTTTTTCTCT-3’ 
HDM2-P2 Rv 5’-TCCGAAGCTGGAATCTGTGAG-3’ 
P53 Fw 5’-CTCTCCCCAGCCAAAGAAGAA-3’ 
P53 Rv 5’-TCCAAGGCCTCATTCAGCTCT-3’ 
HDMX total Fw 5’-AGGTGCGCAAGGTGAAATGT-3’ 
HDMX total Rv 5’-CCATATGCTGCTCCTGCTGAT-3’ 
HDMX-FL Fw  5’-TCGCACAGGATCACAGTATGG-3’ 
HDMX-FL Rv  5’-CCCACTCCTCAAATCCAAGGT-3’ 
PUMA Fw 5’-GACCTCAACGCACAGTA-3’ 
PUMA Rv 5’-CTAATTGGGCTCCATCT-3’ 
p21 Fw 5’-AGCAGAGGAAGACCATGTGGA-3’ 
p21 Rv 5’-AATCTGTCATGCTGGTCTGCC-3’ 
SURVIVIN Fw 5’-GAGACAGAATAGAGTGATAGG-3’ 
SURVIVIN Rv 5’-GACAGATGTGAAGGTTGG-3’ 
GADD45a Fw 5’-GCGACCTGCAGTTTGCAATA-3’ 
GADD45a Rv 5’-ATCCCCCACCTTATCCATCCT-3’ 
CAPNS1 Fw 5’-ATGGTTTTGGCATTGACACATG-3’ 
CAPNS1 Rv 5’-GCTTGCCTGTGGTGTCGC-3’ 
TBP Fw 5’-CACGAACCACGGCACTGATT-3’ 
TBP Rv 5’-TTTTCTTGCTGCCAGTCTGGAC-3’ 
SRPR Fw 5’-CATTGCTTTTGCACGTAACCAA-3’ 
SRPR Rv 5’-ATTGTCTTGCATGCGGCC-3’ 
 
Antibodies used in this study:  
Anti-HDMX rabbit polyclonal (A300-287A, Bethyl Laboratories, Montgomery, TX), anti-
p53 monoclonal antibodies PAb1801 and DO-1, anti-HDM2 mouse monoclonal antibodies 
4B2 [Chen et al., 1993] (kind gift of Dr. A. Levine) and SMP14 (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-p21WAF1 mouse monoclonal antibody CP74 (Upstate 
Biotechnology), anti-HAUSP mouse monoclonal antibody 7G9 [Kessler et al., 2007] and 
rabbit polyclonal anti-USP7 (A300-033A, Bethyl Laboratories), anti-PUMA rabbit 
polyclonal antibody (Sigma-Aldrich). Secondary antibodies goat-anti-mouse-HRP and 
goat-anti-rabbit -HRP were obtained from Jackson Laboratories. 
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Abstract 
 
Proper regulation of the p53 pathway is essential for normal cell proliferation, 
differentiation, DNA damage repair and the prevention of tumorigenesis.  
Post-translational modifications play an important role in p53 pathway, including 
modifications of p53 itself and its main regulators Hdm2 and Hdmx (also known as Mdm2 
and Mdmx/Mdm4). Whereas the significance of ubiquitination in this process is evident, 
modification of the p53 pathway members by the small ubiquitin-related modifiers, 
SUMO’s, has been studied less extensively. In this study we have focused on the role of 
SUMOylation of p53, Hdm2 and Hdmx, the presence of a putative cross-talk between 
SUMOylation and ubiquitination and the role of the SUMO-specific ubiquitin ligase RNF4 
in this process. We found that that under certain circumstances the SUMOylated fractions 
of these proteins are preferentially ubiquitinated and degraded. We also confirmed previous 
reports stating that relative SUMOylation of p53 decreases upon p53 activation and we 
found a stress-induced increased degradation of SUMOylated Hdm2, whereas Hdmx seems 
to be degraded in a SUMO-independent way. Although the ubiquitination of SUMOylated 
p53, Hdm2 or Hdmx seemed to be independent of RNF4, we showed that RNF4 
overexpression stabilized transfected Hdm2 protein levels. Interestingly, RNF4 attenuated 
the apoptotic response upon treatment with the small-molecule p53 activator RITA. Lastly, 
we have shown that upon various types of treatments (e.g. IR, cisplatin) RNF4 protein 
levels decrease, which coincided with the apoptotic response. These results suggest the 
involvement of RNF4 in the apoptotic response after DNA damage and RNF4 levels in 
tumors might serve as a prognostic factor for the response to chemotherapeutic treatment. 
Moreover, this study might indicate an oncogenic function of RNF4 in certain cancers. 
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Introduction 
 
The transcription factor p53 is a critical regulator of the cell fate. Upon DNA damage, p53 
is rapidly stabilized and conformational changes occur to enable p53 to activate target 
genes leading to cell cycle arrest or apoptosis 1. The p53 pathway is the most commonly 
affected pathway in human tumors 2,3. Integrity of the p53 pathway is critical to suppress 
tumor formation and p53 tumor suppressor activity is decreased in virtually all tumors 4. 
 
P53 stability and activity are mainly controlled via post-translational modifications 
including phosphorylation, acetylation and ubiquitination 5. Under normal growth 
conditions, the p53 protein is rapidly degraded via the ubiquitin-proteasome system. 
Ubiquitin chains are covalently conjugated to p53 by the RING finger protein Hdm2 
(Mdm2), functioning as an E3 ligase 6. The Hdm2-homolog Hdmx (Mdmx/Mdm4) is a 
second RING finger protein that is critical for p53 regulation, best illustrated by the 
observation that mice lacking Mdmx die during embryonic development due to increased 
p53 activity 7-9, similar to Mdm2-deficient mice 10,11. Moreover, the significance of p53 
regulation by Hdm2 and Hdmx is illustrated by the frequent occurrence of elevated levels 
of Hdm2 and/or Hdmx in a considerable proportion of human tumors 12-15. Despite the 
similarities between both proteins, Hdmx and Hdm2 exert distinct non-redundant functions 
in the regulation of p53. Although Hdmx has a RING domain very similar to that of Hdm2, 
it has not the ability to ubiquitinate p53, but mainly functions by inhibiting p53 
transcription activity by binding to its N-terminal transcription activation domain 16,17.  
The Hdm2 gene is a transcriptional target of p53, involved in a negative feedback-loop with 
p53 18. Upon p53 activation by DNA damaging agents, Hdm2 transcription increases 
leading to accumulation of Hdm2 protein. The Hdm2 protein is needed for degradation of 
Hdmx, which is needed for a full-blown p53-response 19-22. Conjugation of poly-ubiquitin 
chains to p53 by the E3 ligase Hdm2 leads to proteasomal degradation, although for poly-
ubiquitination and subsequent degradation an additional function for the p300/CBP proteins 
has been suggested 23. Mono-ubiquitination is involved in altered subcellular localization or 
functional inhibition of p53. Several lysines on p53 have been identified as target for 
ubiquitination 24, although probably not all sites have been determined. Interestingly, many 
of the C-terminal lysines targeted by ubiquitination are also targets for other modifications, 
like acetylation and SUMOylation. Acetylation of several C-terminal lysines of p53 by 
p300/CBP interferes with the functional interaction with Hdm2, since deacetylation of these 
lysines of p53 is required for efficient degradation of p53, and conversely, ubiquitination by 
Hdm2 prevents acetylation of p53 25,26. In addition to the C-terminal acetylations, which 
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interfere with ubiquitination, p53 is acetylated on lysines K120 and K164, which are 
located in the DNA binding domain, thereby inhibiting the binding of Hdm2 and Hdmx to 
p53 on DNA, allowing the activation of p53 transcriptional activities 27. Whereas individual 
acetylation defects can be compensated by acetylation of the other lysines, the loss of all 
these acetylation sites results in a complete inhibition of p53-mediated p21 activation and 
growth arrest 27, indicating the importance of acetylation on the regulation of the p53 
response.  
In addition, the conjugation of the small ubiquitin related modifiers (SUMO) can fine-tune 
the p53 regulation. SUMOylation of the C-terminal K386 of p53 was reported to inhibit the 
p53 transcriptional activity by interfering with the acetylation of that same site. In contrast, 
earlier reports showed an enhanced p53 activity upon SUMOylation 28-31. In humans, three 
forms of SUMO are expressed, SUMO-1, SUMO-2 and SUMO-3, of which SUMO-2 and -
3 are very similar and able to form polySUMO chains 32,33. A consensus SUMO-
conjugation site, ψKxE (ψ, a large hydrophobic residue; x, any amino acid) was identified 
34, although recent results has yielded more insight into SUMOylation that occurs at non-
consensus sites 35. SUMOylation has been implicated in the regulation of proteins in 
various ways, such as subcellular localization, activity, and degradation of target proteins 
36. Whereas K386 in p53 31,37 and two lysines (K254 and 379) in Hdmx 38 were identified to 
be the main SUMO target sites in these proteins, no SUMOylation sites could be defined in 
Hdm2, probably due to alternative conjugation sites 39,40. Nevertheless, Hdm2 
SUMOylation was reported to take place in the nucleus, by PIAS and RanBP2 proteins 41. 
Deconjugation of SUMO-1 from Mdm2 by the SUMO-protease SUSP4, a mouse 
homologue of the human SENP2 (SSP3), has been suggested to activate the p53 response 
by stimulating Mdm2's autoubiquitination and degradation 42. In contrast, a more recent 
report indicates that de-SUMOylation of Hdm2 by the SUMO protease SENP2 (SSP3), 
which takes place at the nuclear PML bodies, negatively regulates the p53 response after 
DNA damage 43. In this study it is suggested that SUMO-1 conjugation to Hdm2 somehow 
interferes with the degradation of p53 by Hdm2. It is important to note that most of the 
above studies have been focusing on SUMO-1 conjugation, and hardly information is 
available on conjugation of SUMO-2 or SUMO-3 to e.g. Mdm2 and Mdmx.  Although 
conjugation of SUMO-2 and SUMO-3 to p53 in vitro has been shown, no functional studies 
have been reported to date.  
 
Recently, a new kind of SUMO-ubiquitin interaction has been elucidated, with the 
discovery of ubiquitin E3 ligases that specifically target SUMOylated proteins. These 
STUbLs (SUMO Targeted Ubiquitin Ligases) contain SUMO Interacting Motifs, (SIMs) 
thereby enabling the specific targeting of SUMOylated proteins 44. The Ring Finger protein 
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4 (RNF4) was identified as a STUbL in human 45, containing 4 SIM domains, thereby able 
to recognize specifically poly-SUMOylated proteins. The first reported target for this poly-
SUMO-specific ubiquitination was the promyelocytic leukemia protein (PML), which is 
specifically degraded by RNF4 upon treating cells with arsenic trioxide 46-48.  
SUMOylation can be regulated in various ways, for instance by regulation of the activity of 
SUMO E3 ligases or SUMO-specific proteases. An important role for members of the 
Mitogen Activated Protein Kinase (MAPK) pathway in regulation of SUMOylation has 
been shown. On the one hand, the phosphorylation of target proteins by activated ERK, p38 
or JNK has been reported to either induce SUMOylation 49 or prevent the SUMO 
conjugation 50. On the other hand, the MAPK pathways might also be involved in the 
regulation of SUMOylation by phosphorylation of SUMO E3 ligases, reviewed in Guo et 
al. (2007) 51. Arsenic-induced phosphorylation of PML by the MAPK pathway, especially 
by the ERKs, JNKs and p38 52,53, is an important step in the RNF4-mediated degradation of 
PML, enhancing its SUMOylation, possibly by recruiting an E3 SUMO ligase to PML.  
In this study we have investigated a putative SUMO-dependent ubiquitination of p53, 
Hdm2 and Hdmx and a possible role of RNF4 in this process. 
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Material and Methods 
 
Cell Culture and Reagents 
MCF7 and U2OS cells were maintained in DMEM supplemented with 10% fetal bovine serum, 1% glutamine and 
antibiotics. H1299 cells were maintained in RPMI supplemented with glutamine and antibiotics. Stable MCF7 
cells lines expressing His6-SUMO-2 were continuously grown under neomycine selection. For hypoxia 
experiments cells were maintained at 1% oxygen for at least 48 hours. Cells were treated with arsenic trioxide 
(Sigma-Aldrich, St Louis, MO, USA), etoposide (Sigma-Aldrich), Neocarzinostatin (Sigma-Aldrich), MG132 
(Sigma-Aldrich), MEK1/2 inhibitor U0126 (Calbiochem), JNK inhibitor SP600125 (Calbiochem), cisplatin 
(Sigma-Aldrich), RITA (Gift from Galina Selivanova), Nutlin-3 (Cayman Chemical, Ann Arbor, MI, USA) for the 
indicated times and doses.  
 
Plasmids, lentiviral transduction 
Expression vectors encoding Flag-RNF4 and p-DEST-V5-RNF4 for transfection assays and the lentiviral pRRL 
vectors encoding Flag-RNF4-GFP, Flag-RNF4-puro, RNF4-Flag-GFP or RNF4-Flag-puro were obtained from 
Vertegaal and coworkers, and will be described in detail elsewhere. The V5-RNF4 Ring mutant C133S was made 
by site directed mutagenesis using the following primer pairs:  
Forward: 5'-CCTCAGGTACTGTCAGTTCTCCCATCTGCATGGACGG-3' and Reverse: 5'-CCGTCCATGCAG 
ATGGGAGAACTGACAGTACCTGAGG-3'. 
His6-SUMO-2 and His6-Ubiquitin lentiviruses were made by inserting the His6-SUMO-2 or His6-Ubiquitin into 
the EcoRV site of plasmid pLV-CMV-IRES-eGFP 54. Other plasmids used for transfection were pcDNA3.1-HA-
Hdmx and pcDNA3.1-HA-Hdmx-K254/379R, pRcCMV-p53 and pRcCMV-p53-K386R 31, pcDNA3.1-HA-
Hdm2, pcDNA3.1-GFP and pcDNA3.1 empty vector.  
Transfections were performed using Fugene transfection reagens, according to the manufacturer’s protocol. 
Production of lentiviruses by transfection into 293T cells has been described previously 55. Lentivirus expressing 
shRNA against RNF4 and control shRNA-lentiviruses (sh-luciferase, SHC007 or non-targeting, SHC002) were 
obtained from the Mission Library (Sigma-Aldrich). The sh-RNF4-expressing lentivirus #2 was made by cloning a 
short hairpin sequence containing the target sequence 5’- AACCAACAUCTGAUAUGUAAA-3’ in the pRRL-
puro lentiviral expression plasmid.  
Cells were seeded 24 hours prior to lentiviral infection. To obtain specific knockdown, cells were infected with 
RNF4- or control-shRNA expressing lentiviruses. For all infections, a multiplicity of infection of ~ 1.5 (MOI 1.5) 
was used. Cells were transduced overnight in the presence of 8 μg/ml polybrene (Sigma-Aldrich). The next day, 
the medium was replaced with fresh medium. Transduced cells were seeded for experimental purposes 3 to 4 days 
post-transduction. 
 
Antibodies 
Antibodies used in this study were anti-Hdmx rabbit polyclonal ( A300-287A, Bethyl Laboratories, Montgomery, 
TX), anti-Hdmx monoclonal mouse antibody MX-82 (Sigma), anti-p53 monoclonal antibodies PAb1801 and DO-
1, anti-Hdm2 mouse monoclonal antibodies 4B2 56 (kind gift of Dr. A. Levine) and SMP14 (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-p21WAF1 mouse monoclonal antibody CP74 (Upstate Biotechnology), rabbit 
polyclonal anti-USP7 (A300-033A, Bethyl Laboratories), anti-RNF4 rabbit polyclonal antibody K39 (gift from 
Alfred Vertegaal), anti-phospho-ERK1/2 mouse monoclonal antibody (Sigma), anti-ERK1/2 rabbit polyclonal 
antibody (Sigma), anti-HA.11 mouse monoclonal antibody (Covance), anti-KAP1 mouse monoclonal antibody 
(BD Transduction Laboratories), anti-HIF1-alpha antibody (BD Transduction Laboratories), anti-vinculin mouse 
monoclonal antibody (Sigma-Aldrich ), anti-Flag rabbit polyclonal antibody M2 (Sigma-Aldrich), anti-V5 
antibody (Invitrogen), anti-GFP mouse monoclonal antibody (Roche), anti-PUMA rabbit polyclonal antibody 
(Sigma-Aldrich), anti-PML mouse monoclonal antibody PML-97 (Abcam). 
Secondary antibodies goat-anti-mouse-HRP and goat-anti-rabbit -HRP were obtained from Jackson Laboratories. 
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Immunoblotting analysis 
Cells were lysed in Giordano 250 buffer (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM 
EDTA), supplemented with a mixture of protease- and phosphatase inhibitors. Protein content was determined 
using Bradford Reagent (Biorad) and equal amounts of protein were separated by SDS-PAGE. Proteins were 
transferred onto polyvinyldene difluoride membranes (Immobilon-P, Millipore). Membranes were blocked in Tris-
buffered saline, 0.2% Tween-20 (TBST) containing 10% non-fat dry milk, and subsequently incubated with the 
appropriate primary antibody diluted in TBST containing 10% milk. Membranes were washed three times with 
TBST and incubated with HRP-conjugated secondary antibody (Jackson Laboratories). Bands were visualized by 
enhanced chemiluminescence (Super Signal; Pierce) followed by detection with the ChemiGenius XE3 system 
(Syngene, Cambridge, UK) or X-ray film (Fuji). Alternatively, membranes were blocked with Blocking Buffer for 
Fluorescent Western Blotting (Rockland), incubated with the appropriate primary antibodies, washed three times 
with TBST and incubated with secondary antibodies coupled to IRdye-680 and IRdye-800 near Infrared dyes (LI-
COR Biosciences) and analysed with the Odyssey Infrared Imager (LI-COR Biosciences). Signals were quantified 
using the Odyssey 2.1 analysis software (LI-COR Biosciences). 
 
Ubiquitination/SUMOylation assay in cells 
Cell-based ubiquitination and SUMOylation assays were adapted from the established methods 57 with the 
following modifications. After harvesting the cells by scraping in PBS, 20% of the cells was used for total protein 
extraction as described above. The remaining cells were used for His-pull-down assays, after correction for protein 
content. His-Ubiquitin or His-SUMO-2 pull-downs were performed with 40 μl of Ni-nitrilotriacetic acid beads 
(Qiagen) overnight at 4 °C in 6 ml of 6 M guanidinium-HCl, 0.1 M Na2HPO4·NaH2PO4, and 0.01 M Tris-HCl (pH 
8.0) plus 10 mM imidazole and 10 mM β-mercaptoethanol (buffer A). After incubation, the beads were 
successively washed with 1 ml of each of the following buffers: buffer A lacking imidazole but with 0.2% Triton 
X-100; buffer B (8 M urea, 0.1 M Na2HPO4·NaH2PO4, and 0.01 M Tris-HCl (pH 8.0), 10 mM β-mercaptoethanol, 
and 0.2% Triton X-100);  buffer C (8 M urea, 0.1 M Na2HPO4·NaH2PO4, and 0.01 M Tris-HCl (pH 6.3), 10 mM 
β-mercaptoethanol, and 0.2% Triton X-100; buffer C containing 0.1% Triton X-100. Ubiquitinated proteins were 
eluted in 2X Laemmli sample buffer containing 100 mM imidazole. The samples were boiled and analyzed by 
Western blot analysis with indicated antibodies.  
 
RNA isolation, Reverse Transcription and q-RT-PCR 
RNA was isolated from cells using the SV Total RNA Isolation System (Promega) according to the 
manufacturers’ protocol. cDNA was made from 1 µg of total RNA in an Reverse Transcriptase reaction containing 
ImPromII Reverse Transcriptase, RNasin RNAse inhibitor, MgCl2 and 5x RT-Buffer (Promega). Quantification of 
mRNA expression was performed by Quantitative-Real-Time PCR, in an ABI 7900HT thermocycler, using the 
FastStart Universal SYBR Green Master (ROX) mix (Roche). Relative mRNA quantities were calculated using an 
internal standard curve, made from a dilution series of the pooled samples, using the SDS2.3 analysis program 
(Applied Biosystems). Expression levels of the mRNAs were normalized to the geometric mean of the control 
genes CAPNS1, TBP, SRPR. Primer sequences are available in Supplemental Information. 
 
Proliferation assays, Drugs sensitivity assays, Colony formation assays  
For proliferation assays, 2000-5000 cells were seeded in triplicate in a 96-wells plate, and the assays were 
performed as described earlier 55. Drugs sensitivity was assessed by performing proliferation assays on cells 
treated with a range of drug concentrations, Dose-Effect analysis was performed using the CompuSyn program 58. 
For colony forming assays 10,000 cells were seeded in duplicate per condition in 6-wells plates; cells were treated 
for three hrs with the indicated drug or mock-treated, after which cells were re-fed with fresh medium. Colonies 
were allowed to grow for eight to ten days, fixated with methanol/acetic acid (3:1) and stained with Giemsa. 
Colonies were quantified with the Odyssey Infrared Imager and Odyssey 2.1 analysis software (LI-COR 
Biosciences, Lincoln, Nebraska USA). 
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Results 
 
SUMOylation of p53, Hdm2 and Hdmx. 
Ubiquitin-conjugation of p53, Hdm2 and Hdmx has been implicated in the regulation of 
these proteins and their interactions. To study a putative role of SUMOylation in the 
ubiquitination of these proteins, we made use of MCF-7 cells stably expressing His6-tagged 
SUMO-2, enabling the purification of SUMOylated proteins using Ni-NTA beads.  
In untreated His6-SUMO-2 cells, one main SUMO-p53 species is present, likely reflecting 
SUMOylation at p53-K386, as has been reported (Fig. 1A) 31,37. Strikingly, treatment with 
the proteasome inhibitor MG132, thus blocking the degradation of poly-ubiquitinated 
proteins, resulted in the accumulation of more, particularly high molecular weight species, 
most likely reflecting SUMOylated- and ubiquitinated p53 species. However, the total 
levels of p53 also increased strongly, suggesting that under normal growth conditions 
SUMOylated p53 species are not preferentially ubiquitinated and degraded. Similar results 
were obtained for Hdm2; an increase in high molecular weight proteins in the His-pull-
down fraction upon MG132 treatment is concomitant with an increase of total Hdm2 levels. 
However, no SUMOylation of Hdm2 could be detected in the absence of MG132. This 
result could suggest that SUMOylated Hdm2 is more efficiently degraded than unmodified 
Hdm2. This difference in stability between SUMO-modified versus total protein is even 
more clear with Hdmx. Total levels of Hdmx are not affected by this relatively short 
MG132 treatment, since Hdmx has a long half-life in MCF-7 cells. In contrast, a strong 
accumulation of SUMOylated Hdmx and higher molecular weight bands is observed upon 
proteasome-inhibition. This result strongly indicates a higher turn-over of SUMOylated 
Hdmx compared to the total Hdmx pool. Interestingly, total levels of KAP1 are not affected 
by MG132 treatment, suggesting a relatively stable protein, but SUMOylated KAP1 
actually decreases. This might be the result of a lack of free SUMO-2, since most of it is 
now trapped in stabilized proteins (Figure 1A).  
To further show the specificity of the His-pull down, we made stable MCF-7 cell lines 
overexpressing His6-SUMO-2 together with HA-tagged Hdmx or HA-Hdmx-K254/379R, 
which has both identified SUMO consensus sites mutated. Only in cells expressing wild-
type HA-tagged Hdmx, SUMOylated Hdmx and a ladder of SUMOylated/ ubiquitinated 
species upon MG132 treatment is detected (Fig. 1B). Similarly, when we transfected 
murine B16 cells with His-SUMO-2 and either human wild-type p53 or K386R-p53, to 
enable specific detection of the human p53, we observed a major decrease of the amount of 
p53 pulled-down in the cells transfected with K386R-p53 in which the major SUMO-
conjugation site is mutated. Some SUMOylated p53 is still detected, suggesting the 
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presence of a minor SUMOylation site on p53. Under these conditions, the total amount of 
p53 is only slightly increased upon MG132 treatment, whereas the SUMOylated fraction of 
p53 is increased significantly, indicating that a small fraction of p53 might be degraded in a 
SUMO-dependent manner (Fig. 1C (left panel)). Although K386 is an ubiquitin acceptor 
site as well, mutation of this site did only slightly decrease the amount of total ubiquitinated 
p53 (Fig.1C (right panel)), mainly correlating with the somewhat lower total mutant-p53 
levels. Altogether, these results suggest that SUMOylation only plays a minor role in the 
regulation of the ubiquitination of p53. Nevertheless, we show here that SUMO-specific 
degradation of both Hdm2 and Hdmx takes place, which might indirectly play a role in the 
p53 regulation.   
 
Activation of ERK1/2 plays a role in the SUMO dependent ubiquitination of p53 and 
Hdmx. 
The MAPK signaling cascade plays important roles in the determination of the outcome of 
diverse stimuli. It has been shown that Hdmx mRNA expression is regulated via mitogenic 
stimuli, via the Raf-Ras-ERK pathway, which results in enhanced Ets-1 or Elk-1 binding to 
the Hdmx promoter 59. Hdm2 expression has also been shown to be influenced by the ERK-
MEK pathway, by regulating the Hdm2 mRNA nuclear export 60 and, similar to Hdmx 
regulation, its transcription is induced by oncogenic Ras via activation of the MAPK 
pathway 61. Since it has been shown that activation of MAPK pathways can regulate the 
SUMOylation status of several proteins 49-53, we used a MEK inhibitor to prevent ERK1/2 
activation and investigated the effects on the SUMOylation and ubiquitination status of the 
p53 pathway (Figure 2). Already 2 hours after MEK inhibition, the phosphorylation of 
ERK1/2 is already completely blocked (Fig. 2A). Inhibition of MEK was accompanied by a 
fluctuating p53 protein level and a decrease in Hdm2 total protein level. The decrease of 
Hdm2 levels could not be rescued by proteasome inhibition, suggesting a regulation at the 
mRNA level, confirming previous reports 60. We did not observe any significant changes in 
Hdmx levels upon MEK inhibition (Fig. 2A; left panel). Especially in the absence of 
MG132 the p53 SUMOylation decreases in time, suggesting a role of the MAPK pathway 
in the SUMOylation of p53. Furthermore, we also observed a decrease in basal 
SUMOylation and the levels of higher molecular weight species upon MG132 treatment of 
Hdm2 and Hdmx, particularly at the 24 hrs time point (Fig. 2A; right panels). Since total 
Hdmx levels remained constant, these results might indicate that SUMOylation of Hdmx is 
partially dependent of the activation of ERK1/2. Although total Hdm2 levels decrease upon 
ERK1/2 inhibition, the relative SUMOylation of Hdm2 seems to decrease even more, 
suggesting that also the SUMOylation of Hdm2 is at least partially regulated by ERK 
signaling.
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Figure 1. p53, Hdm2 and Hdmx are subject to SUMO-dependent ubiquitination. 
(A) MCF7 cells or MCF7 cells stably expressing His6-SUMO-2 were treated with MG132 (10 µM) or mock 
treated for 6 hours. Cells were lysed and His6-SUMO-2 conjugates were purified using Ni-NTA beads. Total cell 
lysates and His6-SUMO-2 purified fractions were analyzed by immunoblotting using the indicated antibodies. 
Tubulin expression was used as a loading control. (B) MCF7 cell lines stably expressing expression vectors 
encoding HA-tagged Hdmx or the SUMOylation deficient mutant HA-Hdmx-K254/379R were transfected with 
His6-SUMO-2. Cells were treated with MG132 (10 µM) or mock treated for 6 hours at day 1 post-transfection. 
Cells were lysed and His6-SUMO-2 conjugates were purified using Ni-NTA beads. Total cell lysates and His6-
SUMO-2 purified fractions were analyzed by immunoblotting using an anti-HA antibody. (C) Stable murine B16 
cells expressing wild-type p53 (wt) or SUMO-deficient mutant p53-K386R (KR), were lentivirally infected with 
an expression vector for His6-SUMO-2 or His6-Ubiquitin. At day 4 post-infection, cells were treated with MG132 
(10 µM) or mock treated for 6 hours. Cells were lysed and His6-SUMO-2 or His6-Ubiquitin conjugates were 
purified using Ni-NTA beads. Total cell lysates and His6-SUMO-2 or His6-Ubiquitin purified fractions were 
analyzed by immunoblotting using a mix of the anti-p53 antibodies DO-1 and PAb1801.  
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Preliminary results indicate that the ubiquitination of p53 and Hdmx is also decreased upon 
MEK inhibition, which might be the result of decreased Hdm2 levels, whereas the relative 
ubiquitination of Hdm2 does not change (data not shown).  
To find out more about the role of MAPK pathways, we compared the MEK inhibitor 
U0126 with the JNK inhibitor SP600125. The JNK inhibitor induced a p53 response, 
illustrated by the induction of p53 and Hdm2, whereas Hdmx levels decreased. These 
changes were reflected in the SUMOylated fractions, indicating JNK signaling is not 
required for SUMO-dependent ubiquitination (Fig. 2C). Summarized, we have shown here 
that activation of ERK1/2 might be involved in the SUMOylation of p53, Hdm2 and Hdmx; 
it might thereby also indirectly regulate p53 activity. However, we could not show that the 
regulation of Hdmx SUMOylation also affected Hdmx levels. Furthermore, the reduced 
SUMOylation of Hdm2 upon MEK inhibition was accompanied by a decrease in total 
Hdm2 levels, most likely caused by a decrease in Hdm2 mRNA level. 
 
Role of RNF4 in the ubiquitination of SUMOylated p53, Hdm2 and Hdmx. 
RNF4 was identified as a STUbL 45, (SUMO Targeted Ubiquitin Ligase), a class of E3 
ubiquitin ligases that might specifically ubiquitinate poly-SUMOylated proteins and is 
essential for arsenic trioxide-induced proteasomal degradation of PML 46-48. Since we found 
accumulation of ubiquitinated, SUMOylated p53, Hdm2 and particularly Hdmx upon 
proteasome inhibition, we wondered whether RNF4 would play a role in this process. The 
RNF4 levels in MCF-7 cells stably expressing His6-SUMO-2 or His6-ubiquitin were 
reduced by transduction with RNF4-shRNA expressing lentiviruses. Cells were mock-
treated or treated for 6 hours with MG132; SUMO-2 conjugated proteins were purified and 
analyzed by western blotting. As shown in figure 3A, the accumulation of SUMOylated 
(and ubiquitinated) p53 is strongly reduced in the RNF4 knock-down cells (left), whereas 
total p53 ubiquitination is only slightly decreased (Fig. 3B). However, levels of mono-
SUMOylated and total p53 were also reduced upon RNF4 knockdown in the His6-SUMO2 
cells, indicating no specific role of RNF4 in the ubiquitination of SUMOylated p53. The 
basal SUMOylation of Hdmx and the accumulation of high molecular SUMOylated species 
of Hdm2 and Hdmx upon proteasomal inhibition, all decrease after RNF4 knockdown. 
However, this might be just a reflection of the decreased total protein levels (Fig. 3A; right 
panel). Furthermore, p21 protein levels are slightly reduced upon RNF4 knockdown (Fig. 
3A). These effects are likely to take place at the protein level, since no alterations in mRNA 
levels of P53, HDM2, HDMX and P21 were observed (data not shown). In His6-ubiquitin 
expressing cells, p53 levels were not significantly affected by RNF4 knock-down (Fig. 3B). 
In these cells, RNF4 knockdown did also not result in reduced Hdm2 levels and the 
reduction in Hdmx protein level was much less compared to the effect in SUMO-2 
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expressing cells. Altogether, these results suggest that RNF4 has no essential role in the 
SUMOylation and ubiquitination of SUMOylated p53, Hdm2 or Hdmx, although indirect 
effects on protein level cannot be excluded.  
 
 
 
Figure 2. Activation of ERK1/2 plays a role in the SUMOylation and SUMO- dependent 
ubiquitination of p53 and Hdmx. 
MCF7 cells stably expressing His6-SUMO-2 were treated with (25 µM) U0126 for 2, 6 or 24 hours or mock-
treated; 6 hours before harvesting cells were incubated with 10 µM MG132 or mock-treated. Control MCF7 cells 
were treated with 25µM U0126 for 24 hours or mock-treated, 6 hours before harvesting, cells were additionally 
treated with 10 µM MG132 or mock-treated. Cells were lysed and His6-SUMO-2 conjugates were purified using 
Ni-NTA beads. Total cell lysates (3A) and His6-SUMO-2 purified fractions (3B) were analyzed by 
immunoblotting with the indicated antibodies. Figure 3C. MCF7 cells stably expressing His6-SUMO-2 were 
treated with (25 µM) U0126 or (20 µM) SP600125 for 6 and 24 hours or mock-treated. Cells were treated with 10 
µM MG132 or mock-treated 6 hours before harvesting. Cells were lysed and His6-SUMO-2 conjugates were 
purified using Ni-NTA beads. Total cell lysates (left panel) and His6-SUMO-2 purified fractions (right panel) 
were analyzed by immunoblotting with the indicated antibodies.  
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Figure 3. Role of RNF4 in SUMOylation and ubiquitination of p53, Hdm2 and Hdmx.   
MCF7 cells were lentivirally infected with a His6-SUMO-2 or His6-ubiquitin expression vector and either an 
expression vector encoding a non-coding shRNA or a shRNA against RNF4. Four days later, cells were treated 
with MG132 (10 µM) or mock-treated for 8 hours. Cells were lysed and His6-SUMO-2 and His6-ubiquitin 
conjugates were purified using Ni-NTA beads. Total cell lysates and His-purified fractions were analyzed by 
immunoblotting with the indicated antibodies. (A, left panel) SUMOylation of p53 and total protein levels of p53, 
RNF4, p21 and USP7 of His6-SUMO-2 transduced cells. (A, right panel) SUMOylation of Hdm2 and Hdmx and 
total protein levels of Hdm2 and Hdmx of SUMO-2 infected cells. USP7 expression was analyzed as a loading 
control. (B) Ubiquitination of p53 and total protein levels of Hdm2, Hdmx, p53, RNF4, p21 and USP7 of His6-
Ubiquitin infected cells.  
 
RNF4 overexpression stabilizes Hdm2 protein levels, RING-dependently.  
To further study a putative function of RNF4 in the p53 pathway, we overexpressed V5- or 
Flag-tagged RNF4 in various cell lines. We observed very slight differences in endogenous 
Hdm2 levels upon RNF4 overexpression, possibly because only a minor fraction of the 
cells were transfected. Therefore, we co-transfected Hdm2 together with V5-tagged RNF4 
in p53 wild-type MCF-7 cells, p53/mdm2 double knockout MEFs, p53-negative H1299 
cells and p53-/- and p53+/+ HCT116 cells. In all cases we observed an increase of 
exogenously expressed Hdm2 protein when RNF4 was co-transfected, which was 
independent of endogenous p53 expression (Fig. 4A). Similar effects were observed when 
HA-Hdm2 together with Flag-tagged RNF4 was used (Fig. 4B; left panel), However, level 
of exogenously expressed HA-Hdmx was not affected by RNF4 co-expression (Fig. 4B; 
right panel). Furthermore, an RNF4 RING mutant (C133S) was not able to increase Hdm2  
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Figure 4. RNF4 overexpression stabilizes Hdm2 protein levels in a RING-dependent manner.  
(A) MCF7, p53/mdm2-/-MEFs, H1299, HCT116 p53-/- and HCT116 p53+/+ cells were transfected with a vector 
encoding Hdm2 (1 µg), V5-RNF4 (2 µg) or with an empty vector to a total of 3 µg per 6-cm dish, as indicated. All 
cells were co-transfected with 0.3 µg GFP encoding vector as a transfection control. Cells were lysed 24 hours 
post-transfection, total cell lysates were analyzed by immunoblotting with the indicated antibodies. (B) MCF7 and 
H1299 cells were transfected with 1 µg HA-Hdm2, HA-Hdmx or empty vector, together with either 1 µg (+) or 2 
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µg (++) Flag-RNF4 encoding vector or empty vector was added to a total of 3 µg per 6-cm dish. All cells were co-
transfected with 0.3 µg GFP encoding vector as a transfection control. Cells were lysed 24 hours post-transfection, 
total cell lysates were analyzed by immunoblotting with the indicated antibodies. (C) H1299 cells were transfected 
with 1 µg V5-RNF4, the RING-deficient V5-RNF4-C133S mutant or an empty expression vector, without or with 
co-transfection of 1µg Hdm2. As a transfection control 0.3 µg GFP encoding vector was co-transfected. Cells were 
lysed 24 hours post-transfection, protein levels were analyzed by immunoblotting with the indicated antibodies. 
(D). RNA extracts were analyzed using q-RT-PCR and are displayed as normalized relative HDM2 mRNA levels. 
(E) H1299 cells were transfected with an empty expression vector or 2 µg V5-RNF4 expression vector and co-
transfected with 1 µg (+) or 2 µg (++) Hdm2 encoding vector or empty vector was added to a total of 3 µg per 6-
cm dish. All dishes were co-transfected with 40 ng p53 expression vector. Cells were treated with 10 µM MG132 
or mock treated for 5 hours 24 hours post-transfection. Cells were lysed and protein extracts were analyzed by 
immunoblotting with the indicated antibodies, USP7 expression was used as a loading control. (F) MCF7 and 
H1299 cells were transfected with transfection vectors encoding Hdm2 (1 µg), V5-RNF4 (+ = 0.5 µg; ++ = 1 µg; 
+++ = 2 µg) as indicated and all were co-transfected with 1µg His6-ubiquitin. One day post-transfection cells were 
lysed and His6-Ubiquitin conjugates were purified using Ni-NTA beads. Total cell lysates and His6-Ubiquitin 
purified fractions were analyzed by immunoblotting using the indicated antibodies. (G) MCF7 cells stably 
expressing His6-SUMO-2 were transfected with an empty expression vector or a Flag-RNF4 overexpression 
vector, both 6 µg per 10-cm dish. One day post-transfection, cells were treated with MG132 (20 µM) or mock 
treated for 6 hours. Cells were lysed and His6-SUMO-2 conjugates were purified using Ni-NTA beads. Total cell 
lysates and His-purified fractions were analyzed by immunoblotting with the indicated antibodies. USP7 
expression was analyzed as a loading control. 
 
levels (Fig. 4C). No significant changes in HDM2 mRNA levels occurred upon RNF4 
overexpression (Fig. 4D), excluding a possible effect of RNF4 on transcription. The 
increase in Hdm2 protein levels is most likely caused by increased protein stability, which 
is dependent of an intact RING domain of RNF4. Indeed, the observed increase in Hdm2 
protein levels upon RNF4 expression was absent in cells that were treated with MG132, 
suggesting that RNF4 overexpression somehow interferes with the proteasomal degradation 
of Hdm2 (Fig. 4E). Furthermore, in the same experiment, the overexpression of RNF4 
seems to induce p53 protein levels, which is absent in the presence of MG132. However, no 
significant changes of the ubiquitinated fraction of p53 (data not shown) or Hdm2 could be 
detected upon RNF4 overexpression (Fig. 4F). Interestingly, in a His-pull-down of 
MCF7/His6-SUMO-2 cell extracts, mainly the amount of high molecular species of 
SUMOylated Hdm2 and p53 decreased when cells were transfected with Flag-RNF4 (Fig. 
4G). However, this effect was only noticeable when cells were treated with MG132, 
suggesting a, most likely indirect, interfering effect of RNF4 on the ubiquitination of the 
SUMOylated proteins. No change in Hdmx SUMOylation was found upon RNF4 
overexpression (data not shown). The basal protein levels of p53 and Hdm2 are only 
slightly enhanced in the RNF4 overexpressing cells, whereas MG132 treatment prevents 
this effect. These results are confirming that the SUMOylation of p53 only slightly affects 
the total p53 levels, as shown in figure 1 and 4. Furthermore, based upon these results, a 
direct role of RNF4 in the ubiquitination of SUMOylated p53 or Hdm2 is not likely, since 
then an increase of SUMO/ubiquitination would be expected upon RNF4 overexpression.  
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Role of SUMOylation in the p53 response upon various stresses. 
Modulation of p53, Hdm2 and Hdmx levels and/or activity plays an important role in the 
cellular response to various types of stress, especially DNA damage. Since situations of 
stress will induce a p53 response, the interaction between p53 and its inhibitors needs to be 
attenuated. Several types of post-translation modifications, including SUMOylation, may 
be involved in the regulation of the functional interaction of these proteins upon stress. 
Therefore, the SUMOylation status of these proteins upon various stresses was studied.   
 
SUMO-dependent ubiquitination of p53 is regulated by hypoxia. 
The p53 pathway is activated under hypoxic conditions 62. Therefore, we investigated 
whether SUMOylation would play a role in the p53 response to hypoxia. Hypoxia has been 
reported to regulate other proteins via SUMOylation, such as the Hypoxia-Induced Factors 
1 and 2 63-66. Stable MCF-7/His6-SUMO-2 cells were used to study the effects of hypoxia 
on the ubiquitination of SUMOylated p53, Hdm2 and Hdmx. As expected, we observed a 
strong induction of HIF1-alpha and some increase in p53 protein levels after 48 hours of 
hypoxia (1% O2), which was absent in cells that were treated with MG132. On the other 
hand, Hdm2 and Hdmx levels were reduced upon hypoxia. This reduction could not be 
rescued by inhibition of the proteasome, suggesting that it is not mediated by increased 
protein degradation (Fig. 5A). Furthermore, we observed a decrease of p53, Hdm2 and 
Hdmx SUMOylation and ubiquitination of the SUMOylated proteins (Fig. 5B). The 
observed decrease in Hdm2 and Hdmx SUMOylation could very well be explained by the 
decreased total protein levels, indicating that the relative SUMOylation is not affected. 
However, the increase in p53 total protein levels might be the result of reduced p53 
SUMOylation and ubiquitination under hypoxic conditions. These results indicate that 
hypoxia leads to reduced mRNA expression of Hdm2 and Hdmx, but does not influence the 
SUMOylation status of these proteins. In contrast, SUMOylation and ubiquitination of p53 
are reduced under hypoxic conditions, thereby stabilizing the protein.   
 
SUMOylation of p53 is reduced and SUMOylated Hdm2 is degraded upon DNA 
damage. 
To find out more about the role and regulation of SUMOylation in the activation of the p53 
pathway after stress, we treated cells with various types of DNA damaging agents. His6-
SUMO-2 expressing MCF-7 cells were treated with the proteasomal inhibitor MG132 with 
or without etoposide, or mock-treated. The relatively unstable p53 protein is strongly 
stabilized by MG132 treatment and also in response to etoposide (Fig. 5C). Confirming the 
results presented in figure 1, the relative amount of SUMOylated p53 does not increase 
upon proteasome inhibition. Etoposide treatment leads to an increase in the SUMOylated 
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p53 fraction in absence of MG132, reflecting the increase in total p53 levels. However, 
MG132 treatment upon etoposide incubation results in a decreased accumulation of high 
molecular SUMOylated/ubiquitinated p53 species, suggesting that p53 SUMOylation is 
reduced after DNA damage, similar to what is observed under hypoxic conditions. In 
contrast, the amount of the relatively stable protein Hdmx is not significantly affected by 
proteasomal inhibition up to 6 hours, but Hdmx protein levels are strongly decreased upon 
etoposide treatment via Hdm2-mediated ubiquitination. The SUMOylated Hdmx fraction is 
increased when the proteasome is inactivated, indicating a rapid degradation of SUMO-
ylated Hdmx species, as already presented in Figure 1. Upon treatment with etoposide, the 
relative amount of SUMOylated Hdmx appears to be slightly increased, both noticed in 
presence and absence of MG132 treatment (Fig. 5C). Treatment of the cells with the DNA 
damaging agent NCS resulted in a similar effect on both total and SUMOylated Hdmx (Fig. 
5D). These results suggest that upon DNA damage, Hdmx is degraded in a SUMO-
independent way.  
Interestingly, the SUMOylated fraction of Hdm2 is decreased upon NCS treatment, 
whereas after combined NCS and MG132 treatment a strong increase of ubiquitinated 
SUMOylated Hdm2 species is observed (Fig 5D). This result suggests that DNA damage 
stimulates the ubiquitination and degradation of SUMOylated Hdm2, whereas total Hdm2 
levels actually increase, due to increased p53-mediated transcription of the Hdm2 gene.  
 
Role of RNF4 in the DNA damage response. 
RNF4 and its yeast counterparts Slx8/Rfp are involved in the DNA repair response upon 
DNA damage and are essential for genomic stability 44,67; cells lacking RNF4 or its yeast 
counterparts are suggested to be more sensitive for DNA damage 44. It has been suggested 
RNF4 plays a role in DNA repair mechanisms via demethylation of the DNA, for which 
both its SIM and RING domain are required 68. Notably, PML, an RNF4 target, is a 
negative regulator of DNA repair genes 69 and its RNF4-mediated degradation might 
enhance DNA repair.   
Upon arsenic trioxide (ATO) treatment, PML is degraded via RNF4-mediated poly-SUMO-
dependent ubiquitination 46,47. Furthermore, ATO treatment has been shown to induce ATR, 
resulting in activation of CHK2 and p53 70. Indeed, ATO treatment of U2OS cells for 24 or 
48 hrs resulted in induction and activation of p53 and p53 targets, such as the cell cycle 
inhibitor p21 and the pro-apoptotic PUMA, and in decreased PML levels (Fig. 5E). 
Surprisingly, RNF4 levels were also decreased after ATO treatment (Fig. 5E). Interestingly, 
the amount of high molecular species of SUMOylated p53, Hdm2 and Hdmx was also 
reduced upon ATO treatment, also when the proteasome is inhibited (Fig. 5F), whereas 
total protein levels were not reduced. These results suggest a decrease in SUMO-specific 
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ubiquitination of certain SUMOylated proteins after ATO treatment, which might be 
associated, or at least coincide, with the observed decrease in RNF4 levels.  
 
RNF4 degradation correlates with induction of apoptosis. 
The degradation of RNF4, as seen after ATO incubation, was also observed upon various 
other treatments, including UV-C, cisplatin, Nutlin-3, IR and RITA (Fig 6A and B), which 
all induce a p53 response. The small molecule RITA has been reported to induce apoptosis 
in tumor cells, in a p53-dependent way, and elicits a DNA damage response 71,72. 
Interestingly, in contrast to wild-type HCT116 cells, no decrease of RNF4 levels was found 
in p53-/- HCT116 or Chk2-negative HCT116 cells when treated with RITA (Fig. 6B), 
suggesting that a p53-Chk2 pathway is required in this process. Both p53-/- and Chk2-/- 
HCT116 cells are very resistant to RITA-induced apoptosis (71 and De Lange et al., 
personal communication), suggesting a correlation between induction of apoptosis by RITA 
and decrease in RNF4 levels. The p53-dependency of the observed RNF4 degradation 
might be depending on cell-type or drug concentrations, since a similar RNF4 decrease in 
U2OS control and U2OS p53-knockdown cells upon ATO treatment is observed (Fig. 6C).  
Confirming a role for RNF4 in the response to certain drugs, MCF-7 cells that 
overexpressed Flag-tagged RNF4 were more resistant to RITA-treatment than control cells 
in short-term growth assay (Table 1 and Fig. 6D).  
 
Table 1. Effective Dose of RITA treatment on MCF7 and HCT116 cells expressing a 
control- or an RNF4 expression vector. 
 MCF7  HCT116 
Fa ctrl RNF4  ctrl RNF4 
50% 2.54 5.27  285.41 382.30 
75% 7.85 17.83  645.32 882.07 
90% 24.32 60.37  1459.08 2035.17 
95% 52.44 138.39  2541.31 3593.86 
MCF7 and HCT116 cells were lentivirally infected with a control- (pLV-
mCherry-GFP) or a Flag-RNF4-GFP expression vector. At day 4 after 
infection, cells were seeded for WST-1 proliferation assays and cells were 
mock treated or treated with a range of concentrations of RITA. Doses used for 
MCF7 cells were 10, 20, 40 and 80 nM RITA, whereas HCT116 were treated 
with 100, 200, 400 and 800 nM RITA, all for 24 hours. Medium was replaced 
with fresh medium without RITA, and relative survival was measured 72 hrs 
later and effective dose-curves were calculated using the CompuSyn program. 
The effective dose for the indicated Affected Fractions (Fa) was calculated 
using these curves. 
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Figure 5. Regulation of SUMOylation in the p53-pathway by stress. 
MCF7 cells stably expressing His6-SUMO-2 were incubated at hypoxic (1% O2) conditions, or maintained at 
normoxia (20% O2) for 48 hours, followed by treatment with 10 µM MG132 or mock treated for 6 hours. Cells 
were lysed and His6-SUMO-2 conjugates were purified using Ni-NTA beads. Total cell lysates (A) and His6-
SUMO-2 purified fractions (B) were analyzed by immunoblotting with the indicated antibodies. (A,B) MCF7 cells 
stably expressing His6-SUMO-2 were either mock treated (-), treated with 10 µM MG132 for 1 hour (+) or 6 
hours (++) and treated with 10 µM etoposide (A) or 500 ng/ml NCS (B) for 6 hours, with or without the addition 
of MG132, 15 min before drug treatment, as indicated. Cells were lysed and His6-SUMO-2 conjugates were 
purified using Ni-NTA beads. Total cell lysates and His6-SUMO-2 purified fractions were analyzed by 
immunoblotting with the indicated antibodies. (C) U2OS cells were treated with 3 µM arsenic trioxide (ATO) or 
mock-treated for 24 and 48 hours. Cells were lysed; protein extracts were analyzed by immunoblotting with the 
indicated antibodies. (D) MCF7 cells stably expressing His6-SUMO-2 were either mock-treated or treated with 3 
µM arsenic trioxide for 6 and 24 hours; 6 hours before harvesting 10 µM MG132 was added. Cells were lysed and 
His6-SUMO-2 conjugates were purified using Ni-NTA beads. Total cell lysates and His6-SUMO-2 purified 
fractions were analyzed by immunoblotting with the indicated antibodies. Vinculin expression was analyzed as a 
loading control.  
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Figure 6. Functions of RNF4 in the apoptotic response upon various drug treatments. 
(A) MCF7 cells were irradiated with UV-C (10 J/m2) or mock treated, treated with 5 µM cisplatin or treated with 
10 µM Nutlin-3. HCT116/p53+/+ were mock treated or irradiated with ionizing radiation (IR; 10 Gy). Cells were 
harvested at the indicated times after start of treatment, protein extracts were analyzed by immunoblotting with the 
indicated antibodies. (B, upper panel) HCT116/p53+/+, HCT116/p53-/- and HCT116/Chk2-/- cells were treated 
with 1 µM RITA or mock-treated for 24 hours; protein extracts were analyzed by immunoblotting with the 
indicated antibodies, USP7 expression was analyzed as a loading control. (B, lower panel) HCT116 p53+/+ and 
HCT116 p53-/- cells were treated with 1 µM RITA for the indicated times. Protein extracts were analyzed by 
immunoblotting with the indicated antibodies. Tubulin expression was analyzed as a loading control. (C) U2OS 
cells were lentivirally infected with either an expression vector encoding a non-coding shRNA or a shRNA against 
p53. Four days after transduction, cells were treated with the indicated concentrations ATO for 24 hours. Cells 
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were harvested and protein extracts were analyzed by immunoblotting with the indicated antibodies. USP7 
expression was analyzed as a loading control. 
(D) MCF7 cells were lentivirally infected with an empty control vector or a vector encoding Flag-RNF4 or RNF4-
Flag. Four days after transduction, cells were seeded for WST-1 proliferation assays, colony formation assays and 
protein analysis. For WST-1 proliferation assays cells were seeded at a density of 2500 cells per well. One day 
after seeding, cells were treated with the indicated concentrations of RITA for 24 hours or mock-treated. Relative 
survival was determined at day 3 after treatment. (E, F) Cells were seeded for colony formation assays in 6-well 
plates with a density of 10,000 cells per well and treated with 50 nM RITA for 3 hours, or irradiated with IR with 
the indicated doses, one day after seeding. One week later colonies were quantified and displayed as relative 
colony formation compared to the corresponding mock-treated cells. (G) For analysis of protein expression levels, 
cells were treated with 160 nM RITA for 24 hours or mock-treated, one day after seeding. Cells were harvested 
and protein extracts were analyzed by immunoblotting with the indicated antibodies. USP7 expression was 
analyzed as a loading control. (H) HCT116 cells were lentivirally infected with either an empty control vector or a 
vector encoding Flag-RNF4. Four days later, cells were treated with 800 nM RITA for 24 hours or mock treated, 
after which the cells were harvested and protein extracts were analyzed by immunoblotting with the indicated 
antibodies. USP7 expression was analyzed as a loading control. A-specific bands detected with the anti-RNF4-
antibody are indicated with *. 
 
Moreover, long-term colony formation assays also indicated that cells with increased RNF4 
levels were more resistant to RITA treatment (Fig. 6E). In contrast, no differences were 
found when the same cells were treated with ionizing radiation, NCS or topotecan (Fig. 6F 
and data not shown).  
 
In the RNF4-overexpressing MCF7 cells, protein analysis showed no differences in p53 
phosphorylation on Ser15, no differences in Hdm2 induction, but reduced PARP cleavage, 
an indicator for apoptosis, after treatment with RITA (Fig. 6G). However, the effect of 
RNF4 overexpression appears to be cell-type and/or dose dependent, since overexpression 
of RNF4 in HCT116 cells only very slightly increased resistance of RITA-induced growth 
inhibition/ apoptosis, and did not significantly affect PARP cleavage (Table 1 and Fig. 6H). 
On the other hand, HCT116 cells are much more resistant for RITA-induced apoptosis than 
MCF7 cells, so a comparison between these cell lines is difficult to make.  
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Discussion  
 
Key proteins in the p53 pathway are strongly regulated by post-translational modifications, 
such as phosphorylation, acetylation, ubiquitination and SUMOylation. The function of the 
latter modification is not very well understood yet; it might fulfill roles in localization, 
activity and degradation. Evidence exists for several ways of cross-talk between SUMO and 
ubiquitin 73,74, which may have different outcomes, varying from protein stabilization to 
degradation, depending on the type of interaction. The SUMOylation of p53 and Hdm2 
have been reported to inhibit transcriptional activity 29 and auto-ubiquitination42, 
respectively. SUMOylation of Hdmx has not been reported to have a distinct function yet, 
as a SUMO-mutant Hdmx did not respond differently from wild-type Hdmx regarding 
Hdm2-mediated degradation, subcellular localization, DNA damage response and p53 
inhibition 38. 
 
In this study we investigated the regulation of the SUMOylation of p53, Hdm2 and Hdmx 
and observed that under certain circumstances the SUMOylated proteins were preferentially 
ubiquitinated and degraded. This phenomenon is especially clear with regard to Hdmx; 
proteasome inhibition hardly affects total Hdmx levels, but a strong accumulation of high 
molecular weight species of the SUMO-conjugated Hdmx protein is observed, most likely 
representing poly-ubiquitinated Hdmx species. These findings indicate a role for 
SUMOylation and SUMO-dependent ubiquitination in the regulation of p53. We found that 
inactivation of ERK1/2 reduces the ubiquitination of SUMOylated p53, Hdm2 and Hdmx, 
whereas Hdm2 protein expression is also reduced, most likely at the mRNA level. 
Consistent with a previous published observation that SUMOylation inhibits p53 activity 29, 
we observed a reduced p53 SUMOylation and ubiquitination of SUMOylated p53  after p53 
activation by various stresses, such as hypoxia and DNA damage. SUMOylation of Hdm2 
is reduced after stress, most likely due to increased degradation of SUMOylated Hdm2, 
whereas Hdmx seems to be degraded in a SUMO-independent way. 
 
A putative candidate E3 ligase for SUMO-dependent ubiquitination of the proteins in the 
p53 pathway is the STUbL RNF4. RNF4 has been reported to specifically ubiquitinate 
poly-SUMOylated PML, but no other targets have been identified to date. If SUMOylated 
p53, Hdm2 and Hdmx are also targets for RNF4-mediated ubiquitination, RNF4 
knockdown should reduce the ubiquitination of SUMOylated proteins, resulting in 
stabilization of the SUMOylated species. However, upon RNF4 knockdown we actually 
observed a decrease in both SUMOylated and ubiquitinated p53, Hdm2 and Hdmx. 
RNF4 and SUMOylation in the p53 pathway 
- 157 - 
Moreover, also total protein levels of Hdm2 and Hdmx are somewhat decreased, whereas 
p53 levels are not much affected, or slightly induced in RNF4 knockdown cells. 
Overexpression of RNF4 seems to stabilize Hdm2, suggesting its main activity on Hdm2 is 
SUMO-independent or an indirect interaction.  
 
Upon DNA damage, p53 is activated, resulting in either cell cycle arrest, to enable the 
repair of damaged DNA, or apoptosis, when the damage is not repairable.   
RNF4 can be associated in several ways with the DNA damage response and thereby 
possibly with the p53 pathway. First of all, RNF4 has been shown to have a role in DNA 
demethylation, involving the Base Excision Repair (BER) pathway 68. Consistently, RNF4 
knockout MEFs showed a strongly increased accumulation of DNA damage during cell 
culture. Importantly, there is evidence that p53 might regulate this DNA repair pathway 75; 
therefore, it is not excluded that RNF4 might influence the DNA repair system via the p53 
pathway. Another possibility is that RNF4 affects the p53 pathway indirectly via PML. It 
has been reported that PML enhances the p53 activation upon DNA damage by recruiting 
p53 and several kinases to the PML bodies, resulting in phosphorylation of p53 on Thr18 
and Ser20, which protects from Hdm2 inhibition 76,77. Upon arsenic trioxide treatment, the 
SUMOylation of PML is greatly enhanced, followed by degradation by RNF4 46,47. 
Although the degradation of PML is only seen upon treatment with arsenic trioxide, the 
control of PML by RNF4 under normal conditions or in response to other drugs cannot be 
excluded and might have a function in the regulation of the p53 pathway. Furthermore, it 
has been shown that PML interacts with Hdm2, mediating its localization to the nucleoli 
after DNA damage 78 . The activity of RNF4 on PML may therefore also have an effect on 
Hdm2 stability. Not much is known about the interaction between Hdmx and PML, but it is 
well possible that Hdmx is also regulated by PML.  
Overexpression of RNF4 stabilized the Hdm2 protein, which makes a role of RNF4 in the 
regulation of the p53 response feasible. We found that RNF4 levels decrease upon various 
drugs treatment. In the case of RITA, the downregulation of RNF4 correlates with 
activation of p53 and an apoptotic response, which was found to be absent in p53 and 
Chk2-negative HCT116 cells. Interestingly, in some cases the downregulation of RNF4 is 
concomittant with the activation of p53, and is, for example, also observed after treatment 
with the p53 activator Nutlin-3. However, activation of p53 is not sufficient for RNF4 
downregulation since treatment of MCF-7 cells with etoposide or topotecan is activating 
p53 but does not or hardly affect RNF4 levels. In addition, downregulation of RNF4 by 
ATO treatment is similar in control and p53-knockdown U2OS cells.  
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Nevertheless, elevated RNF4 levels in MCF7 cells attenuated the apoptotic response upon 
RITA treatment, indicating that the degradation of RNF4 might facilitate an appropriate 
apoptotic response, which might well be p53-independent.  
It would, therefore, be useful to investigate the response to apoptosis-inducing drugs in 
cells that have reduced RNF4 levels, as it may be expected that these cells will be more 
sensitive for such drugs. Preliminary results indicate that RNF4-knockdown cells show a 
strong growth inhibition upon a few passages and, therefore, the analysis of drug responses 
is complicated. It could be informative to screen a large set of tumor and normal cells for a 
putative correlation between RNF4 expression levels and the induction of apoptosis.  
 
More insight into the mechanism by which RNF4 is degraded to allow an apoptotic 
response might serve as a potential lead to development of new anti-cancer drugs, since 
reducing RNF4 likely will enhance the killing effect of conventional anti-cancer treatments. 
On the other hand, reduced RNF4 levels were found to be associated with testicular tumor 
progression, due to a growth inhibiting function in this specific cell-type 79-81. Interestingly, 
these tumor cells are in general very sensitive to chemotherapeutic treatments 82. Even so, it 
is not excluded that overexpression of RNF4 may act as an oncogene in other tissues. 
Enhanced RNF4 expression was found to be associated with tumor formation in BALB-
neuT mammary glands and found to be enhanced in breast tumors 83. These results would 
be consistent with our results; overexpression of RNF4 might also inhibit oncogene-
mediated p53 activation or apoptosis, thereby promoting tumourigenic transformation.  
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Supplemental Information 
 
q-RT-PCR primer sequences 
 
Hdm2-Exon2 Fw 5’-ACGCACGCCACTTTTTCTCT-3’ 
Hdm2-Exon2 Rv 5’-TCCGAAGCTGGAATCTGTGAG-3’ 
CAPNS1 Fw 5’-ATGGTTTTGGCATTGACACATG-3’ 
CAPNS1 Rv 5’-GCTTGCCTGTGGTGTCGC-3’ 
TBP Fw 5’-CACGAACCACGGCACTGATT-3’ 
TBP Rv 5’-TTTTCTTGCTGCCAGTCTGGAC-3’ 
SRPR Fw 5’-CATTGCTTTTGCACGTAACCAA-3’ 
SRPR Rv 5’-ATTGTCTTGCATGCGGCC-3’ 
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Abstract 
 
The FAU gene (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-Associated 
Ubiquitously expressed gene) was originally identified as a pro-apoptotic gene and its 
downregulation has been associated with tumourigenicity and drug resistance in tumour cell 
lines of various origins. The FAU mRNA encodes for a fusion product of the ubiquitin-like 
protein FUBI and the ribosomal protein S30, which is cleaved after a Gly-Gly motif, 
yielding the mature proteins. It has been demonstrated that the FUBI protein can be 
conjugated to the pro-apoptotic Bcl-2 family member Bcl-G, which was reported to be 
essential for the induction of apoptosis by FAU. In contrast, others have reported that FAU 
and FUBI overexpression has transforming capabilities, whereas FAU and S30 
overexpression conferred arsenite resistance. In this study we investigated the function of 
the FAU gene in osteosarcoma and found that FAU expression is essential for cell 
proliferation. Knockdown of FAU resulted in a strong decrease of the proliferation rate 
caused by a G2/M arrest, accompanied by an increase of the checkpoint protein GADD45-
alpha. This effect could only be rescued by the ectopic overexpression of the complete FAU 
mRNA, suggesting an essential function for both FUBI and S30. Furthermore, we 
demonstrated that cells with reduced FAU expression showed less sensitivity to treatment 
with various types of chemotherapeutical drugs, confirming a role of FAU in determining 
drug sensitivity.  
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Introduction 
 
Ubiquitination is an important post-translation protein modification involved in the 
regulation of many cellular processes. Ubiquitin is conjugated to a target protein by 
formation of an isopeptide bond between the C-terminal glycine of ubiquitin and a lysine in 
the target protein. A target protein can be (multiple) mono-ubiquitinated or poly-
ubiquitinated. Dependent on the ubiquitination status, ubiquitination may lead to altered 
localization or function of the protein, or can trigger the 26S-proteasome-mediated 
degradation of the target protein, reviewed recently 1,2. A number of ubiquitin-like 
modifiers have been identified, like SUMO and NEDD8 3, the functions of which are being 
gradually unraveled, reviewed in Gareau and Lima (2010) 4 and Watson et al. (2011) 5. One 
of the least studied ubiquitin-like proteins is FUBI, which is translated as a fusion protein 
named FAU. The FAU gene encodes a 133 amino acid fusion protein, consisting of the N-
terminal ubiquitin-like FUBI protein (74 amino acids) and the C-terminal ribosomal protein 
S30 (59 amino acids). The FUBI protein contains a C-terminal di-glycine motif, like 
ubiquitin, enabling it to be conjugated to target proteins. The FUBI protein is ~ 35% 
identical to ubiquitin, but, strikingly, lacks almost all internal lysines with the exception of 
lysine 25, corresponding to lysine 27 in ubiquitin. Not much is known about the function of 
K27 linkage in ubiquitin, although it has been suggested that all ubiquitin linkages can 
target proteins for proteasomal degradation 6. K27 linkage was reported to be assembled by 
U-box-type 3 E3 ligases under certain stress responses 7, or by TRAF6 overexpression 8. 
Furthermore, the RingB1 E3 ligase promotes self-ubiquitination using mixed a-typical 
ubiquitin chains, including K27, which are required for its ligase activity towards Histone 
H2A 9. Interestingly, the FUBI (Ubi-L) domain of FAU has been reported to bind non-
covalently to Histone H2A 10.  
 
The FAU gene (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-Associated 
Ubiquitously expressed gene) was identified in two independent studies by functional 
expression cloning to be a novel apoptosis regulator. Originally, the FAU gene was 
identified as the cellular homologue of the fox sequence in FBR-MuSV, isolated from a 
radiation-induced mouse osteosarcoma 11. The viral fox sequence is expressed as an 
antisense of the mouse FAU cDNA sequence and was found to posses transforming 
capabilities, most likely by inactivating endogenous FAU expression 12. The FAU gene is 
conserved in higher eukaryotes and expressed in all mammalian tissues 12,13. 
 
The FAU antisense sequence inferred resistance to cisplatin and UV-radiation in mouse T-
cells. Moreover, overexpression of FAU was shown to induce apoptosis in several cell 
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lines, revealing a pro-apoptotic function 14. In these studies the putative distinct functions of 
FUBI and S30 were not addressed. A possible explanation for the role of FUBI in 
regulation of apoptosis was initially provided by Nakamura et al. (2003). They showed that 
the FUBI domain of FAU, also called MNSFbeta, could be conjugated to the pro-apoptotic 
Bcl-2 family member Bcl-G 15, thereby inhibiting the ERK cascade 16. In subsequent 
studies it was shown that regulation of Bcl-G by FUBI modification is essential for its pro-
apoptotic activity, and that FAU expression is frequently downregulated in breast cancer 
development, which was associated with poor patient survival 17,18. Selection for low FAU 
expression was also observed in ovarian and prostate cancer, correlating with reduced Bcl-
G expression 19,20. Furthermore, reduction of FAU expression in the A2780 ovarian cancer 
cell line conferred some carboplatin resistance to these cells 20. In line with these results, 
the downregulation of FAU and Bcl-G expression in the prostate cancer cell line 22Rv1 as 
well as the breast cancer cell line T-47D resulted in decreased sensitivity to UV-C 
irradiation 18,19. These results were recently repeated in a study containing three more 
human cell lines, and it was shown that FAU overexpression somewhat decreased the 
number of viable cells 21. All these studies indicate a tumour suppressor role for FAU in 
cancer development.  
In contrast, in another study, the FAU sequence was shown to protect against arsenic-
induced apoptosis 22. The same authors later showed that overexpression of FAU or its 
FUBI domain could transform the osteosarcoma cell line HOS to anchorage-independence, 
whereas the FAU or the S30 subunit alone both induced arsenite resistance 23. These results 
would suggest an oncogenic function for FAU.  
Furthermore, it was demonstrated that the FAU ubiquitin-like domain is involved in the 
immune response, although this might be independent from its pro-apoptotic function 24. 
 
We investigated the role of FAU in the sensitivity of osteosarcoma cell lines to several 
types of drugs, including arsenic trioxide (ATO). Arsenic trioxide is used to induce 
apoptosis in acute promyelocytic leukemia (APL) and was also reported to induce apoptosis 
in solid cancer cell lines 25,26. Furthermore, it was shown that arsenic trioxide treatment 
induced apoptosis via p73, which could be enhanced with MEK1 inhibitors 27-29. Recently, 
it has been reported that ATO treatment reduced motility, migration and invasiveness in the 
osteosarcoma cell lines HOS and MNNG, probably by the inhibition of phosphorylation of 
MAPK family members ERK and MEK 30. Several groups report that in other 
osteosarcoma cell lines, such as MG-63 or SaOS-2, ATO treatment successfully can induce 
apoptosis and act synergistically with other drugs 31-33.   
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On the other hand, exposure to low concentrations of ATO has been suggested to act 
carcinogenic 34-36, possibly by the observed activation of the p38-MAPK, ERK1/2 and Akt 
pathways upon low dose treatment with ATO 37.  
 
To investigate FAU functions on drug sensitivity, we performed both knockdown of FAU 
and overexpression of FAU, FUBI or S30 and assessed the effects of drug treatments. 
Surprisingly, we found a significant growth inhibiting effect of FAU knockdown, which 
could only be rescued by concomitant overexpression of the whole FAU sequence. 
Furthermore, we observed decreased sensitivity for arsenic trioxide, cisplatin and 
doxorubicin in cells with decreased FAU levels. On the other hand, overexpression of FAU 
and FUBI increased the sensitivity for these drugs.   
 
Material & Methods 
 
Cell Culture and Reagents 
U2OS, OST and OSA cells were maintained in RPMI supplemented with 10% FBS and antibiotics. Cells were 
treated with arsenic trioxide, doxorubicin, cisplatin, Actinomycin D (all from Sigma-Aldrich, St Louis, MO, 
USA), MEK1/2 inhibitor U0126 (Calbiochem), MEK1 inhibitor PD98059 (Calbiochem), RITA (Gift from Galina 
Selivanova) and Nutlin-3 (Cayman Chemical, Ann Arbor, MI, USA) for the indicated times and concentrations.  
 
Plasmids, Lentiviral Transduction  
A FAU cDNA clone was obtained from Origene Technologies Inc. (Rockville, MD, USA). The coding sequences 
of FAU, FUBI or S30 were amplified, with the use of 5’ primers containing a BamHI and 3' primers containing an 
XbaI restriction site. The resulting fragment was cloned into a pcDNA3.1 expression vector containing an HA-tag 
such that the HA-tag is N-terminal of the FAU, FUBI or S30 coding region. Lentiviral expression vectors for HA-
FAU, HA-FUBI and HA-S30 were made by cloning the corresponding cDNA sequences into pLV-CMV-bc-puro 
using NdeI and NheI restriction sites. 
cDNA sequences are available in supplemental information. 
For FAU knockdown 2 different lentiviral vectors containing a short hairpin RNA targeting FAU are used (Sigma 
MISSION Library; Sigma-Aldrich). Targeting sequences are: shFAU #1: 5’- CAGACTCCTAAGGTGGCCAAA-
3’ and shFAU#2: 5’- GAAGAAGACAGGTCGGGCTAA-3’. These shRNAs target the S30 coding region with 
the FAU sequence; unfortunately the other shRNAs targeting FAU within the FUBI coding region were very 
inefficient in downregulating FAU mRNA (not shown).  
Other lentiviral shRNA expression vectors were the non-targeting shRNA expression lentivirus shc002 (Sigma 
MISSION Library; Sigma-Aldrich), shRNA targeting human p53 38 or mouse mdmx 39 as a control. 
The construction of lentiviral vectors expressing specific shRNAs and the production of lentivirus particles have 
been described recently 39.  
 
Proliferation assay, Colony Forming assay, FACS analysis 
For growth assays, 2000 cells were seeded in triplicate in a 96-wells plate; 24 hours after seeding, cells were 
treated with the indicated drugs for the indicated times. To measure cell survival, cells were incubated with WST-1 
reagent (Roche Biochemicals, Indianapolis, IN) for 1-2 hours followed by quantification with a plate reader 
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(Victor3 Multilabel Counter 1420-042, Perkin-Elmer) measuring absorbance at 450 nm. The growth inhibitory 
effect of the drug was analyzed with the use of CompuSyn software 40.   
For colony forming assays 3000-4000 cells were seeded in duplicate per condition in 6-wells plates; cells were 
treated for three days with 3 µM ATO or mock treated and fixated and stained with Giemsa reagens eight days 
after seeding. Colonies were quantified with the Odyssey Infrared Imager and Odyssey 2.1 analysis software (LI-
COR Biosciences, Lincoln, Nebraska USA). 
For FACS analysis 100,000 cells were seeded in 6-cm dishes 24 hours before the indicated treatment. Cells and 
medium were harvested after 48 hours of treatment, fixated and analyzed on the Flow cytometer (Beckton 
Dickinson, Franklin Lakes, NJ USA) using FACS DIVA software after incubation in PBS with 50 µg/ml 
propidium-iodide (PI) and 50 µg/ml RNase. 
 
RNA isolation, Reverse Transcription, Q-RT-PCR  
RNA was isolated from cells using the SV Total RNA Isolation System (Promega) according to the 
manufacturers’ protocol. cDNA was made from 1 µg of total RNA in an Reverse Transcriptase reaction containing 
ImPromII Reverse Transcriptase, RNasin RNAse inhibitor, MgCl2 and 5x RT-Buffer (Promega). Quantification of 
mRNA expression was performed by Quantitative-real-time PCR, in an ABI 7900HT thermocycler, using the 
FastStart Universal SYBR Green Master (ROX) mix (Roche). Relative mRNA quantities were calculated using an 
internal standard curve, made from a dilution series of the pooled samples, using the SDS2.3 analysis program 
(Applied Biosystems). Expression levels of the mRNAs were normalized to the geometric mean of the control 
genes CAPNS1, TBP, SRPR. Primer sequences are available in Supplemental Information.  
 
Protein extraction, Western Blotting and Antibodies 
Cells were lysed in Giordano 250 buffer (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM 
EDTA), supplemented with a mixture of protease- and phosphatase inhibitors. Protein content was determined 
using Bradford Reagent (Biorad) and equal amounts of protein were separated by SDS-PAGE. Proteins were 
transferred onto polyvinyldene difluoride membranes (Immobilon-P, Millipore). Membranes were blocked in Tris-
buffered saline, 0.2% Tween-20 (TBST) containing 10% non-fat dry milk, and subsequently incubated with the 
appropriate primary antibody diluted in TBST containing 10% milk. Membranes were washed three times with 
TBST and incubated with HRP-conjugated secondary antibody (Jackson Laboratories). Bands were visualized by 
enhanced chemiluminescence (Super Signal; Pierce) followed by detection with the ChemiGenius XE3 system 
(Syngene, Cambridge, UK) or X-ray film (Fuji).  
Antibodies used inthis study were anti-HA.11 monoclonal mouse antibody (Covance), rabbit polyclonal anti-USP7 
(A300-033A, Bethyl Laboratories), anti-S30 rabbit polyclonal antibody (405, gift of Dr. J.C. Marine ), anti-B23 
mouse monoclonal antibody NA24 (Santa Cruz), anti-phospho-ERK1/2 monoclonal mouse antibody (Sigma), 
anti-ERK1/2 rabbit polyclonal antibody (Sigma), anti-phospho-Akt-S473 rabbit polyclonal antibody (Cell 
Signaling), anti-Akt1/2 rabbit polyclonal antibody (Upstate), anti-phospho-T246 PRAS40 rabbit polyclonal 
antibody (Cell Signaling), anti-cyclin D1 rabbit polyclonal antibody (Santa Cruz) and anti-p27 rabbit monoclonal 
antibody (Epitomics). Secondary antibodies goat-anti-mouse-HRP and goat-anti-rabbit-HRP were obtained from 
Jackson Laboratories. 
Immunofluorescence:  
Cells were seeded onto coverslips 24 hours pre-fixation. Cells were washed with PBS before fixation with 4% 
paraformaldehyde for 10 min at room temperature (RT). Cells were subsequently washed with PBS, permeabilized 
in PBS with 0.2 % Triton X-100 solution for 10 min at RT, washed with PBS and washed with PBS containing 
0.05% Tween-20. Cells were blocked with PBS containing 0.05% Tween-20 and 5% Normal Goat Serum (NGS) 
for 1 hour at RT, incubated with the indicated primary antibodies, diluted in PBS/Tween-20/NGS, for 1.5 hours. 
After washing, cells were incubated for 30 min with goat anti-mouse-Rhodamine secondary antibody (Jackson) 
diluted 1:100 in PBS/Tween20/NGS. After washing, coverslips were mounted onto microscope slides using 
DAPI-DABCO mounting solution, containing 90% glycerol, 10% 0.2M Tris-HCl pH8.0, 2.3% DABCO (1,4 
Diazabicyclo [2,2,2] octane) and 0.002% DAPI.   
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Results 
 
FAU expression is essential for cell proliferation  
To assess a putative role of FAU expression in drug sensitivity of osteosarcoma cell lines, 
we performed both FAU knockdown- and overexpression experiments. Initially, we 
performed a knockdown of FAU, with 2 different lentiviral knockdown constructs, in 3 
osteosarcoma cell lines, U2OS, OST and OSA, which have slightly varying basal FAU 
mRNA levels (Fig. 1A). Knockdown resulted in at least a 50% decrease in FAU mRNA 
levels (Fig. 1A). Strikingly, in all three cell lines, knockdown of FAU resulted in a marked 
growth inhibition with both knockdown vectors (Fig. 1B and C).  
To investigate whether the observed inhibition of growth is indeed caused by the reduced 
FAU expression, we tried to rescue the knockdown effect by overexpression of FAU, FUBI 
or S30. To that end, U2OS cells were transduced with lentiviral vectors expressing HA-
FAU, HA-FUBI or HA-S30 or a control vector, and stably transduced cells were obtained 
by puromycin selection. Subcellular localization of the exogenously expressed proteins was 
investigated with by immunofluorescence. HA-FAU was found to be present in the nucleus, 
including the nucleoli (Suppl. Fig. 1A). HA-S30 was predominantly localized in the 
nucleoli, as demonstrated by co-localization with the nucleolus-specific protein B23 (Suppl. 
Fig.1B). HA-FUBI was localized throughout the cell, both nuclear and cytoplasmic; 
however, patterns were strongly variable and might be determined by e.g. cell cycle phase. 
(Suppl. Fig. 1A). Not all cells transduced with HA-FUBI or HA-S30 lentiviruses detectably 
expressed the corresponding protein as determined by immunofluorescence, whereas 
virtually all HA-FAU transduced cells do express HA-FAU. Expression of endogenous 
FAU, FUBI or S30 was not detectable with the available antibodies; neither by 
immunofluorescence nor by western blotting.  
Subsequently, FAU was knocked down with the same lentiviral knockdown constructs 
mentioned above, which target endogenous FAU mRNA in its coding region, in the S30 
part of the sequence. Consequently, exogenous FAU and S30 will also be targeted for 
shRNA-mediated degradation upon transduction with these knockdown constructs, whereas 
exogenous FUBI should not be affected.  
The FAU knockdown efficiency in all 4 stable U2OS cell lines is shown in Supplemental 
Figure 1C. Depicted are the relative mRNA quantities determined with the use of primer 
sets for respectively endogenous FAU, total FUBI and total S30. At the mRNA level, both 
FAU and FUBI are highly expressed, whereas S30 is somewhat lower. Both FAU and S30 
are decreased upon FAU knockdown, whereas FUBI mRNA levels remain constant. 
Nevertheless, compared to control cells, the FAU overexpressing cells still have much 
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higher FAU mRNA levels after FAU knockdown, and even S30 overexpressing cells still 
retain about 5-10x higher S30 mRNA levels compared to control after knockdown of FAU.  
 
At the protein level (Suppl. Fig. 1D) both HA-FAU and HA-S30 expression are decreased 
upon FAU knockdown, although the HA-FAU expression is still well detectable. HA-FUBI 
expression is not significantly affected, as expected. In the HA-FAU cells we also detect a 
band of the same size as HA-FUBI. This most likely indicates that FAU is cleaved at the 
GG-motif, which essentially yields an HA-FUBI protein (detected with anti-HA antibody) 
and the untagged S30 protein, which is not detected. Interestingly, a smear of high 
molecular species is detected in both HA-FUBI and HA-FAU expressing cells, which most 
likely consists of FUBI-conjugates. Since S30 is lower expressed, a longer exposure of the 
blot is shown. Probably therefore some aspecific bands were detected in both Ctrl and S30 
cells, but the intensity is much lower than the FUBI-conjugates detected in the FUBI and 
FAU cells.     
Immunofluorescence on cells that had FAU knocked down, confirmed the results found on 
western and RNA; HA-FAU overexpressing cells showed a slightly decreased signal for 
FAU and nucleolar staining was more obvious. HA-FUBI expression and localization 
seemed to be unaffected, whereas the specific S30 signal in HA-S30 cells was significantly 
reduced (Suppl. Fig. 1A).   
Although FAU has been reported to be a pro-apoptotic gene and, therefore, a growth 
reduction might be expected 21, overexpression of both FAU and FUBI did not significantly 
change the growth rate of the cells, whereas cells with S30 overexpression showed a 
somewhat reduced proliferation rate (Fig. 1D).  
In contrast, knockdown of FAU resulted in growth inhibition in control-, HA-FUBI- and 
HA-S30 overexpressing cells, but was almost completely rescued by HA-FAU 
overexpression (Fig. 1E). Furthermore, we also observed partial rescue of the growth 
inhibitory effect upon FAU knockdown by HA-FAU overexpression in a long term growth 
assay, a colony forming assay (Fig. 1F).  
FACS analysis was performed to find an explanation for the growth-inhibition seen upon 
knockdown of FAU (Suppl. Fig. 2A). The most striking change observed is a strong 
increase of the number of cells in G2/M phase upon FAU knockdown, with concomitant 
reduced G1- and S-phase cells. Furthermore, a slight increase of cells in SubG1 is observed, 
suggesting some induction of apoptosis. Overexpression of FAU, FUBI or S30 did not 
significantly change the cell cycle profile (Suppl. Fig. 2A). Importantly, HA-FAU 
overexpression largely rescued the cell cycle effects seen upon FAU knockdown. The 
constitutive expression of FUBI or S30 could not or only slightly rescue the cell cycle 
effects. However, since particularly the levels of HA-S30 are lower than the HA-FAU  
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Figure 1. FAU expression is essential for cell proliferation 
U2OS, OST and OSA cells were lentivirally transduced with control-, or two different FAU knockdown 
constructs. Cells were seeded for proliferation assays and RNA isolation 24 hours after infection. RNA extracts 
were isolated at day 4 post-infection. Expression levels of FAU mRNA were quantified using q-RT-PCR and are 
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shown as normalized relative mRNA levels (A). Metabolic activity as a measure of proliferation was measured at 
the indicated days and displayed as relative growth to day 0 (B) or as relative survival at day 2 compared to 
control cells (C). U2OS cells were lentivirally transduced with either control vector or expression vectors for HA-
FUBI, HA-S30 or HA-FAU. Stable cell lines were established by puromycine selection and survival relative to 
control cells was measured 3 days after seeding using WST-1 proliferation assays (D). Stable cell lines were 
lentivirally infected with either control or two different FAU knockdown constructs. Cells were seeded for WST-1 
proliferation assays and colony formation assays 48 hours after infection. Relative survival of transduced cells was 
measured 3 days after seeding (E). Colony formation of stable control or HA-FAU expressing cells transduced 
with either control or FAU knockdown was quantified 10 days after seeding and displayed as relative colony 
formation compared to the corresponding control cells (F).   
 
expression after FAU knockdown, the rescue effect might be attenuated compared to the 
effect of FAU overexpression. However, based on the observations in short and long term 
proliferation assays and the results of flow-cytometry, it seems that the expression of the 
complete FAU sequence is needed to rescue the growth inhibiting effect of FAU 
knockdown. 
 
FAU expression enhances sensitivity for ATO treatment in U2OS cells.  
To assess a putative effect of FAU levels on the sensitivity to arsenic trioxide (ATO) in 
osteosarcoma cells, we treated the above described stable cell lines for 24 hours with 3 µM 
ATO and cell survival was determined. Although the control cells show a relative survival 
of only 25% after 72 hrs, cells that overexpress FAU show an even lower relative survival 
(Fig. 2A). Moreover, as illustrated in the growth curves (Fig. 2B), ATO-treated control 
cells are just growth arrested, whereas the number of ATO-treated FAU overexpressing 
cells actually decreases, suggesting cell loss through apoptosis. Furthermore, cells with 
FAU knockdown, which already have a somewhat reduced growth rate, show almost no 
further reduction upon ATO treatment (Fig. 2C). Cells that have FAU overexpression and 
FAU knockdown combined, show an intermediate survival (Fig. 2B). FACS analysis 
showed an increased number of control cells in G2/M phase after 48 hours of ATO 
treatment, which was not significantly influenced by FAU overexpression. In FAU 
knockdown cells, ATO treatment did not further increase the amount of cells in G2/M 
arrest (Supp. Fig. 2B). Even more, in a colony formation assay, arsenic trioxide treatment 
could not further reduce colony formation after FAU knockdown, whereas cells with FAU 
overexpression showed a higher sensitivity for this treatment (Fig. 2D). FAU 
overexpression also sensitizes p53-knockdown cells for ATO treatment (Fig. 2E), 
suggesting that the increased ATO sensitivity induced by FAU overexpression is not 
dependent on p53. However, when cells were treated with higher concentrations of this 
drug, to induce an apoptotic response, no differences were observed between control-, 
FAU- or FUBI-overexpressing cells, whereas S30 overexpressing cells seemed to be 
slightly more resistant (Fig. 2F). Interestingly, cells with reduced FAU levels were also 
more resistant to the high ATO treatment (Fig. 2G).  
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Figure 2. FAU expression enhances sensitivity for ATO treatment, independent of p53. 
Stable U2OS cells expressing a control vector or HA-FAU were lentivirally infected with either a control- or two 
different FAU knockdown vectors. Cells were seeded for WST-1 proliferation assays and colony formation assays 
2 days post-infection and treated with 3 µM ATO for 24 hours or mock treated one day after seeding. Proliferation 
was measured using WST-1 and displayed as relative survival at day 3 compared to the corresponding mock-
treated cells (A). Growth curves of mock- or ATO (3 µM 24 hours) treated control and HA-FAU cells are depicted 
in (B), growth curves of mock- or ATO (3 µM 24 hours) treated control cells or cells that have decreased FAU 
levels due to expression of one of two different FAU knockdown contructs are depicted in (C). Colony formation 
of ATO (3 µM 24 hours) treated control- or FAU-knockdown cells is displayed as relative colony formation 
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compared to the corresponding mock treated cells (D). Stable U2OS cell lines expressing either a control vector or 
an expression vector encoding HA-FAU or short-hairpin RNA’s against p53, or both, were seeded for WST-1 
proliferation assays. One day after seeding cells were treated with 3 µM ATO for 24 hours or mock treated. 
Relative survival of ATO treated cells at day 3 after treatment is depicted in (E). U2OS cells were lentivirally 
infected with a control vector or an expression vector encoding HA-FUBI, HA-S30 or HA-FAU or either a 
control-knockdown vector or two different FAU knockdown vectors, and seeded for WST-1 proliferation assays 
four days post-infection. One day after seeding the cells were treated with the indicated concentrations of ATO for 
24 hours or mock-treated. Relative survival of control-, HA-FUBI-, HA-S30 and HA-FAU cells at day 2 after 
treatment is depicted in (F). Relative survival of control- and FAU-knockdown at day 2 after treatment is depicted 
in (G). 
 
FAU increases ATO sensitivity of U2OS cells, independently from the ERK1/2 
pathway.  
Since it has been reported that inhibition of the MEK/ERK1/2 pathway increases ATO 
sensitivity 27-29, we treated control- and FAU-overexpressing cells with arsenic trioxide in 
the presence or absence of a MEK inhibitor, U0126. Both control and FAU overexpressing 
cells showed increased ATO sensitivity when co-treated with the MEK inhibitor (Fig. 3A). 
Indeed, we find that ATO treatment induces phosphorylation of ERK1/2 in both control and 
HA-FAU overexpressing cells (Fig. 3B). ERK1/2 activation actually functions as a survival 
signal, thereby attenuating the effect of ATO. Addition of MEK inhibitors U0126 and 
PD98059 reduced both basal (Fig. 3C, lower panel) and ATO-induced ERK1/2 
phosphorylation (Fig. 3C, upper panel). Interestingly, we observed an increase of ERK1/2 
phosphorylation upon FAU knockdown, which could still slightly be enhanced by ATO 
treatment and which was found sensitive to co-treatment with MEK inhibitors (Fig. 3C). A 
combination treatment with ATO and MEK inhibitors slightly reduced the survival of the 
FAU knockdown cells, whereas single ATO treatment had no effect (Fig. 3D). 
Interestingly, treatment with each MEK inhibitor alone seemed to enhance the growth of 
the FAU knockdown cells somewhat, whereas no effect was observed in the control cells, 
suggesting that the enhanced ERK1/2 activation in these knockdown cells might have an 
anti-proliferative function, as has been reported before 41,42. Altogether, these results 
suggest that FAU expression modulates the sensitivity of cells for ATO, independent of 
ERK1/2 activation. However, the activation of ERK1/2 seems to attenuate the growth 
inhibiting effect of ATO treatment, independent of the FAU levels. Furthermore, the FAU 
knockdown experiments suggest that endogenous levels of FAU inhibit basal 
phosphorylation of ERK1/2, as was published before 16, although we did not observe 
decreased phospho-ERK levels in FAU overexpressing cells, suggesting that endogenous 
levels are sufficient for this function of FAU (Fig. 3B).  
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Knockdown of FAU and ATO treatment induces gadd45-alpha mRNA expression.  
Upon FAU knockdown and also upon ATO treatment we observed an increase of p-
ERK1/2, as well as a marked G2/M arrest (Fig. 3C and Supp. Fig. 2B). A candidate protein 
involved in the biological response to ATO treatment and FAU manipulation is GADD45-
alpha. GADD45-alpha is a checkpoint protein, arresting cells at G2/M phase by inhibiting 
the activity of cyclinB/p34cdc2 complex in response to stress 43 and it has been reported 
that the transcription of the gadd45-alpha gene can be regulated independently from p53 by 
the MAPK pathways 44. Furthermore, it was shown that both JNK1 and ERK1/2 activation 
could enhance the DNA damage induced GADD45-alpha expression, by interacting with 
transcription factors such as Oct-1 and NF-YA that bind to OCT-1 and CAAT motifs in the 
gadd45-alpha promoter 44,45.  
Indeed we found increased gadd45-alpha mRNA expression in cells with reduced FAU 
levels (Fig. 4A), which might, at least partly, explain the G2 arrest seen upon FAU 
knockdown. This increase could partially be rescued by FAU overexpression, although it 
did not affect basal gadd45-alpha expression. ATO treatment also induced gadd45-alpha 
levels, p53-independently. ATO did not further increase gadd45-alpha in FAU knockdown 
cells, which already have increased levels (Fig. 4B), which might suggest that ATO and 
FAU regulate gadd45-alpha via the same pathway. FAU overexpression did not affect the 
ATO-induced expression of gadd45-alpha (Fig. 4C), indicating that the increased 
sensitivity of FAU overexpressing cells is not caused by reduced gadd45-alpha induction. 
Even though these data correlate well with the regulation of phospho-ERK shown in Figure 
3, it seems unlikely that the phosphorylation of ERK1/2 is the primary trigger for the 
induction of gadd45-alpha. On the contrary, the use of MEK inhibitors together with ATO 
even further enhanced the expression of gadd45-alpha and slightly stimulated the growth 
inhibitory effect of ATO treatment (Fig. 4C and Fig. 3A). Together, these results suggest 
that both ATO treatment and reduced FAU expression lead to p53-independent induction of 
gadd45-alpha, resulting in G2/M arrest, possibly via activation of MAPK pathways, 
although the observed ERK1/2 activation appears not to be required.  
 
It has also been reported that levels of active, phosphorylated-Akt are transiently 
upregulated upon ATO treatment but decrease at later time-points 46. Prevention of the 
transient activation of Akt strongly increased the apoptotic response. Importantly, Akt is 
inactivated upon ATO treatment at later time points through induction of c-Cbl proteins. 
This inactivation of Akt was found to be important for the apoptotic response upon ATO 
treatment 46,47. Moreover, in another study it was found that the inhibition of Akt activation 
enhanced the ERK1/2 phosphorylation after certain types of stress 48. Therefore, we 
analyzed whether FAU overexpression would affect the Akt activation by ATO treatment, 
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by investigation of phospho-Akt levels and the expression of genes whose expression can 
be regulated via Akt activation. In both control and FAU cell lines we find Akt inactivated 
at later time points upon ATO treatment (Fig. 4D).  
 
 
 
Figure 3. FAU increases ATO sensitivity independent from the ERK1/2 pathway. 
Stable U2OS cells expressing either a control vector or a HA-FAU expression vector were seeded for a WST-1 
proliferation assay, 24 hours after seeding cells were treated with 3 µM ATO or 3µM ATO and 10 µM U0126 for 
8 hours or mock treated. Relative survival compared to mock-treated corresponding cells 48 hours after start of 
treatment is displayed in (A). Stable control-vector or HA-FAU expressing U2OS cells were treated with 3 or 5 
µM ATO for 24 hours or mock treated, after which protein extracts were isolated. Protein extracts were analyzed 
with immunoblotting using the indicated antibodies. USP7 expression was used as a loading control (B). U2OS 
cells were lentivirally infected with either a control- or two different FAU knockdown vectors. At day 2 post-
infection cells were treated with 3 µM ATO, 10 µM U0126, 15 µM PD98059 or a combination of ATO and one of 
both inhibitors for 24 hours, or mock treated. Protein extracts were isolated and analyzed with immunoblotting 
using anti-phospho-ERK1/2 and anti-ERK1/2 antibodies (C). Relative survival compared to mock-treated 
corresponding cells 96 hours after start of treatment is displayed in (D).  
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Figure 4. Knockdown of FAU and ATO treatment induces gadd45-alpha mRNA expression.  
Stable U2OS cells expressing a control vector or HA-FAU were lentivirally infected with either a control- or two 
different FAU knockdown vectors. RNA extracts were isolated at day 6 post-infection and GADD45-alpha mRNA 
levels were analyzed using q-RT-PCR and are shown as normalized relative mRNA levels (A). Stable U2OS cells 
expressing a control- or p53-knockdown vector were lentivirally infected with either a control- or two different 
FAU knockdown vectors. At day 4 post-infection cells were treated with 3 µM ATO for 48 hours or mock treated 
and RNA extracts were isolated. Expression levels of GADD45-alpha mRNA were analyzed using q-RT-PCR and 
are shown as normalized relative mRNA levels (B). Stable U2OS cells expressing a control vector or HA-FAU 
were treated with 3 µM ATO, 3 µM ATO together with 10 µM U0126 or mock-treated for 24 hours. Total RNA 
was isolated and mRNA levels of GADD45-alpha were analyzed using q-RT-PCR and are shown as normalized 
relative mRNA levels (C). Stable U2OS cells expressing a control vector or HA-FAU were treated with 3 µM 
ATO for the indicated times, after which protein extracts were isolated and analyzed with immunoblotting, using 
the indicated antibodies. USP7 expression was used as a loading control (D).  
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FAU overexpression does sensitize U2OS cells for cisplatin and doxorubicin 
treatment.  
To study the effect of FAU expression on the response to other drugs, we treated control or 
FAU overexpressing U2OS cells with various concentrations of cisplatin and doxorubicin, 
enabling us to calculate the effective dose for a certain affected fraction (Fig. 5A and Table 
1). FAU overexpressing cells were slightly more sensitive for both cisplatin and 
doxorubicin; differences were the clearest when concentrations were used that affected 
more than 90% of the cells. Results were confirmed in colony forming assays, when the 
cells were treated with low concentrations of either cisplatin or doxorubicin for 24 hours. 
Again, FAU overexpressing cells were relatively more sensitive (Fig. 5B). However, using 
these concentrations, it seemed that the cells just arrest their growth but did not show an 
apoptotic reaction, as no floating cells were observed. Indeed, FACS analysis showed that 
24 and 48 hours treatment with 1 µM cisplatin resulted in a large increase in number of 
G2/M cells of both control- and FAU-overexpressing cells (Fig. 5C). Importantly, hardly 
any increase in sub-G1 fraction was observed, indicating that this low dose of cisplatin does 
not notably induce apoptosis at this time-point. Some increase of the sub-G1 fraction was 
observed when the cells were treated with 0.5 µM doxorubicin (Fig. 5C), although this did 
not correlate with the increased sensitivity of the FAU overexpressing cells (Supp. Fig. 
3A).  
 
Table 1. Effective dose of cisplatin and doxorubicin on U2OS control and FAU-
overexpressing U2OS cells. 
 Effective dose [nM] 
 CisPlatin  Doxorubicin 
Fa Ctrl FAU  Ctrl FAU 
0.50 3111 2231  26.2 26.1 
0.75 8929 5186  108.2 84.2 
0.90 25628 12055  447.6 271.3 
0.95 52499 21394  1175.3 601.4 
0.99 87446 32178  2336.1 1059.7 
 
U2OS cells stably tranduced with either a control vector or HA-FAU 
expression vector were seeded for WST-1 proliferation assays and colony 
formation assays. Next day the cells were treated with the indicated 
concentrations cisplatin or doxorubicin for 24 hours or mock-treated. 
Proliferation was measured at day 3 after treatment and effective doses 
were calculated using the CompuSyn programme. Fa = affected fraction. 
For cisplatin, r = 0.99422, and for doxorubicin treatment r = 0.99337. 
 
Reduction of FAU increases the resistance of U2OS cells to various drugs 
Confirming the effects that were observed in cells that overexpressed FAU, cells with 
reduced FAU levels were more resistant to cisplatin and doxorubicin. U2OS cells with 
reduced FAU levels were in a short-term growth assay slightly more resistant to cisplatin (1 
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µM) and significantly more resistant to doxorubicin (0.5 µM) (Fig. 5D). Similar effects 
were observed in long-term colony assays, in which the growth inhibition by the drugs was 
more severe. Even so, cells with reduced FAU levels the inhibitory effect of the drug 
treatment on colony formation was less (Fig. 5E). When cells were treated with higher 
concentrations cisplatin and doxorubicin, the differences between FAU overexpressing 
cells and control cells were diminished, but FAU knockdown cells remained more resistant 
(Supp. Fig. 3B and C). Similarly, when the cells were treated with other drugs, such as 
Actinomycine D, RITA and Nutlin-3, we observed a reduced sensitivity for the FAU 
knockdown cells (Supp. Fig. 3D).  
 
 
Discussion 
 
The FAU gene was reported to exhibit tumor suppressing and pro-apoptotic activities, 
although also oncogenic functions have been designated to this gene.  
It has been shown that the regulation of Bcl-G by FAU is required for its apoptotic 
functions 15,16. In several tumor types the expression of both genes was found to be reduced 
17-20, correlating with tumor progression, worse patient survival 18 and increased drugs 
resistance 18-20. On the other hand, FAU overexpression has been associated with increased 
arsenic trioxide resistance and transformation in HOS osteosacoma cells 23. In that study, 
the S30 domain was responsible for the increase ATO resistance and the FUBI domain for 
the transforming ability. Furthermore, FUBI-conjugated Bcl-G was shown to inhibit the 
MAPK pathway, by inhibiting the phosphorylation of ERK1/2 16.  
In this study, we investigated the role of FAU on the proliferation and drugs resistance in 
osteosarcoma cell lines. We found a clear growth inhibition, marked by a strong G2/M 
arrest, as a result of FAU knockdown, which could only be fully rescued by the expression 
of a complete FAU RNA. In a recently published study, FAU knockdown did not lead to 
reduced cell viability or apoptosis, however, analyses of cell-cycle progression and growth 
rate were not performed 21.  
An increase in ERK1/2 phosphorylation was observed upon FAU knockdown, which is 
consistent with findings that FAU is involved in the inhibition of the MAPK pathway 16. 
The growth inhibition caused by FAU knockdown might be the result of GADD45-alpha 
induction, since we observed increased gadd45-alpha mRNA levels upon FAU knockdown, 
which could partly be rescued by FAU overexpression. This checkpoint protein can be 
induced by MAPK activation and induces G2/M arrest 44,45. Given the observed enhanced 
ERK1/2 activity in these knockdown cells and some rescue of the growth inhibition by  
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Figure 5. FAU overexpression sensitizes cells for cisplatin and doxorubicin treatment. 
Stable U2OS cells expressing a control vector or HA-FAU were seeded for WST-1 proliferation assays and colony 
formation assays. At day 1 after seeding, cells were treated with the indicated concentrations cisplatin or 
doxorubicin for 24 hours or mock-treated. Proliferation was measured at day 3 after treatment and displayed as 
relative survival compared to mock-treated corresponding cells (A). Colony formation of control- and HA-FAU 
cells is displayed as relative colony formation compared to the corresponding mock-treated cells (B). FACS 
analysis was performed with cells that were treated with cisplatin (1 µM), doxorubicin (0.5 µM) or mock-treated 
for 48 hours. Indicated are percentages of cycling cells in G1, S or G2/M phase and percentages of single cells in 
SubG1 (C). U2OS cells were lentivirally infected with either a control- or two different FAU knockdown vectors. 
At day four post-infection cells were seeded for WST-1 proliferation assays and colony formation assays. One day 
after seeding, cells were treated with the indicated concentrations cisplatin or doxorubicin for 48 hours or mock 
treated. Proliferation was measured at day 2 after treatment and displayed as relative survival compared to mock-
treated corresponding cells (D). Colony formation of control- and HA-FAU cells, treated for 48 hours with the 
indicated concentrations and drugs, is displayed as relative colony formation compared to the corresponding 
mock-treated cells (E).  
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MEK inhibitors, the growth inhibition might be a direct consequence of an activated 
MEK/ERK cascade. Prolonged ERK1/2 activation has been reported to cause cell cycle 
arrest and even apoptosis in some circumstances 41,42. 
In contrast to the reported pro-apoptotic function of FAU in other cells, overexpression of 
FAU did not influence growth of U2OS cells, nor did it inhibit the activation of ERK1/2. 
Probably an increase in FAU levels only is not sufficient to induce apoptosis. To exert a 
pro-apoptotic effect FUBI needs to be conjugated to Bcl-G 15,16,21, and Bcl-G levels might 
be limiting. It is more likely that simultaneous overexpression of both Bcl-G with FAU or 
FUBI is needed to induce apoptosis. The pro-apoptotic function of FAU is more 
pronounced when cells are treated with drugs that induce an apoptotic response. Upon 
various drug treatments, Bcl-G levels will also increase, for instance due to p53 activation 
49. Under these conditions, overexpression of FAU will co-operate with the induced Bcl-G 
levels, which might explain the observed increased drug sensitivity.  
Indeed, we find that cells with enhanced FAU levels show increased sensitivity to p53 
inducing treatments with ATO, cisplatin or doxorubicin. Importantly, cells with decreased 
FAU levels were found to be more resistant to these drugs, again indicating that FAU levels 
are affecting the response to various drugs. 
Interestingly, in p53 knockdown cells FAU overexpression did have a sensitizing effect 
comparable to control cells, indicating a p53-independent mechanism. Since Bcl-G is a p53 
target gene, it suggests that more mechanisms are involved in the FAU-mediated drug 
sensitivity than only the p53-dependent induction of Bcl-G alone. It would, therefore, be 
interesting if FAU overexpression still sensitizes these p53-negative cells for drug 
treatments when Bcl-G levels are reduced. It has been reported that Bcl-G knockdown 
decreases FAU- and UV- induced apoptosis 21. However, in these experiments just 
knockdown of Bcl-G resulted in increased basal apoptosis, whereas the total amount of 
apoptotic cells after FAU transfection or UV treatment was not significantly decreased. So, 
it is very difficult to interpret these results.  
          
Strikingly, we found some similarities between the effects observed upon FAU knockdown 
and ATO treatment. ATO treatment induced ERK1/2 phosphorylation, which could be 
prevented by MEK inhibitors, thereby enhancing the growth inhibiting effect of ATO. 
These results suggest that ERK activation is pro-survival in this cell system. Depending on 
the cells used, activation of ERK by ATO has been reported to inhibit or to enhance ATO-
induced apoptosis 28,29,50,51. Arsenic trioxide induced gadd45-alpha expression, which has 
also been reported to be regulated by JNK and negatively, by NF-κB 52. FAU knockdown 
cells also showed induced p-ERK1/2 levels and increased gadd45-alpha mRNA expression, 
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suggesting again that FAU regulates the activation of some players in the MAPK pathways 
and might play a role in the equilibrium between proliferative and growth inhibiting factors. 
FAU expression might be required for optimal proliferation under normal conditions, 
whereas upon certain types of cellular stress FAU expression might stimulate the apoptotic 
response. In this model, apparently contrasting results reported previously might be 
explained. The transforming activity of FAU and FUBI in HOS cells 23, can be explained 
by the proliferative effects of FAU under normal conditions, whereas its tumor suppressing 
role is activated under stress conditions.  
In conclusion, in this study we show that FAU expression is needed for the normal 
proliferation of osteosarcoma cells, and that FAU levels influence the sensitivity to several 
types of drugs, including some that are frequently used in the clinic for osteosarcoma 
treatment.   
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Supplemental Figure 1. Overexpression of HA-tagged FAU, FUBI and S30 in U2OS cells. 
U2OS cells were lentivirally transduced with either control vector or expression vectors for HA-FUBI, HA-S30 or 
HA-FAU. Stable cell lines were established by puromycine selection. Stable cell lines were lentivirally infected 
with a control- or a FAU knockdown vector. Localisation and expression of the exogenous HA-tagged proteins 
was determined by immunofluorescence with anti-HA antibodies. DAPI staining was used to visualise nuclei (A). 
Co-localisation of exogenous HA-S30 and the nucleolar protein B23 was visualized in stable control or HA-S30 
expressing U2OS cells using immunofluorescence with anti-B23 and anti-S30 antibodies. DAPI staining was used 
to visualise nuclei and merged images are shown in the most right panel (B). Protein and mRNA extracts of stable 
control-, HA-FAU, HA-FUBI and HA-S30 expressing U2OS cells were isolated 6 days after lentiviral infection 
with control- or FAU knockdown vectors. Expression levels of endogenous FAU, total FUBI and total S30 mRNA 
were analyzed using q-RT-PCR and are shown as normalized relative mRNA levels (C). Protein extracts were 
analyzed with immunoblotting using an anti-HA antibody, USP7 expression was used as loading control (D).  
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Supplemental Figure 2. FAU overexpression rescues FAU-knockdown induced G2/M arrest; 
FAU knockdown cells are resistant to ATO treatment. 
Stable U2OS cells expressing a control vector or expression vectors for HA-FAU, HA-FUBI or HA-S30 were 
lentivirally infected with either a control- or two different FAU knockdown vectors. At day 6 post-infection cells 
were harvested for FACS analysis (A). U2OS cells were lentivirally infected with a control vector, an HA-FAU 
expression vector or a vector expressing a short hairpin RNA against FAU. At day 4 post-infection, cells were 
treated with 3 µM ATO for 48 hours or mock treated and harvested for FACS analysis (B). Indicated are 
percentages of cycling cells in G1, S or G2/M phase and percentages of single cells in SubG1. 
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Supplemental Figure 3. Reduction of FAU levels decreases sensitivity of U2OS cells for various 
drugs at high concentrations. 
U2OS cells stably expressing a control vector or HA-FAU were seeded for WST-1 proliferation assays. Next day, 
cells were treated with the indicated concentrations cisplatin or doxorubicin for 24 hours or mock treated. 
Proliferation was measured 48 hrs later and displayed as relative survival compared to mock-treated corresponding 
cells (A). U2OS cells were lentivirally infected with either a control vector or an expression vector encoding HA-
FAU and seeded for WST-1 proliferation assays four days post-infection. One day after seeding, cells were treated 
with the indicated concentrations of cisplatin or doxorubicin and cell viability was determined 48 hrs later and 
displayed as relative survival compared to mock-treated corresponding cells (B). U2OS cells were lentivirally 
infected with either a control-knockdown vector or two different FAU knockdown vectors, and seeded for WST-1 
proliferation assays four days post-infection. One day after seeding, cells were treated with the indicated 
concentrations of the indicated drug. Proliferation of cisplatin or doxorubicin-treated cells (C) and of cells treated 
with actinomycin D, RITA or Nutlin-3 (D) was measured after 48 hrs of treatment and displayed as relative 
survival compared to mock-treated corresponding cells.  
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Supplemental Information 
 
Q-RT-PCR Primer Sequences 
 
Endogenous FAU Fw 5’-tcgcttcttcctctttctcg-3’ 
Endogenous FAU Rev 5’-agctgcatattggcgactg-3’ 
 
FUBI Fw  5’-caggagctacacaccttcgag-3’    
FUBI Rev  5’-atgccctccagtgaggcta-3’ 
 
S30 Fw   5’-cgtgctggaaaagtgagagg-3’ 
S30 Rev   5’-gcttagcccgacctgtctt-3’ 
 
Gadd45alpha Fw   5’-gcgacctgcagtttgcaata-3’ 
Gadd45alpha Rv  5’-atcccccaccttatccatcct-3’ 
 
CAPNS1 Fw   5’-atggttttggcattgacacatg-3’ 
CAPNS1 Rv   5’-gcttgcctgtggtgtcgc-3’ 
 
TBP Fw   5’-cacgaaccacggcactgatt-3’ 
TBP Rv    5’-ttttcttgctgccagtctggac-3’ 
 
SRPR Fw   5’-cattgcttttgcacgtaaccaa-3’ 
SRPR Rv   5’-attgtcttgcatgcggcc-3’ 
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The p53 tumour suppressor pathway is one of the best studied pathways in cancer, 
indicating its importance in this field. Regulation of p53 is critical for normal functioning of 
any cell or organism. Therefore, the understanding of the function and role of the main 
regulators of p53, Hdm2 and Hdmx, is a crucial part of these studies. Whereas Hdm2, 
which was identified as a p53 binding protein 5 years before its homolog Hdmx 1,2, has 
been extensively studied, (almost 4700 articles), studies featuring Hdmx are still 
underrepresented (only ~300 articles), although the last few years this number is steadily 
growing. It has now become clear that Hdmx is also an essential negative regulator of p53, 
given the non-redundancy in knock-out mice 3-7 and, moreover, the high frequency of 
Hdmx overexpression in certain types of tumours 8-10, indicating an oncogenic function. In 
this thesis we have investigated and now discuss the role of Hdmx overexpression in 
transformation and tumourigenesis in several model systems. The regulation of the Hdmx-
p53 interaction is described in various ways; post-translational modifications on the Hdmx 
protein and alternative splicing of the Hdmx mRNA may all influence the function of 
Hdmx.  
 
Regulation of Hdmx  
Post-translational modifications of the members of the p53 pathway, mediated by several 
upstream activators, contribute to p53 activation upon DNA damage 11. Phosphorylation of 
P53, Hdm2 and Hdmx may lead to reduced interaction between p53 and its negative 
regulators, whereas the Hdm2-mediated degradation of Hdmx is enhanced 12-14, due to 
reduced USP7 activity towards Hdmx 15. The c-Abl non-receptor tyrosine kinase has been 
reported to play an important role in the p53 response by neutralizing the inhibitory effects 
of Hdm2 16,17. We could show that not only Hdm2 is phosphorylated by c-Abl, but that also 
Hdmx is target of this kinase, with tyrosines 55 and 99 as main phosphorylation sites (This 
thesis, Chapter 3, 18). Interestingly, these sites are within the p53 binding domain and it was 
demonstrated that the DNA damage-induced phosphorylation on Y99 inhibits the binding 
between p53 and Hdmx, thereby providing an additional mechanism for the activation of 
p53 after DNA damage. Even more, the phosphorylation of Y55 seemed to counteract the 
effect of Y99 phosphorylation and might be involved in the recovery phase after stress, 
when reduced activity of p53 is required.  
These findings indicate the importance of Hdmx in both the p53 response and the 
regulation of the recovery after DNA damage.  
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Splicing of Hdmx into Hdmx-S regulates the amount of full length Hdmx protein.  
One of the characteristics of the p53 response is a reduction of Hdmx protein. This is 
usually the result of induced Hdm2 levels and Hdm2-mediated ubiquitination activity 
towards Hdmx. However, we show that there might be an additional mechanism to reduce 
Hdmx levels upon DNA damage, which also functions in certain stages of tumour 
formation (This thesis, Chapter 2 and 5). The alternative splice variant Hdmx-S encodes the 
Hdmx-S protein, which consists essentially only of the p53 binding domain plus a few 
unique C-terminal amino acids and this shorter protein was initially reported to be a more 
potent p53 inhibitor 19. We demonstrated that the upregulation of Hdmx-S mRNA 
expression after DNA damage is accompanied by reduced full length Hdmx protein levels. 
Furthermore, we found a relatively increased Hdmx-S mRNA expression in osteosarcoma 
cell lines which express low levels of Hdmx protein, mainly correlating with inactivated 
p53. Moreover, we have shown that relatively high Hdmx-S mRNA expression in 
osteosarcoma tumours is correlated with a more aggressive clinical stage of the tumour, 
characterized by significant higher incidence of metastasis formation and worse disease-
related survival, thereby functioning as a prognostic factor. However, we also demonstrated 
that the endogenous Hdmx-S protein is hardly expressed, as it is not detectable, and 
therefore, most likely is not functional active. Thus, we proposed that increased Hdmx-S 
expression is mainly a way to reduce full length Hdmx protein levels. The association 
between a high ratio Hdmx-S/Hdmx-FL mRNA and mutant or inactivated p53 was 
confirmed in two independent panels of cell lines. In the NCI60 cell panel, consisting of 60 
cell lines derived from different tumour types 20, high Hdmx-S expression was clearly 
associated with p53 mutation and Hdm2 overexpression. Similar results were obtained with 
a panel of 39 breast cancer tumour cell lines, which were characterized recently 21,22. 
Furthermore, in a set of soft tissue sarcoma patients the increased Hdmx-S/Hdmx-FL ratio 
turned out to be a better predictor for overall survival than the mutational status of p53 
(This thesis, Chapter 5).   
 
These results combined strongly indicate that increased Hdmx-S mRNA expression mainly 
functions as a way to reduce the functional, full length Hdmx protein. This mechanism is 
activated upon various p53 activating treatments in normal and tumour cells, whereas it 
seems to be constitutively active in certain tumour cells. Although reduction of Hdmx as an 
advantage for tumour development might be counterintuitive, it might be that Hdmx 
expression may exert growth repressive functions in p53-negative or mutant tumours, 23-25. 
Matijasevic et al. demonstrated in p53-negative MEFs that Mdmx inhibited transformation 
and tumourigenesis by promoting bipolar mitosis 25. These findings fit in a model where in 
later stages of tumourigenesis, tumours with non-functional p53 select for reduced Hdmx 
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expression, to reduce its anti-oncogenic activity, thereby enhancing their tumourigenic 
capabilities.    
 
Oncogenic functions of Hdmx 
Although downregulation of Hdmx might enhance the tumourigenicity and especially the 
agressiveness of p53-negative tumour cells, amplification and overexpression of Hdmx is 
frequently found in several tumour types 8-10 or tumour cell lines 26. The Hdmx 
overexpression usually correlates with wild-type p53 status, suggesting an oncogenic role 
for Hdmx. The oncogenic function of Mdmx in mouse cells was demonstrated by Danovi et 
al. (2004) 8; in human cells this was not clearly proven yet. We have shown that the 
overexpression of Hdmx could replace the loss of p53 during the transformation process of 
human fibroblasts and embryonic retinoblasts (This thesis, Chapter 4). Several growth 
aspects such as proliferation rate, anchorage-independent growth and in vivo tumour growth 
were induced by exogenous Hdmx overexpression, comparable to loss of p53. Furthermore, 
we demonstrated in the same study that high levels of Hdmx can affect the response to the 
p53 activator Nutlin-3.  
Confirming these results, we also have shown that Hdmx knockdown in osteosarcoma cells 
is growth repressive and enhanced the effect of Nutlin-3, cisplatin and doxorubicin. These 
effects were partly p53-dependent, but growth inhibition upon Hdmx-knockdown was also 
observed in p53 mutant cells (This thesis, Chapter 5).  
Altogether, these results indicate that Hdmx overexpression can indeed exert an oncogenic 
function and may cooperate with other factors in the neoplastic transformation of human 
cells. We have demonstrated that Hdmx overexpression enhanced the resistance to 
chemotherapeutic drugs, by inhibiting the p53 response, whereas reducing Hdmx levels 
increased the sensitivity for p53 reactivating drugs. Therefore, the development of Hdmx 
inhibitors 27,28 in combination with conventional drugs may provide a new way of treatment 
for a specific set of tumour types. Especially tumours with wild-type p53 and high Hdmx, 
which are relatively resistant to Hdm2 inhibitors 29, may be treated more efficiently with 
these new type of drugs. However, considering our findings, it might be that highly 
transformed tumours with inactivated p53 will have an opposite response to Hdmx 
inhibitors, since we found that in these tumours a selection for down regulation of Hdmx 
may occur (see above). 
 
SUMOylation and ubiquitination in the p53 pathway 
Ubiquitin-like modifications play an important role in the regulation of cell growth, 
proliferation and the responses to stress, such as growth arrest or apoptosis. Especially in 
the p53 pathway, ubiquitin functions as a regulator of activity and proteasomal degradation 
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30-32. The regulation of p53 levels is for a large part controlled at the protein level, via 
proteasomal degradation. The amount of Hdm2 and Hdmx is also partly regulated at the 
protein level, although transcription from the p53-responsive Hdm2 promoter is greatly 
induced upon p53 activation. The net result of Hdm2-mediated ubiquitination and de-
ubiquitination by DUB’s like USP7 determines the rate of degradation of p53, Hdm2 and 
Hdmx and, thereby, the fate of the cell. The ubiquitination and de-ubiquitination is 
influenced in various ways by post-translational modifications, like phosphorylation, as 
mentioned above, but also other modifications, such as SUMOylation. The conjugation of 
SUMO may lead to several possible outcomes 33: SUMOylation of components of the 
ubiquitination system may enhance or reduce the ubiquitination process 34-37, SUMOylation 
of a target protein may compete with ubiquitination or might enhance it. A SUMOylated 
protein may serve as a target for SUMO Targeted Ubiquitin Ligases, which specifically 
recognize and ubiquitinate (poly)-SUMOylated proteins 38,39. The finding of a huge increase 
of high molecular weight species in the SUMOylated fraction of p53, Hdm2 and Hdmx 
after proteasomal inhibition, might suggest that SUMOylation plays a role in the 
ubiquitination of these proteins (This thesis, Chapter 4). We found that hypoxia and MAPK 
signalling can influence the SUMOylation status of p53 and its regulators, thereby 
indirectly also affecting their ubiquitination.  
The increased SUMO-dependent degradation of Hdm2 and Hdmx and decreased SUMO-
dependent ubiquitination of p53 observed after DNA damage (this thesis, Chapter 4) 
confirms previous findings, as it was suggested that SUMOylation of p53 inhibits its 
activity 40, whereas Hdm2 SUMOylation stimulates auto-ubiquitination 36. Although we 
could not detect any differences in SUMOylation of Hdmx after DNA damage, the 
SUMOylation of Hdm2 might indirectly regulate Hdmx levels. To elucidate the function of 
Hdmx-SUMOylation 41, extensive studies are required, comparing the biological responses 
of SUMO-deficient Hdmx mutants and wild-type Hdmx expressing cells upon various 
treatments.  
Furthermore, we investigated the role of the human STUbL RNF4 38,39 in the SUMO-
dependent ubiquitination of p53, Hdm2 and Hdmx. It has been reported that RNF4 
specifically ubiquitinates poly-SUMOylated PML after arsenic trioxide treatment, leading 
to PML protein degradation 42-44. Interestingly, while wild-type p53 is activated and 
stabilized by arsenic trioxide treatment, it has been reported that mutant p53 is degraded by 
this treatment 45. Mutant p53 was reported to interact with PML, leading to enhanced 
activity 46. These results suggest that a role of RNF4 in the regulation of p53 is well 
possible, although we could not find indications for a direct role of RNF4 in the SUMO-
dependent ubiquitination of p53, Hdm2 and Hdmx. Nevertheless, RNF4 still might be 
involved in the regulation of the p53 pathway. Slight changes in of p53, Hdm2 and Hdmx 
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protein levels were observed upon RNF4 knockdown or overexpression, indicating an 
indirect role of RNF4 on the regulation of p53. Especially the RING-dependent stabilizing 
effect of RNF4 on Hdm2 might be an interesting subject for further study. Strikingly, we 
observed a downregulation of RNF4 when cells were treated with various drugs, which was 
correlated to the induction of apoptosis and the sensitivity to the treatment. Moreover, we 
found that increased RNF4 expression resulted in a reduced apoptotic response after 
treatment with the p53 activating agent RITA.  The role of RNF4 in the DNA damage 
response is not fully clear yet. It has been reported to be required for DNA damage repair 
47, and our results suggest that RNF4 might also be involved in the fine-tuning of the p53 
response after stress or DNA damage. These functions might implicate RNF4 as an 
oncogene, since overexpression might reduce the tumour-suppressing function of p53. 
Enhanced RNF4 expression has been associated with tumour formation in mouse models 
and found to be enhanced in breast tumours 48. The expression level of RNF4 might serve 
as a prognostic factor for therapy response and drug targeting of RNF4 in tumours could 
enhance the effect of chemotherapeutic treatments.  
 
Role of FAU in growth and drugs resistance 
Whereas ubiquitin- and SUMO-chain conjugation on target proteins may lead to altered 
localisation, function or degradation 49, the ubiquitin-like FUBI is not likely to be able to 
form poly-chains, since it lacks most of the internal lysines, which are, in ubiquitin, 
required for chain formation. The only conserved lysine in FUBI, K27, might be used for 
poly-linkages 50, but it is unlikely that this type of chain would lead to proteasomal 
degradation. The FAU gene, which encodes FUBI and the ribosomal protein S30, has been 
associated with apoptosis in several studies 51-55. The conjugation of FUBI to the p53 target 
Bcl-G was reported to contribute to the pro-apoptotic function of FAU 52-55. Furthermore, 
FAU mRNA expression is down-regulated in a number of tumour types 53,54,56,57 and 
overexpression of FAU enhances the apoptotic effect of carboplatin and UV-C treatment 
53,54,57. We report in this thesis, Chapter 5, that FAU knockdown is growth-inhibiting, 
indicating a function for FAU in cell growth. In contrast to what has been reported before 
51,55, we did not observe increased basal apoptosis after FAU overexpression. Since 
conjugation of FUBI to Bcl-G has been demonstrated to be required for the FAU-induced 
enhanced apoptosis, the basal levels of Bcl-G might be limiting for the pro-apoptotic effect 
in these cells. Furthermore, these effects might be cell-type specific. Importantly, we 
demonstrated that FAU overexpression enhances the growth repressive effect of arsenic 
trioxide, cisplatin and doxorubicin. Consistently, cells which have reduced FAU levels are 
more resistant to these treatments. These results are confirming previous reports 53,54,57 
which are indicating FAU as a pro-apoptotic factor. Although it is the FUBI part that 
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interacts with Bcl-G 52, our results suggest that the complete FAU sequence is required for 
the apoptosis enhancing effect. Moreover, in the initial functional expression cloning 
studies 51, which identified the FAU anti-sequence to be anti-apoptotic, the whole anti-FAU 
sequence was found, indicating again that the complete sequence is needed. Interestingly, in 
cells that have reduced p53 mRNA levels, FAU overexpression still sensitizes for arsenic 
trioxide growth inhibition, suggesting that p53 activation is not essential for the FUBI-
mediated apoptotic response. 
Further investigations concerning the role of FAU in the response to drugs are required, 
since it might be a potential new target for anti-tumour therapy.  
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Alle levende wezens zijn opgebouwd uit cellen en elke cel bevat de volledige genetische 
informatie van het organisme, het genoom, opgeslagen in het DNA. De coderende delen 
van het DNA worden genen genoemd, welke elk voor één of meerdere eiwitten coderen. De 
genen bevatten specifieke informatie over hoe een eiwit is opgebouwd, namelijk de 
precieze volgorde van de aminozuren, de bouwstenen van eiwitten. Om een eiwit te maken, 
wordt eerst het desbetreffende stukje DNA overgeschreven in RNA; dit proces wordt ook 
wel transcriptie genoemd. Dit stukje RNA fungeert daarna als een bouwtekening om een 
eiwit te maken, in een proces dat translatie wordt genoemd. Aangezien de eiwitten cruciale 
rollen spelen in bijna elk proces in de cel, is het erg belangrijk dat deze informatie blijft 
bestaan en wordt doorgegeven. Daarom wordt bij elke celdeling het DNA verdubbeld en 
gelijk verdeeld over de dochtercellen. Tijdens dit proces, replicatie genoemd, wordt er 
voortdurend gecontroleerd op fouten of beschadigingen in het DNA, omdat veranderingen 
in het DNA, mutaties genoemd, schadelijk kunnen zijn voor de cel en daardoor mogelijk 
voor het hele organisme. Het DNA verdubbelingsproces wordt gestaakt als er een fout 
wordt ontdekt, en pas hervat als de schade is gerepareerd. Als de schade zo groot is dat 
betrouwbaar herstel niet meer mogelijk is wordt er een geprogrammeerde celdood, 
apoptose genoemd, opgestart. Als deze controlemechanismen niet meer werken kunnen 
beschadigde cellen ongehinderd verder delen en daardoor neemt de kans op het ontstaan 
van kanker aanzienlijk toe. Het is dus voor het organisme beter dat er één cel dood gaat, 
dan dat het gehele organisme in gevaar komt door ongeremde celgroei. 
Een belangrijke spil in dit controlesysteem is het eiwit p53. In gewone, gezonde, groeiende 
cellen doet dit eiwit niet veel. Echter, als er schade van het DNA wordt waargenomen, of de 
cel op een andere manier wordt gestrest, bijvoorbeeld door te laag zuurstofgehalte, dan 
wordt het p53 eiwit wakker geschud, en wordt het actief. Afhankelijk van de mate van 
schade of stress, dirigeert p53 verdere processen, variërend van het stilleggen van de 
celdeling tot aan het inzetten van celdood, zoals hierboven al genoemd. P53 kan deze 
processen beïnvloeden door de transcriptie van genen die belangrijk zijn in deze processen 
te reguleren. Vanwege deze belangrijke functies, die ook tumorgroei voorkomen, is het p53 
eiwit een tumor suppressor en wordt ook wel de 'bewaker van het genoom' genoemd. 
Omdat het p53 eiwit alleen actief mag zijn in geval van nood, is een strenge regulatie 
noodzakelijk voor een normale celgroei. Twee bijzonder belangrijke controleurs van p53 
zijn de eiwitten Hdm2 en Hdmx, die ervoor zorgen dat onder normale omstandigheden de 
hoeveelheid actief p53 eiwit laag blijft. Dit proefschrift behandelt onder andere de functie 
en regulatie van het Hdmx eiwit in relatie tot p53. Hdmx lijkt erg veel op Hdm2, maar een  
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groot verschil is dat Hdm2 voor de afbraak van p53 zorgt, terwijl Hdmx voornamelijk de 
activiteit van p53 remt. Hdmx kan deze functie uitvoeren door te binden aan het p53 eiwit 
en daarmee te verhinderen dat p53 de transcriptie van zijn target genen kan activeren. Veel 
is al bekend is over functies en regulatie van Hdm2, maar er is nog relatief weinig 
onderzoek gedaan over Hdmx.  
 
In hoofdstuk 2 van dit proefschrift wordt de huidige kennis over Hdmx samengevat, 
waarbij vooral de verschillende manieren van Hdmx regulatie aan bod komen.  
 
In hoofdstuk 3 wordt beschreven hoe Hdmx gemodificeerd wordt na DNA schade door het 
signaal eiwit c-Abl. Dit eiwit wordt actief na DNA schade en plaatst fosfaatgroepen op een 
bepaald aminozuur van eiwitten, waaronder Hdm2 en Hdmx. Het plaatsen van deze 
fosfaatgroepen, fosforylering, beïnvloedt de functie van deze eiwitten. We laten zien dat 
Hdmx op 2 aminozuren, tyrosines, wordt gefosforyleerd door c-Abl, waarvan de 
fosforylering op tyrosine 99 zorgt voor verminderde binding tussen Hdmx en p53. Dit leidt 
tot verminderde remming van p53 activiteit door Hdmx en deze modificatie draagt dus bij 
aan de activatie van p53 na DNA schade.  
 
In hoofdstuk 4 en 5 wordt de oncogene functie van Hdmx beschreven. Met andere 
woorden, welke rol speelt Hdmx in het ontstaan van kanker? Voor veel verschillende tumor 
soorten is beschreven dat het Hdmx gen verhoogd tot expressie komt, wat meestal correleert 
met het behoud van functioneel p53. Deze waarnemingen suggereren dat een verhoogde 
hoeveelheid van het Hdmx eiwit de tumor suppressor functie van p53 kan onderdrukken. 
Met gebruik van muizencellen heeft men al laten zien dat verhoogde expressie van Hdmx, 
dat in muizen Mdmx genoemd wordt, kan leiden tot transformatie van normale cellen naar 
tumorigene cellen. In menselijke cellen was nog geen direct bewijs geleverd voor deze 
oncogene activiteit van Hdmx. In hoofdstuk 4 laten we zien, in een studie met gebruik van 
twee soorten normale menselijke cellen, dat verhoogde expressie van Hdmx bijdraagt aan 
de transformatie van deze cellen, vergelijkbaar met het effect dat het verlies van p53 
veroorzaakt. In een vergelijkende studie tonen we dat verhoogde expressie van Hdmx, net 
als het verlies van p53, verschillende groei-aspecten van menselijke cellen versnelt en ook 
de activatie van p53 na behandeling met p53 activerende stoffen kan voorkomen.  
In hoofdstuk 5 wordt de rol van Hdmx in osteosarcoma beschreven, een vorm van 
bottumoren die vooral bij jonge mensen voorkomt. Omdat slechts in ongeveer 20% van 
deze tumoren een defect in het p53 eiwit wordt aangetroffen, en in een vergelijkbaar deel 
een verhoogde hoeveelheid Hdm2 wordt gevonden, ligt een rol voor verhoogde Hdmx 
expressie in het ontstaan van deze tumoren voor de hand. Wij hebben de hoeveelheid Hdmx 
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onderzocht in 51 osteosarcoma tumormonsters, en in 22 osteosarcoma cellijnen. Hoewel er 
slechts in enkele gevallen een verhoogde expressie van Hdmx werd gevonden, konden we 
laten zien dat Hdmx nodig is voor de groei van cellen met functioneel p53 en ook van p53-
mutant cellen, duidend op een deels p53-onafhankelijke functie van Hdmx. Verder laten we 
zien dat er in een hoog percentage van de osteosarcoma tumoren en cellijnen verhoogde 
expressie is van een alternatief Hdmx mRNA, Hdmx-S. Als een gen wordt overgeschreven 
naar RNA, worden alleen de relevante delen van dat gen (exonen) in de RNA codering 
gezet, door stukken die niet voor RNA coderen eruit te laten; dit proces wordt RNA-
splicing genoemd. Als een RNA op een alternatieve manier gespliced wordt, bijvoorbeeld 
door een coderend stukje (exon) over te slaan, ontstaat er na vertaling van dat mRNA vaak 
een (gedeeltelijk) ander eiwit. Het alternatieve Hdmx-S mRNA mist het coderende gedeelte 
van exon 6, resulterend in een verkort Hdmx eiwit, dat slechts het p53 bindingsdomein van 
het oorspronkelijke Hdmx bevat. Volgens sommige eerdere publicaties is dit korte Hdmx 
eiwit een betere p53 remmer en betrokken bij de tumorvorming. Wij laten zien dat het 
Hdmx-S RNA wel in vele tumoren en tumor cellijnen tot expressie komt, maar dat het 
Hdmx-S eiwit zeer onstabiel is of zeer inefficiënt tot expressie wordt gebracht en zeer 
waarschijnlijk geen belangrijke functie vervult. Dat deze RNA variant toch verhoogd tot 
expressie komt in veel tumoren, is mogelijk een manier om de hoeveelheid functioneel 
volledig Hdmx eiwit omlaag te brengen. We laten zien dat een verhoogde Hdmx-S 
expressie samenhangt met verlaagde hoeveelheid Hdmx en meestal met inactief p53. 
Bovendien hebben kanker patiënten met een hoge ratio Hdmx-S / Hdmx in de tumor een 
kortere overleving en lopen een significant hoger risico op het krijgen van uitzaaiingen. Op 
grond van deze resultaten poneren wij een model dat stelt dat het volledige Hdmx eiwit bij 
het ontstaan van de tumor een rol speelt door p53 activiteit te remmen. Maar in tumoren die 
zich in latere, meer agressieve stadia bevinden en waarin p53 gemuteerd of op andere wijze 
geïnactiveerd is, heeft Hdmx een groeiremmende functie en wordt door middel van 
alternatieve splicing de hoeveelheid functioneel Hdmx verlaagd. Door meerdere 
onafhankelijke panels van verschillende tumorcellijnen en patiënt data te analyseren hebben 
we dit model kunnen valideren. 
 
In hoofdstuk 6 worden andere eiwitmodificaties beschreven, namelijk ubiquitinering en 
SUMOylering. Dit betekent het koppelen van ubiquitine en SUMO aan andere eiwitten. 
Ubiquitine en SUMO zijn vergelijkbare kleine eiwitjes die dienen als signaalmoleculen. 
Het koppelen van deze kleine eiwitten aan een ander eiwit kan bijvoorbeeld de activiteit, de 
plaats in de cel en de stabiliteit van dat andere eiwit beïnvloeden. Het vormen van een 
ketting van ubiquitines aan een eiwit is een signaal om dat eiwit af te breken. We laten zien 
dat zowel p53 als Hdm2 en Hdmx geSUMOyleerd worden en dat specifiek deze 
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geSUMOyleerde eiwitten dan geubiquitineerd en afgebroken worden. De rol van RNF4, 
een SUMO-specifieke ubiquitine ligase, dat wil zeggen een eiwit dat ubiquitine aan andere 
eiwitten koppelt als daar al een SUMO aan zit, is onderzocht. Hoewel we geen directe 
regulatie van de SUMO-afhankelijke ubiquitinering door RNF4 hebben kunnen vinden, 
lijkt RNF4 wel een rol in de regulatie van p53 en zijn regulators te hebben, evenals in de 
DNA schade response.  
 
Een minder bekend familielid van de ubiquitine-achtige eiwitten, FUBI, wordt beschreven 
in hoofdstuk 7. Over de functie van FUBI, dat als een fusie-eiwit samen met het 
(ribosomale) eiwit S30 van het FAU mRNA wordt geproduceerd, is nog niet veel bekend. 
Expressie van het gehele FAU gen zou de apoptotische reactie versterken na behandeling 
met verschillende chemotherapeutica. Dat zou kunnen verklaren waarom in sommige 
tumortypes de expressie van FAU verlaagd is. Het FUBI deel van het FAU eiwit zou 
gekoppeld worden aan het pro-apoptotische eiwit Bcl-G en deze binding is nodig voor een 
sterke apoptotische respons. In deze studie tonen wij aan dat de expressie van het gehele 
FAU gen nodig is voor normale groei van osteosarcoma cellen, terwijl overexpressie van 
FAU de cellen gevoeliger maakt voor verschillende chemotherapeutica, zoals cisplatina, 
doxorubicine en arsenicum trioxide, welke onder andere worden gebruikt voor de 
behandeling van osteosarcoma in de kliniek. 
 
Het werk in dit proefschrift biedt meer inzicht in de rol van Hdmx in het ontstaan van 
tumoren (kanker) en kan hierdoor een bijdrage leveren aan het ontwikkelen van nieuwe 
behandelmethoden voor sommige tumoren. Bovendien is meer inzicht verkregen in de 
regulatie van hoeveelheid actief Hdmx, zowel op eiwit niveau door middel van 
modificaties, als op RNA niveau, door de alternatieve splicing van het Hdmx RNA. Daarbij 
geven we in dit werk meer inzicht in de rol van het FAU gen met betrekking tot normale 
celgroei en resistentie tegen chemotherapeutica, hoewel meer onderzoek nodig is om een 
mechanistische verklaring te vinden voor de werking van de bijbehorende eiwit producten. 
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Appendix: List of Abbreviations 
 
ATM   = Ataxia Telangiectasia Mutated 
ATO   = Arsenic Trioxide 
ERK   = Extracellular signal Regulated Kinase 
CAM   = ChorioAllantoic Membrane  
COBRA-FISH  = Combined binary ratio fluorescence in situ hybridization 
FAU   = FBR-MuSV-Associated Ubiquitously expressed  
FBR-MuSV  = Finkel-Biskis-Reilly murine sarcoma virus 
GADD45-alpha  = Growth Arrest and DNA Damage-inducible protein 45a 
HDM2/MDM2  = Human/Murine Double Minute 2 
HDMX/MDMX  = Human/Murine Double Minute X/4 
HER   = Human Embryonic Retinoblast 
HIF1a   = Hypoxia Inducible Factor 1 alpha 
hTERT   = human Telomerase Reverse Transcriptase 
MAPK   = Mitogen Activated Protein Kinase 
MEF   = Mouse Embryonic Fibroblast 
MEK1   = MAP/ERK kinase1 
MNSFbeta  = Monoclonal nonspecific suppressor factor beta 
MSCV   = Murine Stem Cell Virus 
NCS   = Neocarzinostatin 
p14ARF   = p14 Alternative Reading Frame 
PML   = promyelocytic leukemia protein 
PUMA   = p53 Upregulated Modulator of Apoptosis 
Rb   = Retinoblastoma protein 
RING   = Really Interesting New Gene 
RNF4   = Ring finger protein 4 
SIM   = SUMO Interacting Motif 
STUbL   = SUMO Targeted Ubiquitin Ligases 
SUMO   = Small Ubiquitin-like Modifier 
USP   = Ubiquitin Specific Protease 
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